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SUMMARY
Aim:
The aim of this study was to describe the epidemiology of important cardiovascular 
diseases (including angina, AMI, acute coronary syndromes, heart failure, atrial fibrillation 
and obesity) in Scotland using routinely available sources of data as well as data available 
from the Renfrew Paisley study.
Objectives:
• To report on the incidence, prevalence, primary care burden and prescribing 
practices of heart failure, angina and atrial fibrillation in Scotland and explore 
socioeconomic dispaiities.
• To examine trends in population hospitalisation rates for suspected acute coronary 
syndromes and short and long-term outcome following a hospitalisation with an 
acute coronary syndromes between 1990 and 2000
• To examine between hospital variability in 30 day survival following an admission 
to hospital in Scotland with an acute myocardial infarction.
• To examine the long-term cardiovascular consequences of angina and of obesity in 
the Renfrew Paisley study.
Methods:
Data was obtained from primary care (Continuous Morbidity Recording in General 
Practice Scheme), secondary care (Linked Scottish Morbidity Recording Scheme) and 
from a prospective cohort study (Renfrew-Paisley Study).
Prescribing and morbidity data were obtained from a representative sample of all General 
Practices in Scotland participating in the Continuous Morbidity Recording in General 
Practice Scheme for the years 1999-2000 (for heart failure) and 2001-2002 (for angina and 
atrial fibrillation).
The Linked Scottish Morbidity Recording Scheme was used to identify all 225,221 first- 
ever emergency admissions for suspected acute coronary syndromes in Scotland between
1990 and 2000. All emergency admissions for acute myocardial infarction to hospitals in 
Scotland during two time periods 1988-1991 and 1998-2001 were also identified using the 
Linked Scottish Morbidity Recording Scheme.
The Renfrew-Paisley study was used to examine the long-term cardiovascular 
consequences of obesity and angina. In the Renfrew-Paisley study, 15,406 men and women 
aged 45-64 years, living in the two industrialised towns of Renfrew and Paisley in the West 
of Scotland underwent comprehensive cardiovascular screening between 1972 and 1976. 
All deaths and hospitalisations for cardiovascular reasons occurring over the subsequent 20 
years were analysed according to baseline body mass index (BMI) category and the 
presence or absence of Rose angina.
Results:
I have shown that angina is a common condition, more so in men than in women. Deprived 
individuals are more likely to have angina but are less likely to consult their general 
practitioner. Guideline recommended treatments for angina are underused in women and 
the elderly. I also showed that heart failure is a common condition especially in older 
people. In the elderly, the eommunity burden of he ait failure is at least as great as that of 
angina or hypertension. People with heart failure have a high rate of concomitant 
respiratory tract infection. Compared with affluent patients, socioeconomically deprived 
individuals are 44% more likely to develop heart failure, but 23% less likely to see their 
general practitioner on an ongoing basis. Drugs proven to improve survival in heait failure 
ai'e used less frequently in elderly patients and in women however prescribed therapy does 
not differ across socioeconomic gradients. I similarly showed that atrial fibrillation is a 
common condition, more so in men than in women, hi contrast with heart failure and 
angina deprived individuals are less likely to have atrial fibrillation. As for heart failure 
and angina, recommended treatments for atrial fibrillation are underused in women and the 
elderly.
I have also shown that the pattern of emergency admissions with heart disease to Scottish 
hospitals has changed dramatically over recent years. While population hospitalisation 
rates for acute myocardial infarction have declined by a third between 1990 and 2000, 
hospitalisation rates for angina and chest pain have nearly doubled. The long term 
prognosis following an admission for myocardial infarction or angina is similar, when
deaths within the first 30 days are excluded. The average 30 day case-fatality rate 
following admission with an AMI has fallen substantially over the past 10 years. Between- 
hospital variation in 30 day survival is also considerably less marked during the time 
period 1998-2001 than it was during the time period 1988-1991 due to better survival in 
the previously poorly performing hospitals.
Using the Renfrew Paisley study, I found that compared with normal weight individuals 
(BMI 18.5-24.9), obesity (BMI >30) was associated with an increased adjusted risk of 
coronary heart disease, heart failure, stroke, venous thromboembolism and atrial 
fibrillation. Obesity was associated with 8 additional cardiovascular deaths and 30 
additional cardiovascular hospital admissions for every 100 affected middle-aged 
individuals over the subsequent 20 years. Assuming no change in cai'diovasculai' risk 
profile, the increase in prevalence of obesity in 1998, when compared to 1972, is projected 
to lead to an additional 4 cai'diovasculai' deaths and 14 admissions per 100 middle-aged 
men and women over the next 20 years. Again using the Renfrew-Paisley study, I found 
that individuals with Rose angina had an increased risk of cardiovascular death or 
hospitalisation, myocaidial infaiction and heart failure relative to individuals without 
angina. An abnormal ECG increased the risk further and both angina and an abnormal 
EGG further again when compared to those with neither angina nor an ischaemic ECG. 
Compared to men, women with Rose angina were less likely to have a cardiovascular 
event, or myocardial infarction, though there was no sex difference in the risk of stroke, 
atrial fibrillation or heart failure.
Conclusion:
I have demonstrated the potential of using data from the Continuous Morbidity Recording 
in General Practice Scheme to examine the epidemiology and prescribing practices of 
conditions in primary care and explore socioeconomic discrepancies. I have also 
demonstrated the potential of using data from the Linked Scottish Morbidity Recording 
Scheme to examine trends in hospitalisations and outcome for diseases and explore inter­
hospital variability in outcome. I have also used the Renfrew-Paisley study to examine the 
effect of baseline obesity or angina on long term cai'diovasculai' hospitalisations and 
deaths.
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1 INTRODUCTION
In this thesis I will examine the epidemiology of cardiovascular disease in Scotland using 
data from primary care (Continuous Morbidity Recording in General Practice Scheme), 
secondai’y care (Linked Scottish Morbidity Recording Scheme) as well as data available 
from a prospective cohort study, the Renfrew Paisley study, hi this chapter, I will review 
the literature on the prevalence, incidence, morbidity and mortality of angina, acute 
myocardial infarction, heait failure, atrial fibrillation and obesity. In chapter 2 ,1 will 
outline the aims of my thesis, hi chapter 3 ,1 will discuss the Continuous Morbidity 
Recording in General Practice Scheme, the Linked Scottish Morbidity Recording Scheme 
and the Renfrew Paisley study and explore the methods employed in the various studies I 
have performed. In Chapters 4, 5 and 6 ,1 will discuss the prevalence, incidence, primary 
care burden and pharmacological treatment of angina, heart failure and atrial fibrillation 
and also explore socioeconomic disparities. Chapters 7 and 8, address temporal trends in 
hospitalisation rates for suspected acute coronary syndromes and the short and long-term 
prognosis following admission with a suspected acute coronary syndrome. Chapter 9 
explores between hospital variation in 30 day survival following an admission with an 
acute myocardial infarction. Chapters 10 and 11, examine the long-term cardiovascular 
consequences of angina and obesity. Finally in chapter 12,1 will summarise the findings of 
this thesis and discuss limitations of the data and the possible avenues for further research.
1.1 Epidemiology of angina
1.1.1 Prevalence of angina
The prevalence of angina has been estimated in studies by using a number of different 
methods, mainly; the Rose angina questionnaire, a self reported angina diagnosis, a 
physician diagnosis or a general practitioner diagnosis. (Table 1)
1.1.1.1 Prevalence of angina in population studies using Rose angina questionnaire
The majority of population studies examining the prevalence of angina have used the 
World Health Organisation (Rose) questionnaire.* This questionnaire was introduced by 
Rose in 1962 and has since been widely used for determining the prevalence of angina in 
epidemiological studies. The subject is asked if they ever get chest pain or discomfort 
when walking uphill or hurrying. The chest pain is defined as either “definite” or 
“possible” angina depending on whether four additional criteria are fulfilled. These 
additional criteria are 1) the pain must be sited in the sternum or the left anterior chest and 
arm, 2) when it occurs on walking it must make the subject to stop or slow down, 3) it 
must go away if the person stops or slows down and 4) resolve within 10 minutes from the 
time when the subject stands still. Grade I angina is chest pain or discomfort when walking 
uphill or hurrying. Grade II angina is if in addition the subject also reports chest pain or 
discomfort when walking at an ordinary pace on the level. The Rose angina questionnaire 
is an accepted technique with good, population based, repeatability and validity for the 
detection of coronary heart disease. '^"* The validity of the Rose angina questionnaire has 
been tested in studies comparing it to a clinical diagnosis of angina, electrocardiogram 
(ECG) abnormality, thallium scanning and as a predictor of coronary artery disease events 
and m o r t a l i t y . T h e  Rose angina questionnaire has been shown to have a 81% 
sensitivity and a 97% specificity when compared to clinical judgement^ and a 26% 
sensitivity and 79% specificity when compared to exercise thallium testing^. Because the 
questionnaire is standai'dised it can be used to estimate disease prevalence in different large 
populations. Its’ limited sensitivity and specificity are outweighed by its’ ease of use, 
repeatability when applied to the same group of people, and proven validity in identifying 
groups of people at risk of developing the consequences of coronary heart disease."* There 
has been debate about which Rose categories should be included in epidemiological 
studies. Most epidemiological studies exclude possible angina.^'*^ However, in the British 
Regional Heait Study men with ‘possible’ angina were as likely to have an ischaemic ECG 
at rest and had a similar risk of acute myocardial infarction during follow-up as those with 
‘definite’ angina. * Men with ‘possible’ angina have also been shown to have a greater risk 
of dying from coronary heart disease, having an acute myocardial infarct, or needing a 
CAB G than age matched counterparts with no symptoms of angina.*^
In the 1998 Health Survey for England, a nationally representative sample of 15,908 
persons, aged 16 and over, was interviewed.^ The overall prevalence of definite angina
symptoms by the Rose Questionnaire was 2.6% in men and 3.1% in women. It was higher 
in women than in men in all age groups except for those aged 75 and over, where 7.3% of 
men and 5.9% of women reported the symptoms. In the Scottish Heart Health Study^^, the 
self-administered Rose angina questionnaire was given to a representative sample of 
10,359 men and women between 1984 and 1986. Grade 1 and 2 angina was included but it 
is not clear if possible angina was excluded. The prevalence of angina was higher in 
women (8.5%) than in men (6.3%). The British Regional Heart Study'^ is a prospective 
study of 7,735 men who were randomly selected from one general practice in each of 24 
British towns. The prevalence of definite angina at entry (1978-1980) in men aged 40-59 
years was 4.8%. An additional postal questionnaire was sent to surviving men in 1996 (age 
56-77) and the prevalence of definite and possible angina was 13.8%.^° Men belonging to 
the manual social class at baseline had almost double the prevalence of angina compared to 
those from the non-manual group. The prevalence of angina in women in the UK was 
examined in the Royal College of General Practitioners’ Oral Contraception Study in 
1994-1995.'"' The prevalence of definite angina in 11797 women, mean age 55.9 years, 
using a postal questionnaire was 7.4% increasing to 9.9% in women over 65 years. The 
prevalence of angina increased with manual social class. Another UK study conducted in 
1967 in the Rhondda Fach in South Wales found a much higher prevalence of angina in 
women (17.8% aged 45-74 y e a r s ) . I n  the original Whitehall Study carried out between 
1967 and 1969 among male London civil servants aged 40-64 years, the prevalence of 
definite and possible angina was 4.8%.^^ In Whitehall II, the prevalence of definite angina 
in government employees between 1985 and 1988 was 2.4% in men and 4.0% in women 
aged 35-55 y e a r s . T h e  prevalence of angina in middle aged men was found to be similar 
(7.7% and 7.8%) in two community studies carried out in South Wales (Caerphilly) and the 
West of England (Speedwell).
Two European population studies have examined the prevalence of angina, hi the Northern 
Sweden MONICA Project unlike all other studies using the Rose questionnaire the 
prevalenee of definite angina was higher in men than in women. The prevalence of angina 
declined significantly in women aged 35-64 years from 5.9% in 1986 to 2.8% in 1994.".
In the Reykjavik study which took place between 1983 and 1987 the prevalence of angina 
was 6.1% in 1,142 Icelandic men aged 50-79 year s ,Pr ior  myocardial infarction was 
excluded and Rose angina was not defined. The Multifactorial trial in prevention of 
Coronary Heart Disease compared the prevalence of angina in five European countries 
in the 1970s. The prevalence of angina varied significantly between countries and ranged
from 2.3% in Spain up to 5.1% in Poland with an overall average of 4.3%. In the UK the 
prevalence of angina was 3.6% in 18210 men aged 40-59 years.
Two US studies using the Rose questionnaire have also found a higher prevalence of 
angina in women compared to men. The prevalence of definite angina was 6.2% in women 
and 5.2% in women over 40 yeais in NHANES III"' and 4.1% in women and 3.2% in men 
over 30 years in the Lipid Research Program Prevalence S t u d y ' h i  a Canadian 
population-based cross-sectional survey the prevalence of definite angina in 2167 
individuals aged 18 to 74 years was 3.1% in men and 4.1% in women.Poss ible  angina 
was more prevalent among those with less education, lower income and those who were 
unemployed.
The prevalence of angina has been shown in these studies to increase with age. A direct 
compai'ison between the different studies is difficult due to the different age profiles of 
patients studied. Most studies have found a higher prevalence of Rose angina in women 
than men. We do not know whether this difference reflects true difference in the 
prevalence of angina between the sexes or whether it is a differenee in the perception or 
description of chest pain between sexes highlighted by the Rose questionnaire. All-cause 
mortality rates are higher in women with Rose angina compared to women without.'"' 
Coronary artery disease risk has shown to be raised in women with Rose angina even when 
they have high levels of general symptom reporting.'^ Variation in symptom reliability 
between sexes has not been shown to explain the higher prevalence of Rose angina in 
women.^^ The vai'iability of angina symptoms over a 5-year period was examined in the 
British Regional Heart Study and whilst there was considerable variability in response to 
the Rose questionnaire at the two time points, it was shown that persistently reported 
symptoms were associated with severe disease and a poor prognosis.
1.1.1.2 Prevalence of angina in population studies based on a self-report of angina.
Both the Health Survey for England^ and the Scottish Heart Health S t u d y ' i n  addition to 
the Rose questionnaire, estimated the prevalence of angina based on self reported angina. 
In the Health Survey for England in contrast to the prevalence of Rose angina, more men 
(5.3%) than women (3.9%) reported having ever had angina. Similaiiy in the Scottish 
Heart Health Study, the prevalence of a history of angina was higher in men (5.5%) than in 
women (3.9%).
1.1.1.3 Prevalence of angina in population studies using a physician diagnoses.
In the Primary Prevention Study subjects judged to have definite or suspected angina on 
Rose angina questionnaire were then interviewed and examined by a single physician to 
confirm the diagnosis. At the second screening visit, which took place between 1974 and 
1977, the prevalence of angina in men aged 51-59 years was 4.4%.'^ In the Cai'diovascular 
Health Study^^ the prevalence of angina was ascertained in 5,201 adults aged 65 years and 
older. A diagnosis of angina was based on a self-report of angina in combination with 
either use of nitrates, revascularisation, hospital diagnosis of angina or physician diagnosis 
of angina. The prevalence of angina was 15.4% in men and 9.8% in women over 65 years. 
In the Framingham Study"^" the prevalence of physician diagnosed angina was 5.9% during 
14 years of biennial cardiovascular surveillance in a cohort (aged 30-62 at entry) who were 
free of clinical manifestations of coronaiy heart disease at initial screening 1949-1952. 
From 1951 through 1986 in the Framingham Study angina was the initial presenting 
manifestation of coronary disease in 39% of subjects.^'
1.1.1.4 Prevalence of angina based on general practitioner reported diagnoses.
Studies estimating prevalence based on general practitioner (GP) diagnosis of angina have 
strengths and weaknesses compai'ed to the more commonly used alternative of 
administration of a questionnaire. There have been concerns that the questionnaire 
approach may overestimate the prevalence of angina, especially in women. Conversely, 
reliance on a medical diagnosis may underestimate prevalence as individuals with 
unrecognised angina or very mild symptoms might not attend (or be correctly identified 
by) their general practitioner. In addition there is coneern that GP coding of angina in the 
UK may be different since the introduction of the new General Medical Services (GMS) 
contract in 2004 which provides financial incentives for the correct management of 
patients with angina.
Two studies used an analysis of nitrate prescribing to establish the prevalence of angina. 
Nitrates are mostly used for the treatment of angina.^^ Prescription analysis has the 
advantage that it is cheap and can be done quickly and by few staff. In the Nottingham 
nitrate study^^ the prevalence as estimated using nitrate prescriptions in 1984 was 2.6% in 
patients over 30 years.
The prevalence of angina in 1992 was determined by using GPs’ records from 21 general 
practices in the Wakefield region of northern England^"' of patients who ai*e regularly 
taking nitrates. 3.2% of men and 3.0% of women had angina. The prevalence of angina 
was higher in men than in women in all age groups and rose steeply with age. The 
Newcastle General Practice survey"^ ,^ carried out in 1979, reported a prevalence of 1.1% in 
subjects aged 30-59 years which is lower than other studies. This survey was conducted by 
51 general practitioners and identified 336 patients with angina through either repeat 
prescriptions, recent consultations or recall. Case-ascertainment therefore may not have 
been complete.
1.1.1.5 Secular trends in prevalence of angina
Trends in the prevalence of angina have been examined using data from the British 
Regional Heart S t u d y . T h e  Rose angina questionnaire was used to ascertain the 
prevalence of current angina symptoms at four time points between 1978 and 1996. They 
found that over this time period middle-aged British men with and without a diagnosis of 
coronary heart disease were less likely to experience symptoms of angina. In a separate 
study of the same cohort the incidence of diagnosed angina (ascertained from general 
practice record reviews) seems to have increased by 2.6% per year between 1978 and 
2000.^^ A possible explanation for the differences between these two studies may be that a 
greater proportion of angina cases are now formally diagnosed. This may result from 
general practitioners prioritising the early identification and treatment of coronary heart 
disease and an increase in availability of diagnostic investigations for suspected angina. 
The prevalence of angina also increased in England and Wales in the 1990s compared to 
the 1980’s using data from the general practice morbidity survey.''^ The Minnesota Heart 
Survey reported a 56% increase in the discharge rate for angina in men and a 30% increase 
in women between 1985 and 1995 (with a 20% decline in the discharge rate for acute 
myocardial infarction (AMI) in both men and women).
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1.1.2 Incidence of angina
Table 2 shows studies reporting the incidence of angina. There are fewer studies that have 
examined the incidence of angina in men and women as it is more difficult to examine.
The best information on incidence comes from cohort studies.
In a study of referrals to a chest pain clinic at the Royal South Hants Hospital in 
Southampton the incidence of angina was 0.8 per 1,000 in persons aged 31-70 y e a rs .A ll  
general practitioners in Southampton agreed to refer any patient presenting for the first 
time with chest pain, which in their opinion could be stable angina. The denominator was 
all men and women in the practice population. The incidence in this study is lower than 
other studies and may reflect the methods employed. The incidence of angina in men aged 
50-59 years was compared between France and Northern Ireland in the Prospective 
Epidemiological Study of Myocardial Infarction (PRIME) study."^ *^  This was cairied out 
between 1991 and 1994. Angina was defined by the presence of chest pain at rest and/or on 
exertion and one of the following criteria: angiographic stenosis or positive functional test 
(if no angiographic data) or ECG changes at rest (if no angiographic or functional test 
data). The incidence was higher in Northern heland (5.4 per 1,000 per year) than in France 
(2.6 per 1,000 per year). During a 10-year follow-up of the Seven Countries Studies 
cohorts, the average annual incidence of angina as the only manifestation of coronary heart 
disease in men aged 40-59 years was 0.1% in Japan, Greece and Croatia, 0.2-0.4% in Italy, 
Serbia, Netherlands and USA and 0.6-1.1% in Finland."^^
The Framingham Heart Study is a longitudinal study in which 5,127 persons free of 
clinical manifestations of coronary heart disease at initial screening between 1949 and 
1952 were followed for 14 years.^^’"^  ^The annual incidence of angina was 3.1 per 1,000 in 
men and 2.8 per 1,000 in women. The Framingham Cardiovascular Disease Survey was a 1 
year survey in which all new cases of angina in patients over 30 years of age were 
identified in the town of Framingham between 1970 and 1971 using hospital, GP and 
pharmacist records and death certificate data.'^ '^'^  ^The annual incidence of angina was 
lower at 1.8 per 1,000 in men and 0.4 per 1,000 in women. A possible explanation is that 
the Framingham Heart Study used periodic direct examination of a population sample 
whereas short-term population studies like the Cardiovascular Disease Survey aie 
dependent upon patient-initiated contacts and therefore are likely to miss mild angina
pectoris. In both these studies the incidence of angina was higher in men than in women in 
most age groups and increased with age. Two other older US studies with similar 
methodology reported similar incidence rates to the Cardiovascular Disease Survey.' '^^’'*^ 
The incidence of angina in older patients was examined in a US study of members of the 
Kaiser Foundation Health Plan."^ *^  The incidence of angina in those over 80 years in the 
1980-1981 cohort was 12.6 per 1,000 person years in men and 5.1 per 1,000 person years 
in women.
The annual incidence of angina in Japanese American men aged 45-68 years in the 
Honolulu Heart Program was 2.1 per 1,000."^  ^ In the Israel Ischaemic Heart Disease Project 
male civil service employees aged 40 years and over were followed between 1963 and 
1968. The annual age-adjusted incidence of angina was 7.2 per 1,000, which is higher than 
other studies.
1 0
Io
"CcCQ
I«
*o
o;
Xi
i l .
g : g
a c
IL
Ï!I!
Il
£ £
I:i§I»1 « « I l
1 1
s§1
i sîî\o  o<N ^
II
li
c
îi
II
«s#
<N
l l i
eu cc Æ
,1 1  < X
Ss I
S!i
l l i !
u  X a.-ë
b. O
I J
!lt  c/5I
f i l ll i l l
1 1
£  Q
'O
It
o  .2
i l
XIffb, 1/3
j Î I i
! ï
1«1C5
0
<z
cs.«
T3C«
1C/3
"U
a4:
-
o
.2>n13
>-
1.1.3 Angina morbidity
1.1.3.1 Risk of non-fatal events associated with angina
In contrast to case-fatality there are relatively few studies, which have reported non-fatal 
events in patients with angina (Table 3). The British Regional Heart Study^^ examined the 
combined outcome of coronary heart disease death or non-fatal myocardial infarction.
They showed that men with angina were twice as likely to have a coronary heart disease 
death or non-fatal myocardial infarction over 10 years when compared to men without 
angina.
The Framingham study looked at non-fatal myocardial infarction a l o n e .33.4% of men 
and 17.8% of women with angina had a myocardial infarction over a 10 year follow-up. 
The Framingham study also looked at the risk of coronary heart disease events in subjects 
reporting chest discomfort.^ ^ Men with definite angina had a threefold increased risk (OR 
3.7, 95% Cl 2.1, 6.6) and women a fivefold increased risk (5.4 (3.1, 9.3)) of developing 
unstable angina, myocardial infarction or cardiac death within two years of first 
presentation. An excess risk was also present for individuals with possible angina (men 3.0 
(1.3, 6.7); women 2.9 (1.1, 7.2)) however there was no increase in risk associated with 
non-anginal chest discomfort.
During a median follow-up of 15.8 months, 7.5% of patients aged 31-70 years with newly 
diagnosed typical angina referred to a chest pain clinic in Southhampton experienced a 
myocardial infarction and 18.7% underwent coronary revascularisation.^^ The Prospective 
Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK) examined outcome 
following hospitalisation with an acute coronary syndrome without ST segment elevation 
between 1998 and 1999.^^ Patients presenting with acute chest pain and an ischaemic ECG 
or a prior history of coronary heart disease were included. This study therefore included 
both patients with unstable angina and those with non-ST elevation myocardial infarction. 
These two groups were not analysed separately however, and creatinine kinase was not a 
predictor of an adverse outcome. The risk of subsequent myocardial infarction was 7.3% 
during the 6-month follow-up.
In the Rochester Coronary Heart Disease Project^^, women with angina were 53% less 
likely than men to have a cardiac death or non-fatal myocardial infarction.
1 2
Patients with angina are likely to be at increased risk of other complications of coronary 
head disease (e.g. heart failure) and non-cardiac vascular events (e.g. stroke). The British 
Regional Heait S tu d y fo u n d  that 5% of men with angina developed a stroke (identified 
from general practitioner records), a relative risk 2.6 times that of men without angina. 
There is however very little information on the risk of other non-fatal outcomes in patients 
with angina.
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1.1.4 Angina mortality
Studies reporting on mortality outcomes in patients with angina are shown in Table 4. In 
the Framingham Study^' 291 men and 319 women who were free at baseline screening of 
coronary artery disease, developed angina between 1951 and 1986. Their mean age was 61 
and 64 years in men and women respectively. During a mean follow-up of 10 years 41.5% 
of men and 31.5% of women died and 28.2% of men and 16.7% of women died from 
coronary heart disease. In the Rochester Coronary Heart Disease Project^^ the diagnosis of 
angina was identified through review of medical records from physicians offices and 
hospitals in Rochester between 1960 and 1979. Angina was diagnosed in 529 women and 
504 men aged >30 years (33% over 70 years) and they were followed up until 1982. 10- 
year mortality was 29.6% for women and 40.8% for men. Women were 55% less likely to 
die at 1 year' compared to men (RR 0.45 95% Cl 0.37, 0.55).
In the Reykjavik Study^" ,^ 9141 men aged 34-79 at entry (1967-1987) were followed for 4- 
20 years. There were 3 different angina groups a) definite angina by Rose questionnaire 
with ECG manifestation of myocardial ischaemia; b) definite angina by Rose questionnaire 
with normal ECG and physician’s diagnosis; c) definite angina by Rose questionnaire only. 
Ten year mortality was 11-13% in the three groups. Those with angina had a 1.7- to 2.2- 
fold risk of all cause mortality and a 2.5- to 3.2-fold risk of CHD mortality depending on 
the subgroup of angina over the follow-up period, hi the Primary Prevention Study'^ 7,100 
men, aged 51-59 years, and living in Goteborg, Sweden were screened between 1974 and 
1977 and followed for at least 16 years. Angina was identified by questionnaire and 
confirmed by examination by a physician, in 314 men with no prior myocardial infarction. 
In men with angina there were 33.0 deaths per 1000 observation years and 17.6 coronary 
heart disease deaths per 1000 observation years. The adjusted risk of all cause death was 
1.63 (1.38, 1.93) and coronary heart disease death was 2.60 (2.04, 3.31) relative to no 
coronary heart disease.
In the British Regional Heait Study^^ 7,735 men, aged 40-59 years at entry (1978-1980) 
were followed up for 15 years. There were two angina groups, those with diagnosed angina 
(n=123) and those with angina symptoms (n=349) (defined as definite or possible on Rose 
angina questionnaire with no prior history of ischaemic heart disease). The 10 year risk of 
death was 3.0 (2.1, 4.2) and of caidiovascular mortality was 4.3 (2.7, 6.9) for the diagnosed
15
angina group when compared to men with no coronary heart disease. The equivalent 
hazard ratios for the angina symptoms group was 2.0 (1.5, 2.6) and 2.6 (1.8, 3.8). In the 
Whitehall S tu d y an g in a  was classified according to Rose angina questionnaire however 
they do not define whether possible Rose angina was included. The 5 year coronary heart 
disease mortality rate in 40-64 year old men was 7.1%. In the Whitehall II study^^ 6,895 
men and 3413 women, aged 35-55 years, were followed up for a mean of 11 years. Angina 
was defined as a GP or hospital diagnosis of angina and the presence of angina on Rose 
angina questionnaire. The mortality rate, adjusted for age and sex, was 3.4 per 1000 person 
years at risk.
In the Royal College of General Practitioners’ Oral Contraception Study angina as 
defined as definite angina on the Rose Angina Questionnaire was identified in 640 women. 
The 5-year mortality rate was 6.3%. In a study by Campbell et af'^ 1428 women aged 45- 
74 years living in Wales, were followed for 12 years. Angina was defined as definite 
angina on Rose Angina Questionnaire. The 12-year mortality rate for 45-74 year olds with 
angina was 22.8%.
The mortality of patients hospitalised with unstable angina was examined using population 
data from Alberta, Canada and the outcome in men and women com pared.B etw een 1993 
and 2000 there were 8,441 admissions with unstable angina. Five-year mortality was 
similar in men and women (19.7% versus 21.6%). After multivariable adjustment women 
with unstable angina had a survival advantage over men (HR 0.81, 95% Cl 0.72, 0.92).
The risk of death following admission with unstable angina increased with age.^^’^ ^
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1.2 Epidemiology of acute myocardial infarction
1.2.1 Incidence of acute myocardial infarction
Studies reporting the incidence of acute myocardial infarction (AMI) are shown in Table 5. 
The methodology employed differs between studies. Some studies use hospitalised patient 
registries to report the incidence of AML However these do not inelude approximately 
40% of AMI which occur as out of hospital cardiac deaths. Alternatively some studies 
report both fatal and non fatal AMI by including both AMI which are admitted to hospital 
and out of hospital cardiac deaths. Studies also differ as to whether they look at first events 
only, or include individuals with first or subsequent AMI or look at AMI attack rates 
(which may include the same individual on more than one occasion). Different diagnostic 
criteria between different studies occur and this determines whether mild cases are 
included as AMI or not. In addition measurements of more sensitive biomarkers for 
myocardial damage such as cardiac troponins were introduced around 2000. This is likely 
to result in individuals with a mild troponin lealc being labelled as AMI that would 
previously have been labelled as unstable ang ina.A no ther potential problem with 
myocardial infarction registries is that unrecognised AMI are not included. AMI are more 
likely to be unrecognised in women.^° In the Reykjavik study 33% of non-fatal AMI in 
women were unrecognised. More unrecognised events occurred in the younger age groups 
(40%) than in the older (27%).^^
1.2.1.1 Incidence of acute myocardial infarction in hospitalised patient registries
Using the resources of the Rochester Epidemiology Project^^ all individuals hospitalised 
with a first AMI between 1979 and 1994 were identified. The diagnosis of AMI was 
validated by review of case notes, hi 1994, the age adjusted annual incidence was 260 per
100,000 in men and 180 per 100,000 in women. The Minnesota Heart Survey^^ randomly 
selected a sample of all case notes of individuals aged 30-74 years discharged from 
hospital with a diagnosis of acute CHD in the Twin Cities of Minneapolis and St Paul in 
1985, 1990 and 1995. Standardised criteria were use to validate a diagnosis of AMI. First 
and recuiTent events were distinguished by examining medical records. The age adjusted 
annual incidence of first AMI was 272 per 100,000 in men and 105 per 100,000 in women 
in 1995. The Worcester Heart Attack Study*^  ^ included all 3,148 individuals hospitalised
19
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with a first AMI in Worcester, Massachusetts between 1975 and 1988. In 1988, the age- 
adjusted incidence rate of first AMI was 240 per 100,000 in men and 137 per 100,000 in 
women. The Atherosclerosis Risk in Communities Study (ARIC) '^^ examined incidence of 
coronary heart disease in individuals aged 35 to 74 years in four communities in the United 
States, hi 1994, the age adjusted incidence of first AMI was 180 per 100,000 in women 
and 410 per 100,000 in men. The Corpus Christi Heart Project^^ examined all residents 
aged 25-74 years in Nueces County, Texas hospitalised with a first AMI between 1988 and 
1992. There was a greater incidence of hospitalised first AMI among Mexican Americans 
(367 per 100,000 in men and 205 per 100,000 in women in 1991/92) than among non- 
Hispanie whites (342 in men and 150 in women). The age adjusted rate of hospitalisation 
for AMI in 1997 was 482 per 100,000 using data from the National Hospital Discharge 
Survey®*^ . All discharges from non-institutional hospitals in Columbia were included and 
no distinction was made between first and recurrent AMI.
1.2.1.2 Incidence of acnte myocardial infarction including out of hospital deaths
The World Health Organization MONICA project is a study that consists of 39 
collaborative centres in 26 countries and monitors deaths from coronary heart disease, 
myocardial infarction, coronary care and risk f a c t o r s . T h e  Toulouse MONICA Study^^ 
reported on the incidence of first AMI in men and women aged 35 to 64 years living in the 
French department of Haute-Garonne in south-western France. Out of hospital deaths were 
included. In 1993, the age adjusted incidence for first AMI was 162 per 100,000 in men 
and 29 per 100,000 in women, hi the Oxford myocardial infarction incidence study^\ all 
patients with AMI in Oxfordshire, England in 1994-95, were identified using WHO 
MONICA diagnostic criteria. The annual rate for a first or recurrent coronary event (fatal 
and non-fatal) per 100,000 was 273 for men and 66 for women aged <65 years and 1350 
for men and 677 for women aged 65-74 years.
Using the National AMI Register for Sweden^^’^ ,^ all 303,324 Swedes discharged from 
hospitals, or deceased with a diagnosis of AMI between 1987 and 1995 were identified. 
The age standardised attack rate of AMI in 1995 was 881 per 100,000 in men and 381 per
100,000 in women. These studies have been consistent in their findings that the incidence 
of AMI increases with age and is higher in men than in women in all age groups. The 
Regicor Study "^  ^used a community based registry to determine the incidence of AMI in the 
province of Gerona, Spain from 1990 to 1992. Age standardised incidence rates (first AMI
2 0
cases only) for definite and fatal possible AMI were 130.4 per 100000 men and 27.1 per 
100000 women aged 25-74 years.
In the NHANES Epidemiologic Follow-up Study^^ the incidence of first AMI including 
out of hospital deaths in 9,774 participants aged 35-74 years, was 492 per 100,000 in the 
1982-92 cohort.
In the Hunter Valley Heart Attack Study^^ the AMI attack rate (all AMI including out of 
hospital deaths) in 1979 in a well-defined area in New South Wales, Australia was 258 per 
100,000.
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1.2.1.3 Trends in incidence of acute myocardial infarction
Many studies have looked at trends in AMI event rates. (Table 6) Some studies have 
reported a decline in the incidence of A M f while others have shown that the
incidence has remained stable'^^’^ ’^^ ’^^ .^ In several studies the direction of the trend has been 
different in men and w o m e n . C h a n g e s  in the incidence of AMI are postulated to be 
driven by changes in known coronary risk factors.
Examination of trends in the incidence of AMI over 10 years from the mid 1980s in 37 
populations in 21 countries across four continents in the WHO MONICA Project'^^ showed 
that non-fatal definite AMI fell by 2.1% in men and 0.8% in women per year. When fatal 
events were included there was a similar decline (2.1% and 1.4% in women). Using routine 
data, all deaths and discharges with AMI in Denmark and Sweden were extracted for the 
period 1978-98 for Denmark and 1987-1999 for Sweden.^^ Between 1991 and 1998 there 
was an average annual relative decrease in the incidence of first AMI of 6% in men and 
5.9% in women in Denmark. This was significantly higher than in Sweden where the 
incidence declined by 2.3% in men and 1.8% in women per year between 1991 and 1998. 
Analyses based on the National AMI Register in Sweden^^ showed that between 1987 and 
1995, the age-standardised attack rate of AMI declined by 11% for men and 10% for 
women. Attack rates include all AMI discharges (principal or secondary coding) or AMI 
deaths, and a recurrent AMI after 28 days was included as a new event. The attack rate 
decreased more in younger than in older people and the magnitude of this decline was 
much greater in younger men than in younger women. The incidence of first AMI in 
Stockholm County, Sweden^^ declined between 1984 and 1996 in both men and women. 
The average yearly decline of first AMI was 2% in men and 1.4% in women. The decline 
was seen in all ages above 44 years in men and above 54 years in women.
In the Worcester Heart Attack Study^^, the incidence of first AMI in Worcester, 
Massachusetts decreased by 25% between 1975 and 1995. Temporal trends however show 
an increase initially in age-adjusted incidence rates between 1975 and 1981 after which 
time these rates declined through 1990 and then slightly increased after this period up to 
1995. In the Minnesota Heart Survey^^ AMI discharges for the years 1985, 1990 and 1995 
were identified from discharge diagnoses from the Twin Cities metropolitan area hospitals 
and then validated. The rate of all AMI hospital discharges, declined by almost 20%, 
between 1985 and 1995.
24
The incidence of AMI in Perth, Western Australia, declined by 24% in men and 37% in 
women between 1971 and 1982.^  ^ Fatal and non-fatal AMI were included using MONICA 
definitions.
The Atherosclerosis Risk in Communities (ARIC) Study^^ showed that the age-adjusted 
rate of first hospitalised AMI remained relatively stable between 1987 and 1996 in four US 
communities. These results differed from MONICA although the study was carried out at 
the same time and in association with MONICA. Possible explanations may include use of 
different age groups and diagnostic criteria in the two s tudies . In  ARIC there was a 
modest decline in attack rates of recurrent hospitalised AML Between 1986 and 1996, all 
AMI discharges and all death records with CHD listed as the cause of death among New 
Jersey residents >15 years were analysed.®^ Both first and recurrent events are included in 
the analysis. The age-adjusted rate for AMI hospitalisation remained stable, whereas the 
out-of-hospital death rate increased. There was a non-significant mean annual decline in 
age-adjusted rates of hospitalisation for AMI of 0.8% between 1988 and 1997 using data 
from the National Hospital Discharge S u r v e y I n  NHANES Epidemiologic Follow-up 
Study^^, between 1971-1982 and 1982-1992, age standardised incidence of fatal and non- 
fatal AMI increased slightly however this did not reach statistical significance. In a 
community surveillance study of all AMI from the Pee Dee area of South Carolina, US^^, 
there was a 22.7% reduction in period prevalence of AMI (including hospitalisations and 
out-of-hospital deaths) from 1978 to 1985 in individuals aged 35 to 74 years. Period 
prevalence was defined as a first AMI within one year or an out-of-hospital AMI death. 
The Oxford myocardial infarction incidence study^\ reported a non-significant decline in 
non-fatal, definite, AMI in men and a non-significant increase in women. Between 1966-7 
and 1994-5 when out of hospital deaths were included, there was a decline in both sexes 
over the time period, however this only reached significance in men. In Olmsted County, 
Minnesota‘S^ between 1979 and 1994 the incidence of hospitalised infarction increased in 
women but decreased slightly in men. The incidence of AMI increased over time in older 
persons compared to younger persons.
In summary the incidence of AMI is higher in men than in women and the majority of 
studies have reported a decrease in the incidence of AMI over time especially in men. 
Changes in prevalence of known coronary risk factors in the population are most probably 
responsible for this change. Whilst improved medical intervention and secondary 
prevention are factors in the reduction of recurrent events.
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1.2.2 Acute myocardial infarction morbidity
1.2.2.1 Re-infarction
The Framingham Heait Study showed a second AMI rate of 6% at one year following a Q 
wave AMI and 13% following a non-Q wave AMl'^ whilst Gilpin et al reported a one year 
recurrent AMI rate of 6.7%'^. As expected, patients with a second AMI were older (3 years 
on average) and had more cardiovascular risk factors (e.g. diabetes and hypertension), 
presumably demonstrating the potential of these factors to increase the likelihood of a 
recurrent event. Patients with a second AMI also had more cardiovasculai* co-morbidity, 
probably reflecting the consequences of greater cardiac injury. For example, these patients 
had more atrial fibrillation and a particularly notable excess of heart failure, hi addition, 
individuals with a recurrent AMI had more non-cardiovascular co-morbidity, presumably 
reflecting common aetiological factors (e.g. COPD in relation to smoking) and the older 
age of these patients.
1.2.2.2 Heart Failure
Following an AMI heart failure can occur due to left ventricular systolic dysfunction as a 
consequence of myocardial damage. In the Yorkshire AMI Study, 9% of men and 11% of 
women hospitalised with AMI (either first or recurrent) had a previous history of heart 
f a i l u r e . I n  the Northern Sweden MONICA Project, 6.5% of men and 7.6% of women 
aged 35-64 years hospitalised with an AMI, had a clinical diagnosis of heart failure at the 
time of d i scharge. In  the Goteborg Study, 18% of men and 29% of women with AMI had 
a history of congestive heart failure.^^In the REGICOR Study 8% of men and 19% of 
women hospitalised with a first AMI in Spain had a history of heart failure. The 
prevalence increased substantially with age in both sexes. The National Registry of 
Myocardial Infarction 2^  ^was a prospective observational study of patients admitted to 
participating hospitals in the US with an AMI. Data was collected on 384,878 men and 
women admitted to hospital with an AMI between 1994 and 1998. 13% of men and 21% of 
women had a history of heart failure. In the Alberta Health and Wellness database, 26% of 
women and 17% of men had a diagnosis of previous heart failure on their discharge 
record.^^
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1.2.3 Acute myocardial infarction mortality
1.2.3.1 Short-term survival of patients with acute myocardial infarction
Short term survival following AMI has been reported in many studies (Table 7). 
Comparison between different studies is difficult as some studies do not distinguish 
between first and recurrent AMI and age specific rates are not always reported. In addition 
some studies use 28 or 30 day survival end-points where as others use in-hospital survival 
as a proxy for short term survival.
In the UK the Oxford Myocai'dial Infarction Incidence Study^^ carried out between 1994- 
95 the 28 day case fatality for hospitalised AMI was 12.2% in men and 14% in women 
aged <65 years. If out-of-hospital deaths from AMI were included 28 day case fatality rose 
to 38.6% in men and 36.1% in women.
A number of European studies have examined short term survival after an AMI. In the 
REGICOR Studyunadjusted 28 day case fatality after a Q wave AMI was 18.8% in 
women and 9.3% in men aged <75 years. Between 1989 and 1995, definite AMI was 
monitored in people aged 35-64 years in nine hospitals in Northern Sweden as part of the 
Northern Sweden MONICA Project. '^'  ^A definite AMI was identified in 2,483 men and 
669 women. Pre-hospital case-fatality was significantly higher in men (24.1 vs. 19.3%) but 
in patients treated in hospital, the case-fatality was significantly lower in men (12.7% vs. 
21.2% respectively). Between 1987 and 1995 crude case fatality was 22.6% in men and 
27.5% in women aged 30 to 89 years hospitalised with a first or recurrent AMI using data 
from the Swedish National Acute Myocardial Infarction Register.^^ After adjusting for age 
women were less likely than men to die at 28 days (odds ratio 0.98; 95% Cl 0.96-1.00). In 
the MONICA Bremen Study^^, 2273 German men and women aged 25-69 years with an 
admission for a first AMI were identified. The unadjusted 28 day case fatality rate was 
23.1% in women and 16.1% in men. Adjusting for the older age of women did not 
eliminate the difference in case-fatality between men and women completely. The in- 
hospital case-fatality rate of 921 individuals admitted to a single hospital in Goteborg^^ 
with AMI, was 12% in men and 19% in women (p<0.01). Women were older than men (76 
vs. 69 years). In a multivariable analysis, female sex did not appear as an independent risk 
factor for death.
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In the National Registry of Myocardial Infarction 2^  ^in-hospital case fatality was 16.7% in 
women and 11.5% in men in participating hospitals across the US between 1994 and 1998. 
Similarly in another US study, using data from the National Hospital Discharge Survey^^, 
in-hospital case fatality in individuals aged >35 years between 1988 and 1997 was 11.1%. 
Case fatality was higher among women than men in all age groups except in those above 
age 85 years. Using the resources of the Rochester Epidemiology Project*^ ,^ case fatality 
rates for first hospitalised AMI in Olmsted County, Minnesota were examined. In 1994, 28 
day case fatality rates were 7% in men and 15% in women. In the Minnesota Heart 
Survey^^ in 1990, age adjusted 28 day case fatality was 10% in men and 12% in women in 
the Twin Cities of Minneapolis and St. Paul. The Myocardial Infarction Triage and 
Intervention (MITI) registry database^^ contains information on 4255 women and 8076 
men who developed an AMI in 19 Seattle, Washington area hospitals between 1988 and 
1994. In-hospital case fatality was 13.7% in women and 7.8% in men. After adjusting for 
age women were 20% more likely to die in hospital than men. The EPESE Study^' was a 
prospective cohort study of 2182 individuals aged >65 years who were living in New 
Haven, Connecticut in 1982. Over the next 10 years 223 individuals were hospitalised with 
an AMI. Overall 30 day case fatality did not differ significantly between men (25.0%) and 
women (21.4%). The Worcester Heart Attack Studyexamined survival in 3,148 patients 
hospitalised with a first AMI between 1975 and 1988. The age adjusted in-hospital case 
fatality rates were 17.9% in women and 15.2% in men.
30
BI■cc«s
a£1iI
0£CI
£>>
C/3
£Z
H
? S'
V \0
'Û .5
VO 00II
V -E
Z 3
ItII
II o  < I I IÔ: % < X i £ U ÜLu  < q: <o: ^ £
"O
œ O
CA .3
oc
z o
1.2.3.2 Trends in short-term survival following acute myocardial infarction
Trends in short-term survival following an AMI are shown in Table 8. Whilst it is 
postulated that changes in the incidence of AMI are driven by changes in known coronary 
risk factors^^ it is thought that changes in survival rates are determined by changes in 
medical care (improvements in the immediate management of an AMI and improvements 
in secondary prevention). Comparison between different studies is hindered by differences 
in methodology. Many of the studies do not distinguish between first and subsequent AMI. 
Many studies including the MONICA studies have included out-of-hospital deaths in their 
analysis. Not all studies have adjusted for prognostic factors which may influence changes 
in survival over time.
Using routine data in Scotland, 117,718 patients admitted to hospital in Scotland with a 
first AMI between 1986 and 1995 were ident i f ied.Over  the time period 30 day case- 
fatality fell by 46% in men and 21% in women after multivariable adjustment, hi the 
Oxford myocardial infarction incidence study^^ there was also a significant reduction in 30 
day case-fatality between 1966-7 and 1994-5 in both sexes however the decline was 
greater in women (53%) compaied to men (43%).
Other European studies have also demonstrated a reduction in short-term case fatality 
following AMI. Using routine data Abildstrom et al^  ^ showed a significant reduction in 28 
day case-fatality following an AMI hospitalisation in men and women, in different age 
groups, in Denmark (1978-98) and in Sweden (1987-98). Deaths occurring on the day of 
the infarct were excluded, hnprovements in short-term survival following an AMI have 
also been reported by two other Swedish studies up to 1995.^^’^ "^ The National AMI 
Register in Sweden^^ examined case-fatality in all 303,324 Swedes with an AMI admission 
or death between 1987 and 1995. Age standardised 28 day case-fatality declined from 49% 
to 45% in men and from 45% to 42% in women. The improvement in short-term case 
fatality was even more marked for patients alive on admission i.e. from 30 to 23% in men 
and from 28 to 23% in women, hi the Northern Sweden MONICA Project^"  ^over the 
period 1989 to 1995, age standardised 28 day case fatality following an admission with an 
AMI declined significantly in both men and women. The Toulouse-MONICA Study^° 
showed a significant decline in 28 day case-fatality following a first AMI between 1985 
and 1993 however like many of the MONICA studies deaths in individuals who die before 
reaching hospital with an AMI were included.
32
In-hospital case-fatality for all AMI in the Worcester Heart Attack S t u d y w a s  19.9% in 
1975 and 12.0% in 2001 (p value for trend <0.001). After controlling for age and sex there 
was a 63% decline in case-fatality during the 25 year period. The National Hospital 
Discharge Survey^^ also demonstrated a significant decline in in-hospital case fatality 
following AMI. Age adjusted in-hospital case fatality decreased by neai'ly half, from 7.6% 
inl988 to 3.9% in 1997. The average annual percentage decline was significantly higher 
among older patients in both men and women. In the Ontario Myocardial Infarction 
Database^* ,^ there was a modest improvement in short term survival after an AMI in 89,456 
individuals hospitalised between 1992 and 1996. The 30-day risk-adjusted case fatality rate 
declined from 15.5% in 1992 to 14.0% in 1996. hi New Jersey, between 1986 and 1996, 30 
day case fatality after an AMI admission decreased by 17.3%.^° The Minnesota Heart 
Survey^^ demonstrated an improvement in short term case fatality in men and women. 
Between 1985 and 1990 there was a 26% reduction in 28-day case fatality in men and a 
16% reduction in women. In the ARIC Study*^ "^ , between 1987 and 1994, age-adjusted 28 
day case fatality rate fell by 4.1% per year in men and 9.8% per year in women. This 
decline was statistically significant only among women. In contrast the Rochester 
Epidemiology Project^^, demonstrated no significant temporal trend in 28 day case-fatality 
rates for AMI. Unadjusted case fatality rates for first AMI in men were 10% in 1979 and 
7% in 1994 (14% and 15% respectively in women). The case-fatality rate decreased over 
time in persons younger than 75 years of age, but did not change in persons 75 years of age 
or older.
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1.2.3.3 Longer term survival of patients with acute myocardial infarction
Table 9 shows studies examining the longer term prognosis following AML The 
REGICOR S tudyexam ined  the risk of death in individuals aged 25-74 years who were 
admitted to a tertiary hospital in Gerona, Spain with a first AMI between 1978 and 1997. 
Unadjusted three year case fatality in those who had survived the first 30 days was 12%. 
Women had a worse three yeai' case-fatality compared to men (21.8% versus 10.3%). 
Another European study using the Helsinki Coronary Registry^^ included information on 
388 men and 178 women with a first AMI between 1970 and 1971. Among 28 day 
survivors, age adjusted five year case fatality was 17.3% in women and 26.3% in men.
The Alberta Health and Wellness databases^^ examined longer-term case-fatality in 7,158 
women and 15,809 men admitted to hospital following an AMI between 1993 and 2000 in 
the Western Canadian province of Alberta. Five year crude case fatality was 38.8% in 
women and 26.8% in men.
In the Worcester Heart Attack Study^^, two year case fatality rate in persons hospitalised 
with a confirmed AMI between 1975 and 1995 in Worcester, Massachusetts, was 28.9% in 
women and 19.6% in men. Similarly, two yeai* case fatality was 20% in men and 29% in 
women hospitalised with an AMI from the MITI Registry in Washington.^^ In the 
Minnesota Heart Survey^^, three year- age-adjusted case fatality following a first AMI was 
18% in men and 24% in women aged 30 to 74 years in 1990.
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1.2.3.4 Trends in longer term survival following AMI
There are few studies describing trends in longer term case fatality following AMI (Table 
10). In Scotland, 5 year case-fatality fell from 52.3% in 1985 to 46.3% in 1991.^^ The 
relative risk of death fell by 34% in men and 30% in women using multivariable analysis 
to adjust for age and co-morbidities. In the Minnesota Heart Survey^^ age adjusted three- 
year case fatality after a first AMI declined from 21% to 18% in men and from 29% to 
24% in women between 1985 and 1990, however neither of these falls was statistically 
significant.
In summary in recent years there has been a decrease in the incidence of AMI and a 
decreased occurrence of recurrent coronar y events. In addition case-fatality following an 
AMI has improved. Improvements in primary prevention, the acute management of AMI 
and secondary prevention have contributed to these improvements. To further improve 
mortality however we need to tackle the large proportion of AMI which do not survive to 
reach hospital.
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1.3 Epidemiology of heart failure
1.3.1 Prevalence of heart failure
The prevalence of the clinical syndrome of heart failure in population studies primarily 
comes from two sources. Firstly, studies based on physician records or prescriptions for 
heart failure medications and secondly, cross-sectional or cohort studies where individuals 
are screened for heart failure, hi addition a number of studies have reported on the 
prevalence of left ventricular systolic dysfunction (both symptomatic and asymptomatic) 
and the prevalence of heart failure with preserved systolic function.
1.3.1.1 Population studies based on physician records and prescriptions
The prevalence of heart failure in population studies based on physician records is shown 
in Table 11. The prevalence of heart failure in 211 general practices in England and Wales 
covering 2.6% of the population was examined using the General Practice Research 
Database. Diagnosis and treatment data were recorded by general practitioners 
participating in the General Practice Research Database in the course of their clinical work 
based on clinical judgement or on information given to them by hospital or other medical 
personnel. Diagnostic data were recorded using OXMIS (based on ICD-8) and/or READ 
(based on ICD 9) code terms and submitted to the database on a regular basis. The 
prevalence of heart failure was 1.2% in men and 1.6% in women increasing to 19% in 
those over 85 years in 1998. The morbidity statistics from General Practice also recorded 
diagnostic information from all face-to-face contacts between a General Practitioner or a 
practice nurse and a patient in 60 General Practices in England and Wales during an earlier 
time period, l '^ ' September 1991 to 3F^ August 1992.^ *^  ^Data was entered on a computer in 
the practice using READ codes. The prevalence of heart failure was lower at 0.8% in men 
and 1.0% in women but also increased dramatically with age.
The REACH study was a retrospective study using administrative databases of outpatient 
visits and hospitalisations within the Henry Ford Health S y s t e m . 29,686 patients with 
heart failure were identified between 1989 and 1999. The prevalence in 1999 was 14.5 per
1,000 in men and 14.3 per 1,000 in women. There was an annual increase in prevalence of 
1 per 1,000 in men and 0.9 per 1,000 in women. In the Rochester Epidemiology Project^^^,
40
the overall prevalence of heart failure was 2.1 per 1000 in persons 25 through 74 years of 
age in 1981. Patients who had a diagnosis of heart failure made at an inpatient or outpatient 
visit in Rochester Minnesota were identified and the diagnosis of heart failure confirmed 
through a review of medical records. Again using the resources of the Rochester 
Epidemiology Project’®"^ in 1997 a random sample of 2,042 residents who were at least 45 
years old were identified. Each participant’s medical records were reviewed to see if any 
diagnosis of heart failure had been made and checked to see if the documented clinical 
information fulfilled Eramingham criteria. The overall prevalence of heart failure was 
2.2% increasing to 8.4% in those over 75 years.
There are 4 retrospective studies of heart failure prevalence in the UK, which used drug 
prescriptions as a surrogate for heart failure. Lip et a l reported an overall prevalence of 
heart failure of 24 per 1000 in three GP practices in Birmingham in patients over 40 years 
of age. Mair et al °^  ^reported a prevalence of 80.5 per 1000 among patients over 65 years 
attending 2 general practices in Liverpool in 1994. Clarke et al °^  ^found the prevalence of 
heart failure in six general practices in Nottinghamshire in 1992 was 2.4 per 1000 among 
those under 60 yeais increasing to 32 per 1000 in those over 60 years. Parameshwar et al'^^ 
found the prevalence of heart failure in three general practices in North West London in 
1988 was 0.6 per 1000 among patients under 65 years of age rising to 27.7 per 1000 in 
those over 65 years. In these studies patients were identified through prescriptions for heart 
failure medications (either diuretics alone’° ’^^ °^  or heart failure m e d i c a t i o n a n d  a 
diagnosis of heart failure was confirmed using the clinical case notes. Patients had to 
satisfy one of the four clinical diagnostic criteria: symptomatic response to diuretic 
treatment with evidence of heart disease clinically, on electrocardiogram or on 
echocardiogram; dyspnoea with clinical signs of heart failure on examination; dyspnoea 
with evidence of cardiomegaly or pulmonary oedema on chest X-ray; dyspnoea with left 
ventricular' dysfunction on echocardiogram or left ventriculogram.
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1.3.1.2 Population studies based on clinical criteria
The prevalence of heart failure in cross sectional or cohort studies is shown in Table 12.
The EPICA study* is a cross-sectional observational study where 5,434 individuals 
attending 365 general practitioners in mainland Portugal in 1998 were recruited 
consecutively and stratified by age. Patients with 3 or more points on the Boston 
questionnaire or on any heart failure medication underwent further cardiovascular 
investigations and heart failure cases were identified according to the Guidelines of the 
European Society of Cardiology. The prevalence of heart failure in subjects over 25 years 
of age was 4.4% and increased to 7.6% in subjects aged 60-69 years. The presence of heart 
failure in 5,540 participants of the Rotterdam Study'** which took place between 1990 and 
1993 was determined by assessment of symptoms and signs and use of heart failure 
medications. In this population based cohort study the prevalence of heart failure was 39 
per 1000 in subjects aged 55-94 years. In 1990-91, 501 randomly selected individuals in 
Helsinki born in 1904, 1909 and 1914 were examined clinically and with cardiac 
ultrasound as part of the Helsinki Ageing Study.* *^  Heart failure was diagnosed by criteria 
based on symptoms, clinical examination and chest radiography. The prevalence of heart 
failure was 8.2% in men and women aged 75-86 years. In the study of men born in 1913** ,^ 
a sample of 973 men, 50 years old, born in Goteborg, Sweden, were initially identified in 
1963 and followed for 17 years. Heart failure diagnosis was based on a scoring system 
which included dyspnoea, cardiac disease, heart failure treatment or death from heart 
failure. The prevalence of ‘manifest’ heart failure was 2.1% at 50 years, 4.3% at 60 year 
and 13% at 67 years, hi another Swedish population study*'"* the prevalence of heart failure 
diagnosed on clinical history, examination and chest X-ray, was 11-17% in men and 8- 
11% in women aged 70-75 years. In an earlier study of a random sample of 476 persons 
over 62 years of age from Sheffield, England the prevalence of heart failure was 3% 
increasing to 5% if hypertensive heart disease was included.**^
In the US in the Cardiovascular Health Study^^, 5,201 individuals aged 65 years and older 
underwent baseline screening in 1989-90. Self report of heait failure required confirmation 
by the use of heart failure medications or a physician diagnosis of heart failure or a heart 
failure discharge diagnosis. The overall prevalence of heart failure was 2.0% in those >65 
years and 2.6% in those >85 years which is much lower than other studies. The 
discrepancy could be a consequence of healthy participant bias that resulted in a healthier 
than average study sample. 687 predominantly African-American participants were added 
to the Cardiovascular Health Study in 1992. In 1994-95 clinic visit (n=4,942)
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echocardiograms were recorded along with examinations and interviews."^ The prevalence 
of heait failure was 8.8% (mean age 11 ± 5  years). The prevalence of heart failure 
increased even in the very old age range and this was particularly striking in women in 
whom it increased more than twofold from 6.6% at age 65-69 to 14% at age >85 years.
The authors do not address why the prevalence is so different between these two studies -  
the later time period and the inclusion of African-American participants are unlikely to 
explain the huge discrepancies. In the Framingham Study' during the 1980s, among 
individuals aged > 45 years, the age-adjusted prevalence of heart failure was 2.4% in men 
and 2.5% in women. Using data collected from the National Health and Nutrition 
Examination Survey"^ (NHANES-1, 1971-1975) the prevalence of heart failure was 20 
per 1000 in subjects under 74 years based on self reporting and a clinical scoring system.
In an earlier survey of residents of Evans County, Georgia, US the prevalence of heart 
failure was 21 per 1000 in persons aged 45-74 years.
The prevalence of heart failure varies substantially between the various studies and this 
could be due to the different diagnostic criteria and the different age groups studied, hr 
most of these studies heart failure was diagnosed clinically and no objective evidence of 
left ventricular dysfunction, apart from chest X-ray, was obtained.
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1.3.1.3 Prevalence of left ventricular systolic dysfunction based on 
echocardiograpliic surveys
In the UK in the Echocardiographic Heart of England Screening s t u d y ' 3960 patients 
aged 45 years and older from primary care practices in the West Midlands region of 
England were assessed by history, examination, electrocardiography and echocardiography 
between 1995 and 1999.(Table 13) The prevalence of left ventricular systolic dysfunction 
defined as an ejection fraction <40% was 2,9% in men and 0.7% in women increasing to 
3.6% in those aged over 75 years. 58% of patients with heart failure had preserved systolic 
function and 47% of patients with left ventricular systolic dysfunction were asymptomatic, 
hi the Glasgow s t u d y 1,640 persons aged 25-74 yeai's who had taken part in the Glasgow 
MONICA study were assessed with questionnaires, electrocardiography and 
echocardiography. The prevalence of definite left ventricular systolic dysfunction defined 
as a left ventricular ejection fraction <30% was 2.9%, was higher in men than in women 
(4.0% versus 2.0%) and increased with age. If participants with an ejection fraction of 
<35% were included the prevalence was 7.7%. The prevalence of asymptomatic left 
ventricular systolic dysfunction was 1.4%. In another UK study, 817 elderly patients aged 
70-84 years, from a four centre group general practice in Poole Dorset underwent 
echocardiographic qualitative assessment of left ventriculai* systolic f u n c t i o n . T h e  
overall prevalence of left ventricular systolic dysfunction was 7.5% and was higher in men 
than in women (12.8% versus 2.9%). Prevalence was more than twice as high at age > 80 
than at ages 70-74 years (20.5% in men and 5.4% in women).
A random sample of 433 men and women aged 75 years from the city of Vasteras, Sweden 
were assessed by a single physician for the presence or absence of heart failure using 
clinical history, examination and electrocardiogram.'^^ All patients underwent an 
echocardiogram to which the physician was blinded. The prevalence of left ventricular 
systolic dysfunction (defined as an ejeetion fraction <43% or a wall motion index <1.7) 
was 6.8%. The prevalence of left ventricular systolic dysfunction was significantly higher 
in men (10.2%) than in women (3.4%). 46% of patients with left ventricular systolic 
dysfunction were asymptomatic and 46% of patients with heart failure had preserved left 
ventricular function, hi the EPICA study'"' the prevalence of heart failure due to systolic 
dysfunction was 1.3% and the prevalence of heart failure with normal systolic function was 
1.7%. A higher proportion of women (2.4%) than men (0.9%) had preserved systolic 
function and a higher proportion of men than women had systolic dysfunction (1.9% 
versus 0.8%). In the Rotterdam study'" the prevalence of left ventriculai’ systolic
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dysfunction (fractional shortening >25%) was 2.5 times higher in men than in women 
(5.5% versus 2.2%) however in contrast with other studies the prevalence did not increase 
with age. 60% of persons with left ventricular systolic dysfunction were asymptomatic. In 
a cross sectional survey of a random sample of 2158 patients > 50 years from three general 
practices in Copenhagen, Denmark, 357 patients with definite or suspected heart disease 
were identified through review of case notes and questionnaires and an echocardiogram 
was performed in 126 of these patients.'^"* The prevalence of left ventricular systolic 
dysfunction was 2.9%. 34% of patients with left ventricular systolic dysfunction were 
asymptomatic and 56% of patients with heart failure had preserved systolic function. The 
prevalence of left ventricular systolic dysfunction was 11.3% in elderly persons in the 
Helsinki Ageing Study"^ and 51% of patients had heart failure with preserved systolic 
function.
hi the Rochester Epidemiology Project"*"* the prevalence of left ventricular systolic 
dysfunction was 2.0% in individuals > 45 years and 4.4% in those > 75 years. 44% of 
patients with left ventricular systolic dysfunction were asymptomatic and 55% of patients 
with heart failure had preserved left ventricular function. In the Cardiovascular Health 
Study* 42% of men and 67% of women with heart failure had normal left ventricular 
function (ejection fraction >55%) and 80% had normal or mildly reduced left ventricular 
systolic function (ejection fraction >45%).
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1.3.2 Incidence of heart failure
In the UK, two general practitioner studies have reported on the incidence of heait failure. 
(Table 14) Cowie et al’^  ^ identified new cases of heart failure from a population of 151,000 
served by 82 general practitioners in Hillingdon, West London through surveillance of 
acute hospital admissions and through a rapid access clinic to which general practitioners 
referred all new cases of suspected heai’t failure. The diagnosis of heart failure was 
confirmed by a panel of three cardiologists on the basis of clinical assessment, 
electrocardiography, chest X-ray and echocardiogram. The incidence of heart failure was
1.3 cases per 1,000 population per year for those over 25 years and was higher in men (1.4 
per 1,000 person years) than in women (1.2 per 1,000 person years). The incidence 
increased from 0.02 cases per 1,000 population per year in those aged 25-34 years to 11.6 
in those aged 85 years and over. The incidence of heart failure for the year 1996 in 
individuals 40-84 years using the General Practice Research Database^was  4.2 per 1,000 
person-years (4.4 in men and 3.9 in women). Heart failure cases were identified from the 
database and for a random sample of 1,200 patients a questionnaire was sent to the general 
practitioner to confirm the diagnosis of an incident case of heart failure. The lower 
incidence in the Hillingdon study in similar age groups presumably reflected the difference 
in the criteria for case definition used in the two studies.
In the Study of men born in 1913*’^  the incidence of ‘manifest’ heart failure was 1.5, 4.3 
and 10.2 per 1,000 person years in men aged 50-54 years, 55-60 years and 61-67 years 
respectively. In a population based surveillance study from four rural communities in 
Eastern F i n l a n d t h e  incidence of heart failure was 4 per 1,000 per year in men and 1 per
1,000 per year in women increasing to 8 per 1,000 person per year in those over 65 years.
In the REACH s t u d y t h e  incidence of heart failure in 1999 was 3.7 per 1,000 in men 
and 4.2 per 1,000 in women of all ages. Incidence rates were higher in men and African 
Americans across all age groups. There were no secular trends from 1989-1999. The 
annual incidence during the 1980s in the Framingham s tudy*among persons >45 years 
was 7.2 cases/1,000 in men and 4.7 cases/1,000 in women. In a more recent analysis of the 
Framingham data*^ ® the incidence of heat failure was examined in four periods 1950-69, 
1970-79, 1980-89 and 1990-99. As compared with the rate for the period from 1950 
through 1969, the incidence of heart failure remained virtually unehanged among men in 
the three subsequent periods but declined by 31% to 40% among women (rate ratio for the
50
period from 1990 through 1999, 0.69). Using the resources of the Roehester Epidemiology 
P r o j e c t t h e  incidence of heart failure was 2.8 per 1,000 in 1981 and 1991. The incidence 
was higher in men than in women and increased with dramatically with age to 60 per 1,000 
person years in those over 79 years. There was no difference in incidence rates between the 
1981 and 1991 cohorts.
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1.3.3 Heart failure morbidity
1.3.3.1 Hospitalisations for heart failure
Rates of hospitalisations for heart failure have been increasing in recent years 
In the Leicestershire s t u d y b e t w e e n  1993/94 and 2000/01, rates of first hospitalisations 
for heart failure increased by 62% from 29 to 47/10,000 population. Record linked 
discharge and mortality data were used to identify 12,220 residents aged >40 years who 
were admitted for a first heart failure in any coding position to any of the hospitals serving 
the population of Leicestershire, England. In Scot land^us ing routine data, the number of 
hospitalisations with a principal diagnosis of heart failure increased by 16% in men and 
12% in women between 1990 and 1996. The highest numbers of hospitalisations for heart 
failure were recorded in 1993 for men and 1994 in women suggesting that the epidemic of 
increasing rates of hospitalisations for heart failure seems to have peaked.
Using the Swedish Hospital Dischaige R e g i s t r y ' 156,919 hospital discharges with heart 
failure in men and women aged 45-84 years from 19 Swedish counties (population 2.9 
million) were identified between 1988 and 2000. Hospitalisations for heart failure 
increased until 1993 in both men and women and in all age groups, after which a yearly 
decrease in hospitalisations was observed. In 2000, 24 men and 17 women per 10,000 
inhabitants were discharged with heart failure. In the Netherlands'^^, from 1980 to 1993 
age adjusted discharge rates with a principal diagnosis of heart failure rose by 48% for men 
and 40% for women.
In the US, in the Medicare population'^"', patients over 65 years with an initial hospital 
admission for heart failure in 1986 (n=631,306) and 1993 (n=803,506) were identified. An 
initial hospital admission for heart failure was defined as no prior admission for heart 
failure in the previous two years. Age standardised hospitalisation rates for any diagnosis 
of heart failure were higher in 1993 compared to 1986. The number of hospitalisations for 
heart failure in patients over 35 years between 1995 and 1995 were estimated from the 
National Hospital Discharge S u r v e y . T h e  number of hospitalisations for heart failure 
increased by 49.1% in men and 52.5% in women between 1985 and 1995. Almost 78% of 
men and 85% of women hospitalised with heart failure were >65 years.
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Trends in admissions to hospital in Montreal, Canada 'be tween 1990 and 1997, were 
examined for individuals aged 65 years or greater. The annual rate of admission to hospital 
for heart failure increased from 92 per 10,000 population in 1990/91 to 124 per 10,000 
population in 1997/98.
1.3.3.2 Quality of life
Heart failure impairs self-reported quality of life more so than any other common chronic 
medical condition.
1.3.3.3 Other morbidity
Patients with heart failure have an increased risk of myocardial infarction (as a 
consequence of an ischaemic aetiology), atrial fibrillation and consequently stroke.
1.3,4 Heart failure mortality
1.3.4.1 Prognosis of heart failure in community based stndies
Table 15 shows the prognosis of heait failure in community based studies from Europe, 
Canada and US. The IN-CHE registry'"" prospectively collected information on 3327 
outpatients with heart failure refeiTed to 133 cardiology centres throughout Italy between 
1995 and 1998. One yeai* case fatality was 16.3% and was significantly higher in patients 
over 70 years (22% versus 13.7%). Age was an independent predictor of 1 -year case 
fatality, increasing by 2.8% for each year of age. In the Helsinki Ageing S t u d y " i n  1990, 
46% of individuals aged 75-86 with heart failure died within 4 years. This corresponded to 
an age and sex adjusted relative risk of all-cause mortality of 2.1.
In a study using death certificate data from Quebec, Canada ' dea t h  rates from heart 
failure was 10.4-10.6 per 10,000 population >65 years between 1990 and 1997, and 
increased with age.
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Using the resources of the Rochester Epidemiology Project^^ 4537 Olmsted County 
residents with a diagnosis of heart failure between 1979 and 2000 were identified and a 
sample was validated using clinical and Framingham criteria. Case-fatality at 30 days, 1 
year and 5 years was 6%, 21% and 50% respectively in men and 4%, 17% and 46% 
respectively in women. The case-fatality in patients with heart failure at 30 days, 1 year 
and 5 years in the Framingham 1990-99 c o h o r t w a s  11%, 28% and 59% in men and 
10%, 24% and 45% in women respectively. The Framingham cohort was slightly older 
than Rochester (mean age 80 years versus 74). In both these studies men had a higher age 
adjusted risk of death than women. In NHANES I (1971-1975)"^, the 10 year case-fatality 
was 49.8% for men and 36.0% for women aged 25-74 yeai's with heart failure.
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1.3.4.2 Prognosis of patients hospitalised with heart failure
Hospital based studies reporting the prognosis of heart failure is shown in Table 16. 
hi the Leicestershire s t u d y ' o n e  and five year case fatality following a first hospitalisation 
for heart failure, between 1993 and 2001, was 43% and 73% respectively. There was a 43- 
45% increase in risk of death for each decade of age at admission and a 14-17% increase 
associated with male sex. One and four month case fatality was higher in patients with 
heart failure associated with an acute myocardial infarction. All patients admitted to 
hospital in Scotland with a principal diagnosis of heart failure between 1986 and 1995 
were examined.'"'^ Crude case fatality rates at 30 days, 1 year and 5 yeai's were 19.9%, 
44.5% and 76.5%. Median survival was 1.47 years in men and 1.39 years in women.
In Sweden one year case fatality following a first hospitalisation with heart failure, 
between 1988-2000, was 9% in men and 8% in women aged 45-54 years, increasing to 
35% in men and 30% in women aged 75-84 y e a r s . h r  the Multifactor Primary Prevention 
study'"'"', a random population sample of 7495 men were examined in 1970-73 and 
followed until 1996. 937 men were hospitalised for heart failure during the 27 years of 
follow-up. A diagnosis of heart failure increased the risk of death by more than eight times. 
In another earlier study from Western Sweden'"'^, all hospital records of patients with heart 
failure aged 16-65 years between 1980 and 1987, were examined in all hospitals in the 
region. The five year case fatality rate was 50%. All heart failure cases (principal or 
secondary diagnosis; first or recurrent admission) admitted to hospital in Lombardy, Italy 
were identified using a database of hospital records.'""^ hi-hospital case fatality was 10.9% 
in 1997 and was lower in women than in men and increased with age. In the 
Netherlands'^^, 15.3% of all patients with a principal discharge diagnosis of heart failure in 
1993 died in hospital. In-hospital case fatality was higher in men than in women in all age 
groups.
Crude 30-day and 1-year case-fatality rates after first admissions for heart failure were
11.6% and 33.1% respectively in Ontario, Canada between 1994 and 1 9 9 7 . Case-fatality 
rates increased with age. Patients >75 years were 4 times more likely to die at 30 days and 
one yeai* compared to those aged 20-49 years. After adjusting for age men showed a higher 
30 day and one year case fatality rate than women.
Medicare patients hospitalised with a first admission for heart failure at 29 Northeast Ohio 
Hospitals were identified between 1991 and 1997."^ Crude 30 day and 1-year case fatality
57
rates were 8.6% and 36.5% respectively. In the Post-Acute Care s t u d y i n  519 Medicare 
patients, aged >65 years, from Minneapolis, Pittsburgh and Houston, who were discharged 
alive after a hospitalisation for heart failure during 1988 and 1999, 1 year case fatality was 
higher in men (48%) than in women (35%). In an earlier study of first heart failure 
hospitalisations of a national cohort of Medicai'e patients aged >67yeai's'^° only 19% of 
black men, 16% of white men, 25% of black women and 23% of white women survived 6 
years.
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1.3.4.3 Trends in survival of patients with heart failure
In the Leicestershire s t u d y b e t w e e n  1993/94 and 2000/01 there was a 35% reduction in 
the adjusted risk of death and a 50% reduction in the risk of cardiovascular death.(Table 
17) In Scotland^"^ ,^ 30 day case-fatality rates fell between 1986 and 1995 by 26% in men 
and 17% in women. Longer term ease-fatality rates fell by 18% in men and 14% in 
women.
In Sweden 30 day and 1 year case fatality following a heart failure hospitalisation 
decreased between 1988 and 2000 in both men and w o m e n . T h e  decrease was more 
pronounced in the younger age groups. There was a yearly decrease in one year case 
fatality of 9% in men and 10% in women aged 45-54 years and 4% in men and 5% in 
women aged 75-84 years. In the N e t h e r l a n d s a g e  adjusted in-hospital case fatality 
decreased from 19.9% in 1980 to 15.5% in 1993 in men and from 17.8% to 14.9% in 
women.
In Ontario, Canada from 1992-2000, there was a 2.8% reduction in age-, sex- and co 
morbidity-adjusted 1 year case fatality but no change in 30 day case fatality.'^' hi 
Montreal, Canada^ between 1990 and 1997, in individuals aged 65 years or more age- 
adjusted case fatality rates did not change significantly. From the IN-CHF reg i s t ry^o f  
outpatients with heart failure in Italy, there was a 30% increased adjusted risk of death in 
1995 compared to 1999.
Using the resources of the Rochester Epidemiology Project*^ ,^ age adjusted 5-year survival 
after heart failure diagnosis improved over time from 43% in 1979-84 to 52% in 1996- 
2000. There were age and sex differences in the degree of improvement in survival. 
Survival improved more in younger men than older men. In women survival improved in 
younger women but to a lesser extent than men and did not change in older age groups. In 
the Framingham study’ the 30 day, 1-year, and 5-year age-adjusted case fatality rates 
among men declined from 12%, 30%, and 70% respectively, in the period from 1950 
through 1969 to 11%, 28% and 59%, respectively, in the period from 1990 through 1999. 
The corresponding rates among women were 18%, 28% and 57% for the period from 1950 
through 1969 and 10%, 24% and 45% for the period from 1990 through 1999. Overall, 
there was an improvement in the survival rate after the onset of heart failure of 12% per 
decade. Among Medicare patients hospitalised with heart failure in Northeast Ohio there
61
was a 15.3% decrease in 30-day case fatality and a 14.6% decrease in 1-year ease fatality
between 1991 and 1997.’"’^
In summary heart failure is a common condition affecting approximately 1 % of the 
population. The prevalence of heart failure increases with age to approximately 10% of the 
population over 75 years of age. Around 50% of patients with heart failure have preserved 
systolic function and 50% of patients with left ventricular systolic dysfunction are 
asymptomatic. Hospitalisations for heart failure are common and have increased over time. 
The prognosis for heart failure is poor however there is evidence that survival has 
improved in recent yeai's.
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1.4 Epidemiology of atrial fibrillation
1.4.1 Prevalence of atrial fibrillation
Atrial fibrillation is the most common sustained cardiac a r r h y t h m i a . ' I t  is estimated 
that 2.2 million adults in the United States have atrial fibrillation.'^^ The prevalence of 
atrial fibrillation is increasing because the population is ageing and survival from 
conditions predisposing to atrial fibrillation (such as coronary heart disease and heart 
failure) is i m p r o v i n g . T h i s  prompted Braunwald in his Shattuck Lecture to refer to 
the growing ‘epidemic’ of atrial fibrillation.'^^
Four UK primary care studies'^^’'^' and one primary care study from the Netherlands"^^ 
have reported the prevalence of atrial fibrillation in recent years. (Table 18) The SAFE trial 
was a multicentred randomised controlled trial involving patients > 65 years from 50 
primary care practices across the West Midlands."^' They were randomised to 25 
interventional practices and 25 control practices. GPs and practice nurses in the 
interventional practices received education on the importance of atrial fibrillation detection 
and BCG interpretation. The overall prevalence of atrial fibrillation was 7.2% and was 
higher in men than in women. The prevalence increased with age to 10.3% in those over 75 
years. Analysis of electronic data from 131 general practices in the UK was performed 
using the DIN-LINK database for the period 1994-2003.'^^ Read codes were used to 
identify patients with atrial fibrillation. All ages prevalence of atrial fibrillation increased 
steadily over time (0.84% in men in 1994 compared to 1.49% in 2003, compared with 
0.83% and 1.29% in women). Prevalence rose steadily with increasing age (13.2% in men 
and 11.0% in women >85 years). The prevalence of atrial fibrillation in 211 general 
practices in England and Wales between 1994 and 1998 was examined using the General 
Practice Reseai'ch D a tab a se .A tria l fibrillation was identified by a clinical diagnosis on 
the practice computer system. The prevalence of atrial fibrillation in all ages in 1998 was 
1.21% in men and 1.27% in women and again increased dramatically with age to 10.6% in 
men and 10.9% in women over 85 years old. Unlike other studies the prevalence of atrial 
fibrillation was similar in men and women. The prevalence of atrial fibrillation increased 
by 22% in men and 14% in women between 1994 and 1998. In another UK primaiy care 
study 4843 older patients, registered with 26 general practices in Northumberland, UK had
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electrocardiographic screening for atrial fibrillation.'^'^ The prevalence of atrial fibrillation 
was 10.0% in men and 5.6% in women >75 years.
In the Netherlands all patients over 60 years attending 10 GP practices were screened for 
the PATAF (primary prevention of arterial thromboembolism in patients with atrial 
fibrillation) s t u d y . P a t i e n t s  with atrial fibrillation were identified by an irregular pulse 
on examination followed by an EGG. Medical records were also searched for patients with 
atrial fibrillation. The prevalence of atrial fibrillation in those 60 years and over was 5.1% 
and in those 80 years and over was 10.0%. The prevalence was higher in men than in 
women in all ages.
In a study from the US the prevalence of atrial fibrillation was 0.95% in an adult cohort 
over 19 years and 9% in those >80 years who received care within Kaiser Permanente of 
Northern California, a large group-model health maintenance organisation.'^^ As with most 
other studies the prevalence of atrial fibrillation was greater in men than in women. To 
identify patients with atrial fibrillation, as well as searching a clinical database containing 
all ambulatory visits, they also searched an electrocardiographic and hospital discharge 
diagnosis database.
The prevalence of atrial fibrillation has also been reported in a number of large 
E u r o p e a n a n d  US""^"'^' population based cohort studies.
In the Renfrew Paisley s t u d y 15406 men and women aged 45-64 years, living in two 
industrialised towns in the west of Scotland, were screened between 1972 and 1976. The 
prevalence of atrial fibrillation was 0.75% in men and 0.56% in women. In the Reykjavik 
s t u d y 0.27% of a randomly selected population of 9,067 Icelandic individuals aged 32- 
64 years and screened between 1967 and 1970 had chronic atrial fibrillation. This lower 
prevalence is partially explained by the earlier era studied and the younger age group of 
patients included. Three more recent European studies have also reported on the 
prevalence of atrial f i b r i l l a t i o n . I n  the Copenhagen City Heart Study the prevalence 
of atrial fibrillation diagnosed from electrocai'diograms was determined in 8,606 patients 
examined in 1976-1978, in 8,943 patients examined in 1981 to 1983 and in 6,733 subjects 
examined in 1991-1994 aged 50-89 y e a r s . T h e  age-standardised prevalence of atrial 
fibrillation was 3.3% in men and 1.1% in women in 1991-1994. Looking at secular 
changes in prevalence over time the prevalence of atrial fibrillation more than doubled in 
men from the 1970s to the 1990s but remained unchanged in women. A similar prevalence
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in men of 3.3% and a higher prevalence in women of 2.7% were reported in the Rotterdam 
Study of 6,584 individuals’ aged >55 years which also used an electrocardiographic 
diagnosis of atrial fibrillation."^^ In both these studies a diagnosis of atrial fibrillation was 
made on a single ECG recording and therefore may underestimate the presence of 
paroxysmal atrial fibrillation, hi the Multifactor Primaiy Prevention Study the prevalence 
of atrial fibrillation in a random sample of 7,495 men from Goteborg in the age groups 55- 
64, 65-74 and 75-79 years was 1.2, 4.2 and 8.0% respectively."’"' These men were first 
examined in 1970-73 and followed for a mean of 25.2 yeai's. A diagnosis of atrial 
fibrillation was based on a hospital diagnosis of atrial fibrillation, which differs from other 
studies reported here.
A higher prevalence of atrial fibrillation has been reported in three US longitudinal 
population based s t u d i e s . D i f f e r e n c e s  in prevalence could be related to the 
differences in study criteria including inclusion of younger patients in some of the 
European studies, methods of ascertainment, and techniques of age adjustment for the 
estimation of prevalence and geographical variations, hi the Cardiovascular Health Study 
atrial fibrillation was identified in a sample of 5,201 men and women aged >65 years by 
ECG and self-report of a physician diagnosis. The prevalence was 6.2% in men and 4.8% 
in women increasing to 8.0% in men and 6.7% in women over 79 y e a r s . I n  the 
Framingham Study the prevalence of atrial fibrillation was 9.1% in men and 4.7% in 
women aged 65-84 y e a r s . At r i a l  fibrillation was determined by biennial clinical 
examinations and electrocardiograms, and interim hospitalisations. Age adjusted 
prevalence increased in men but not women in the Framingham study. In the Rochester 
Epidemiology Project the prevalence of atrial fibrillation increased significantly in 
ischaemic stroke patients and their controls from 1960 to 1989 in Rochester, Minnesota, 
independent of age and gender. The rate of increase did not differ significantly between 
men and women. In this study age was a potent risk factor for the development of atrial 
fibrillation: each decade of age was associated with a doubling of the odds of atrial 
fibrillation.
The prevalence of atrial fibrillation is higher in patients with clinical cardiovascular 
d i s e a s e . h i  addition cardiovascular risk factors are independent predictors of atrial 
fibrillation.'^^"^^"^"'
The increase in prevalence of atrial fibrillation with advancing age coupled with the 
steadily increasing numbers of persons reaching very old age, most certainly contributes to
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the growing epidemic of atrial fibrillation. Hypertension, coronary artery disease, diabetes 
mellitus and heart failure are among the age-related co-morbid conditions that are likely to 
play a central role in the propagation of the atrial fibrillation epidemic i.e. a significant 
proportion of the elderly population have survived these conditions which in themselves 
are risk factors for the development of atrial fibrillation.
In summary the prevalence of atrial fibrillation is approximately 1.3% increasing 
dramatically with age to approximately 10% in those over 80 years. The prevalence in 
most studies is higher in men than in women however the overall number of female 
patients with atrial fibrillation exceeds the number of men with this condition because of 
greater longevity in women compared with men'^^.The prevalence of atrial fibrillation is 
increasing rapidly in industrialised nations.
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1.4.2 Incidence of atrial fibrillation
In studies examining the incidence of atrial fibrillation there are differences in case 
ascertainment. (Table 19) Several studies have examined the incidence of a first 
hospitalisation for atrial f i b r i l l a t i o n . T h i s  may potentially underestimate the 
incidence of atrial fibrillation as a diagnosis of atrial fibrillation can be made in primary 
care and often does not require hospitalisation.
In a study from Denmark using routine data 131,728 subjects with an incident hospital 
diagnosis (either inpatient or outpatient) of atrial fibrillation or flutter were identified 
between 1980 and 1999.'^^ The incidence of atrial fibrillation was 4.38 per 1000 in 
individuals aged 40-89 years in 1999. The number of subjects with a diagnosis of atrial 
fibrillation more than doubled during the study period in both men and women. Another 
study using hospitalisations for atrial fibrillation to identify incident atrial fibrillation cases 
was the Multifactor Primary Prevention Study. During the 27 years of follow-up the 
incidence of atrial fibrillation in men was 2.0, 5.8 and 17.3 per 1,000 person years in the 
age groups 55-64, 65-74 and 75-79 years r espec t i ve l y . In  the Renfrew-Paisley study 
subjects aged 45-64 years were screened initially between 1972 and 1976 and again 
between 1977 and 1979.'^^ During the 20 year follow up, the rate of incident 
hospitalisation for atrial fibrillation was 1.9 per 1,000 person years. The four-year 
incidence of atrial fibrillation between the first and second screening was also reported and 
this was 0.54 per 1,000 person years.
In a study of all adult residents in Olmsted County, Minnesota between 1980 and 2000, 
atrial fibrillation was identified from medical r e c o r d s . T h e  age and sex adjusted 
incidence of atrial fibrillation was 3.4 per 1,000. There was a relative increase of 12.6% in 
the age adjusted incidence of atrial fibrillation over 21 years.
The General Practice Research Database and the SAFE trial used a general practitioner 
diagnosis of atrial f i b r i l l a t i o n . I n  the SAFE trial the incidence of atrial fibrillation in 
patients over 65 years in the control group was 1.04%, and was higher in women (1.18%) 
than in men (0.85%).'*^* This is higher than the incidence of chronic atrial fibrillation in the
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General Practice Research Database which was 1.7 per 1000 person-years in patients 40-89 
y e a r s . T h e  incidence increased markedly with age from 0.05 per 1,000 among patients 
40-49 years to 8.6 per 1,000 in patients aged 80-89 years. The incidence was lower in 
women especially in younger age.
The incidence of atrial fibrillation has also been reported in several longitudinal population 
studies. The Framingham Study, used electrocai’diograms from biennial visits, hospital 
records and outside physician records to identify patients with atrial fibrillation.’^  ^The 
incidence of atrial fibrillation was 3.1 per 1000 person years in men and 1.9 in women 
aged 55-64 years and the incidence increased with age to 38.0 per 1000 person years in 
men and 31.4 in women aged 85-94 years. Men were 1.5 times more likely to develop 
atrial fibrillation than women even after adjusting for other risk factors for atrial 
fibrillation. The Manitoba Follow-Up Study in Canada examined 3,983 male air crew 
recruits with an average age of 31 years in 1948 and followed them for 44 ye a r s . At r i a l  
fibrillation was identified on electrocardiograms performed at periodic medical 
examinations or if the subject reported contact with a physician. In the Manitoba Follow- 
Up Study in Canada the incidence of atrial fibrillation was 2 per 1,000 patient years. The 
incidence of atrial fibrillation increased with age from less than 0.5 per 1,000 person years 
before age 50 to 2.3 per 1,000 person-yeai's by age 60, and rose further to 16.9 per 1,000 
person-years by age 85. ‘'^ 2;i82;i83 Cardiovascular Health Study atrial fibrillation was
identified from three sources, annual electrocardiography, self reported atrial fibrillation 
and hospital dischaige d i a g n o s i s . Th e  incidence of atrial fibrillation was 26.4 per 1,000 
in men and 14.1 per 1,000 in women 65 years and over. Paroxysmal as well as chronic 
atrial fibrillation was included. The incidence of atrial fibrillation in the Cardiovascular 
Health Study is much higher than other studies. Including self-reported episodes of atrial 
fibrillation and conducting electrocardiographs yearly may partly explain the differences.
In addition the other US studies covered an earlier time period and the incidence and the 
importance of recognition of atrial fibrillation has increased over time. The low incidence 
of atrial fibrillation in the Manitoba Follow-Up Study is paitly explained by a selection 
bias of young healthy fit recruits.
In summary the incidence of atrial fibrillation varies from 1.7-20 per 1,000 person years 
and as with prevalence is higher in men than in women and increases dramatically with 
age.
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1.4.3 Atrial fibrillation morbidity
1.4.3.1 Stroke
Many studies have shown that atrial fibrillation is an independent predictor of stroke.
(Table 20) The relative risk for stroke was 6.9 (3.0, 13.5) in the Whitehall Study and 2.3 
(0.1, 12.7) in the British Regional Heart Study in individuals with atrial fibrillation.’^ '^  In 
the Renfrew-Paisley study women with atrial fibrillation had a higher risk of stroke than 
men.’^  ^Other studies have also shown that women with atrial fibrillation may be more 
likely than men to have a stroke. In a study of all hospitalisations with atrial
fibrillation in Scotland, the total number of strokes associated with atrial fibrillation 
increased between 1986 and 1996.’ *^^
In the Reykjavik Study fatal or non-fatal stroke occurred in 24% of patients with atrial 
fibrillation at the end of the 14-year follow up period compared to 4.3% of controls 
(P<0.05, RR 7.1)."^^ The relative risk of fatal stroke was 12.3 (p<0.05). Atrial fibrillation 
was also a strong predictor of stroke in men in the Multifactor Primary Prevention 
S t u d y . H o w e v e r  in a more recent analysis extending follow-up through 28 years, 
atrial fibrillation was no longer a significant predictor of stroke after 21 years of follow- 
up’^^ .
In the Framingham study atrial fibrillation was a major independent risk factor for embolic 
stroke or transient ischaemic attack and was associated with a 4-5 fold increased risk 
compared to the unaffected p o p u l a t i on . The  attributable risk associated with atrial 
fibrillation increased with age, in contrast to many stroke risk factors where the attributable 
risk of stroke decreases with age. Thus older patients are not only more prone to atrial 
fibrillation but their risk of stroke is considerably increased when compared with younger 
patients with atrial fibrillation.’^ ’ Atrial fibrillation was also a risk factor for stroke in the 
Rochester Epidemiology P r o j e c t a n d  in men in the Manitoba Follow-Up Study’ It was 
significantly associated with stroke in individuals over 65 years in the Cardiovascular 
Health Study’
In the Western Australia study’ the adjusted risk of fatal stroke (HR 3.8) was increased in 
individuals aged > 60 years with atrial fibrillation. In the Dubbo Study of the Elderly’ a 
cohort of 2805 Australian men and women aged >60 years were first examined in 1988
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and followed for 8 years. 306 men and women manifested an ischaemic stroke and atrial 
fibrillation was a significant independent predictor of stroke increasing the risk by 58%.
1.4.3.2 Heart Failure
Atrial fibrillation was an independent predictor of heart failure in women and men in the 
Renfrew-Paisley s t u d y . I n  the Reykjavik Study 36% of patients with atrial fibrillation 
and 2.1% of controls had heart failure at the end of the study period (P<0.001, RR 24.7).’^  ^
In the Multifactor Primary Prevention Study heart failure was also more common in those 
who had atrial fibrillation compar'ed with those without. In this study heart failure 
hospitalisations prior to, during and after the hospitalisation for atrial fibrillation were 
included in the analysis.’ '^’ hi the Manitoba Follow-Up S t u d y m e n  with atrial fibrillation 
had a 2.98 times risk of heart failure.
1.4.3.3 Myocardial infarction
Ischaemic heart disease often precedes atrial fibrillation and is an independent predictor for 
developing AF, In the Renfrew-Paisley s t u d y t h e  Manitoba follow-up study’ and the 
Reykjavik Study the risk of myocardial infarction was not increased following a 
diagnosis of atrial fibrillation. In the Multifactor Primary Prevention Study patients with 
a hospitalisation for atrial fibrillation had an increased risk of hospitalisation for 
myocardial infarction however this included myocardial infarctions prior to, during and 
after the hospitalisation for atrial fibrillation.
1.4.3.4 Hospitalisations for atrial fibrillation
Atrial fibrillation is a common cause of hospitalisation’^ '’ and rates of hospitalisations for 
atrial fibrillation are increasing.’^ ”’’ ’^’’^ "^’^  ^Between 1986 and 1995 the numbers of 
patients admitted to hospital in Scotland with a principal diagnosis of atrial fibrillation for 
the first time increased by 125% in men and 105% in wo me n . Av e r a g e  length of stay 
fell during this period but because of the overall increase in hospitalisations, atrial 
fibrillation contributed to a growing proportion of cardiovascular-related bed-days utilised 
(from 18% to 37% with atrial fibrillation coded in any diagnostic p o sition ).S im ila rly  in 
Denmark between 1980-1993 hospitalisation rates for atrial fibrillation i n c r e a s e d . I n  the 
US, using data from the National Hospital Discharge Survey, hospitalisations for atrial 
fibrillation increased 2-3 fold between 1982 and 1993.'^^
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1.4.3.5 Cost of atrial fibrillation
In the UK in 2000, the cost of atrial fibrillation was 459 million which was equivalent to 
1% of total NHS expenditure.’^^  Hospitalisations for atrial fibrillation are a major 
determinant of the cost.
1.4.3.6 Summary
Atrial fibrillation is an extremely costly public health problem. It is an independent risk 
factor for stroke and heart failure. It is one of the most common causes of hospitalisation 
and hospitalisation rates for atrial fibrillation ai'e increasing.
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1.4.4 Atrial fibrillation mortality
1.4.4.1 Risk of death in patients with atrial fibrillation
The prognosis of individuals with atrial fibrillation has been examined in two distinct 
groups of individuals. (Table 21) Firstly, in cohort studies, atrial fibrillation was identified 
at screening and individuals were followed prospectively for mortality 
outcomes J 177;184;185;199 Secondly, in several studies the prognosis of patients following 
an incident hospitalisation or outpatient encounter for atrial fibrillation was
The mortality rate of subjects aged 55-94 years who developed atrial fibrillation during 40 
year follow-up of the Framingham Heart S t u d y c o h o r t  was approximately twice that of 
age and sex matched controls. After adjustment for cardiovascular risk factors and pre­
existing cardiovascular disease atrial fibrillation was still associated with a significant 
increased risk of death in men (OR 1.5, 95% Cl 1.2, 1.8) and in women (1.9 (1.5, 2.2)). In 
the Manitoba Follow-Up St udy ' a t r i a l  fibrillation increased the total mortality rate 1.31 
times after multivariable adjustment. Cardiovascular mortality including and excluding 
fatal stroke was also increased (adjusted RR 1.41 and 1.37, respectively).
The Whitehall S t u d y ' w a s  a prospective cohort study of 19,063 male civil servants, aged 
40-69 years, who were screened between 1967 and 1969 and followed for 18 years. There 
was a 2.6 times increased risk of death in the 63 patients with atrial fibrillation compared 
to those without atrial fibrillation, hi a population study from Western Au s t r a l i a t h e  
adjusted risk of all-cause death (HR 1.9) and cardiovascular death excluding stroke (HR 
1.8) were increased in individuals aged > 60 years with atrial fibrillation, hi the Reykjavik 
S tudy 'ind iv iduals with atrial fibrillation had an increased risk of cardiac death (RR 6.1, 
p<0.05) and whilst there was an increase in all-cause mortality (32% in the atrial 
fibrillation group compared with 20% in the control group during 14 year follow-up), 
unlike other studies this was not statistically significant. Atrial fibrillation was also an 
independent predictor of all-cause mortality (men RR 1.5, 95% Cl 1.2, 2.2; women 2.2 
(1.5, 3.2)) and cardiovascular mortality (men 1.8 (1.3, 2.8); women 2.8 (1.9, 4.2)) in the 
Renfrew-Paisley s t u d y . B o t h  heart failure and stroke contributed to this excess mortality. 
In the Multifactor Primary Prevention Study (Goteborg S t u d y ) o f  the group of 754 men 
hospitalised with atrial fibrillation during the 27 year follow-up period mortality was
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increased by 3.3 times. Amongst men with atrial fibrillation at first screening (n=37) 
mortality during follow-up was 79% compared to 44.3% in men without atrial fibrillation 
(OR 4.71, 95% Cl 2.16, 10.28).
In a more contemporary population study using the Marshfield Epidemiologic Study Area 
d a t a b a s e 577 patients with a first episode of atrial fibrillation or flutter were identified 
between 1991 and 1995. They were followed prospectively until 1998. Compai'ed with 
controls, mortality among patients with atrial fibrillation or flutter was nearly 7.8-fold 
higher at 6 months and 2.5 fold higher at the end of the follow-up period after adjusting for 
other risk factors.
Within subsets of patients with heart failure^'''^’^ ''^ , acute myocardial in farctio if or 
acute stroke^^ '^ '^'^, atrial fibrillation has been found to increase mortality in some 
studies"''''^""":"''':""''"''' but not in
1.4.4.2 Secular trends in mortality
Trends in the risk of death following a hospitalisation with atrial fibrillation between 1980 
and 1999 were examined using the Danish National Hospital Discharge data.'^^ There was 
a 20% reduction in the adjusted risk of death in men and an 18% reduction in women 
during the last five-year period compared to the first five-year period. There is no mention 
in this study as to whether different durations of follow-up were taken into account.
In Scotland, the risk of short term (30-day) and medium term (31 days-2 year's) case 
fatality in patients hospitalised with atrial fibrillation between 1986 and 1995 was 
e xami ned . Af t e r  adjusting for age, sex, deprivation and co-morbidities the risk of short­
term case-fatality in 1995 significantly declined by 21% in men and 24% in women in 
comparison to 1986. The medium term case-fatality also declined significantly in men by 
30% and in women by 20% over this period.
Despite the proven efficacy and more widespread use of anticoagulation both of these 
studies still demonstrate an excess mortality associated with atrial fibrillation in recent 
years.
1.4.4.3 Sex and age differences in mortality
The risk of death in individuals with atrial fibrillation varied by sex in the Framingham 
Study, although this finding was not significant (OR 1.2, 95% Cl 0.98, 1.49) for men
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versus women with atrial fibrillation.'^^ The risk of death was greater in men compared to 
women without a diagnosis of atrial fibrillation (1.69 (1.4, 1.7)) and it appears therefore 
that the presence of atrial fibrillation attenuates the survival advantage of women. There 
was no evidence of an age sex interaction in individuals with atrial fibrillation.
In the Danish study the elevated mortality risk associated with atrial fibrillation diminished 
with age.'^^ Persons aged 50-59 years had a 4 fold increased risk of death from any cause 
and a 6-8 fold increased risk of cardiovascular death compared to the Danish population. 
This is in comparison to persons aged 80-89 years with atrial fibrillation having a 2-3 fold 
increased risk of death and a 3-4 fold risk of cardiovascular death compared to the general 
population. In contrast in the Scottish hospitalisation data the adjusted risk of death in the 
short and medium term increased with increasing age.'^^
1.4.4.4 Mortality in lone atrial fibrillation
Atrial fibrillation in the absence of structural heart disease is termed lone atrial fibrillation. 
In the Renfrew-Paisley study, lone atrial fibrillation conferred a non-significant 1.8 fold 
(95% Cl 0.9, 3.8) increased risk of d e a t h . I n  the Marshfield Epidemiologic Study Area 
patients with lone atrial fibrillation had a mortality twice that of controls (p=0.06).'^^ 
Likewise in the Framingham Study lone atrial fibrillation was associated with a doubling 
in mortality (multivariate OR 2.4, 95%CI 1.8, 3.3 in men and 2.2 (1.6, 3.1) in women).
1.4.4.5 Summary
A number of studies have confirmed that atrial fibrillation is an independent predictor of 
mortality. There is a temporal trend towards a reduction in the risk of death associated 
with atrial fibrillation in recent years. However, the excess mortality associated with atrial 
fibrillation demonstrated in more recent studies emphasises the need for improved 
prevention of atrial fibrillation and improved therapeutic modalities for treating and curing 
atrial fibrillation.
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1.5 Obesity and cardiovascular outcomes
The World Health Organisation defines overweight as a body mass index (BMI) of 25 to 
29.9kg/m^, obesity as a BMI > 30 kg/m^ and morbid obesity as a BMI > 40 kg/m^. BMI i; 
calculated as the weight in kilograms divided by the square of the height in metres.
1.5.1 Prevalence of obesity
The prevalence of obesity has reached unprecedented proportions.^^^ Nearly one third of 
Americans are obese.^^’’^ *^  It is estimated that there are up to 200 million obese citizens in 
the recently expanded European Union. The obesity epidemic is also afflicting developing 
countries. There is appropriate concern that this alarming trend will have major public 
health consequences globally, with evidence linldng obesity to an increased risk of more 
than 30 medical conditions.^
According to the last Scottish Health Survey in 2003, 65.4% of Scottish men and 59.7% of 
Scottish women were classified as either overweight or o b e s e . M e n  were more likely 
than women to be overweight (43.0% versus 33.8%). However, women were more likely 
than men to be obese (26% versus 22.4%) or morbidly obese (3.4% versus 1.6%). There 
has been a steady upward trend in mean BMI since 1995 in men and women (men; 26.0 in 
1995, 26.4 in 1998, 26.9 in 2003 and women; 25.7 in 1995, 26.3 in 1998, 26.9 in 2003). 
The proportion of individuals who aie classified as overweight or obese has risen from 
55.6% in 1995 to 64% in 2003 in men and 47.2% in 1995 to 57.3% in 2003 in women and 
the proportion morbidly obese tripled during this time period.
The increased prevalence of obesity is thought to result from a decline in physical activity 
and rising fat intake.^People now have increasingly sedentary life styles and consume 
high fat, energy dense diets. There is also a genetic or other biological predisposition to 
gain weight more readily when exposed to an unfavourable environm ent.B ehavioural 
aspects may also play a role.
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Obesity should be regarded as today’s largely neglected health problem with projections 
for the next decade that are so serious that public health action is urgently required. Merely 
concentrating on children and adults who are obese and have associated health problems is 
not sufficient. What is required are preventative public health strategies, which affect the 
entire society including dietary change (such as easy access to cheap healthy food, 
provision of healthy food to children in schools and health education), alterations in 
physical activity (such as physical activity programs in schools) and behaviour 
modification.
1.5.2 Cardiovascular morbidity associated with obesity
Obesity is associated with a broad range of metabolic and mechanical disorders including 
sleep apnoea, respiratory problems, osteoarthritis, gastrointestinal and gallbladder disease, 
and cancers such as endometrial, breast, prostate and colon cancer. For the purpose of 
this literature review I will focus on the cardiovascular risk factors and cardiovascular 
diseases associated with obesity.
1.5.2.1 Cardiovascular risk factors
The importance of obesity alone in predicting adverse cardiovascular outcomes has been a 
subject of debate because obesity influences the development of other established 
cardiovascular risk factors. Obesity has an adverse effect on several coronary risk factors 
including h y p e r t e n s i o n ^ t y p e  II diabetes mellitus^*^’^ *^ ’^ ^^ ’^ ^^  and dyslipidaemia^^^. 
Risk estimates from population studies suggest that >75% of hypertension can be directly 
attributed to obesity.^^"^
The relationship between body mass index and cardiovascular disease risk factors was
examined prospectively in the Framingham Heart Study^^^ pai'ticipants aged 35 to 75
years, who were followed for 44 years. Relative to normal weight men, obese men had a
multivariable adjusted relative risk of 2.23 for hypertension and 1.85 for diabetes (in
women 2.63 and 1.36 respectively). During follow-up, overweight participants (but not
those who were obese) experienced an increased risk for new hypercholesterolaemia. hi
the Framingham Offspring Study^^^, obesity was significantly and linearly associated with
low-density lipoprotein cholesterol levels. In NHANES III the risk of developing diabetes
and hypertension increases dramatically with increasing BMI in men and women.^^^ While
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men and women with BMI>25 kg/m^ were more likely than persons of normal weight to 
have high cholesterol levels, the prevalence of high cholesterol did not increase with 
increasing weight category. BMI was also positively associated with systolic and diastolic 
blood pressure in 4780 men and women from nine North American populations who 
participated in the Lipid Research Clinic Prevention S t u d y . h i  another relatively large 
US study^^^, of 886 men and 1114 women who were aged 50 years and older when 
examined in 1984-1987, those who gained 10 pounds or more between ages 40 and 60 
years had an increased risk for developing diabetes. The relative risk for diabetes was 1.4 
for every 17% to 31% increase in body weight after age 18 years. In an earlier cross- 
sectional study in the US, more than one million people were screened for hypertension as 
part of the Community Hypertension Evaluation C l i n i c . T h e  overweight group had a 
prevalence of hypertension which was 50% to 300% (in different age groups) higher than 
other participants. The relationship between obesity, fat and the risk of non-insulin- 
dependent diabetes mellitus was examined in the cohort of 51,529 U.S. male health 
professionals aged 40-75 years of age in 1986.^^^ During the five year fo.llow-up here was a 
strong positive association between overall BMI and the risk of diabetes. Men with a BMI 
of >35 kg/m^ had a multivariate RR of 42.1 (95% Cl 22.0, 80.6) compared with men with a 
BMI < 23.0 kg/m^.
Two other American studies examined the association between obesity and cardiovascular 
risk factors in women. The Iowa Women's Health Study^^^ was a prospective cohort study 
of 31,702 Iowa women, aged 55 to 69 years. Body mass index was independently 
associated with self reported diabetes (age-adjusted relative risk 13.8) and hypertension 
(age-adjusted relative risk 2.2). In the Nurses Health Study^^^ the relationship between 
obesity and diabetes was examined in a cohort of 114824 female nurses aged 30-55 years 
who were initially screened in 1976 in the US. After adjusting for age, BMI was a strong 
predictor of the risk of developing diabetes during the 14 year follow-up. Women with a 
BMI of 31 kg/m2 or greater had an age-adjusted relative risk of 40 or more compared to 
women with a BMI of less than 22 kg/ni2.
Two Swedish studies examined the relationship between obesity and risk of diabetes.^^^’^ ^^  
In a 12 year longitudinal study of women in Goteborg, BMI, sum of two skinfolds and 
waist-to-hip circumference ratio, were significantly associated with an increasing incidence 
of diabetes even after multivariable adjustement.^^^ In the study of Men Born in 1913, 792 
54 year old men who were resident in Goteborg, Sweden, were followed for 13.5 years for 
the development of d i a b e t e s . Ev e n  when the confounding effect of body mass index, as a
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measure of the total body fat mass, was accounted for, the waist-to-hip ratio was positively 
and significantly associated with the risk for diabetes.
In the INTERSALT study^^', the relationship between body mass index and blood pressure 
was studied in 10,079 men and women aged 20-59, sampled from 52 centres around the 
world. Overall, a 10 kg higher body weight was associated on average with a 3.0 mmHg 
increase in systolic and a 2.2 mmHg increase in diastolic pressure. The relationship 
between obesity as measured by the pondéral index (height in inches / weight in Ib'^ )^ and 
blood pressure was measured in 637 men and 835 women who attended the Glasgow 
Blood Pressure Clinic with untreated hypertension. There was an association between 
obesity and blood pressure only in non-smoking men. The associations of obesity with 
blood pressure were studied in 5,550 male and female subjects aged 25 to 64 years, 
surveyed in the National Heart Foundation of Australia 1980 Risk Factor Prevalence 
S t u d y . B M I  was significantly and independently associated with blood pressure levels in 
both sexes. 30% of hypertension in the study population could be attributed to overweight.
1.5.2.2 Metabolic syndrome
It is now recognized that overweight and obese persons without diabetes, particularly those 
with abdominal obesity often have a cluster of clinical and metabolic findings that is 
termed the metabolic syndrome.^^^ This syndrome is characterised by insulin resistance 
and a particularly atherogenic dyslipidaemia (high levels of low-density lipoprotein 
cholesterol, very-low-density lipoprotein cholesterol, and triglycerides and low levels of 
high-density lipoprotein cholesterol) but it is also associated with elevated C-reactive 
protein levels, increased propensity to thrombosis and activation of the sympathetic 
nervous system. The metabolic syndrome is a major risk factor for caidiovascular 
events.^ '^^
1.5.2.3 Coronary heart disease and acute myocardial infarction
One of the first medical consequences of obesity to be recognised was coronary heart 
d i s e a s e . h r  response to the emerging body of scientific, medical and behavioural 
data about the link between excess adiposity and coronary heart disease the American 
Heart Association has reclassified obesity is a major modifiable risk factor for coronary 
heart disease.
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Obesity is associated with hypertension, hypercholesterolaemia and hyperglycaemia which 
accelerate atherogenesis. However, obesity has also been shown to be an independent risk 
factor for coronary heart disease. In the Framingham Study^^^, obesity on initial 
examination in persons aged 28-62 years, as measured by Metropolitan Relative Weight 
(the percentage of desirable weight), was a significant independent predictor of 26-year 
incidence of coronary disease. In a more recent analysis of the Framingham cohort^* 
participants aged 35-75 yeai'S were followed for 44 years for the development of coronary 
heai't disease. Obesity was defined as a body mass index > 30. After adjusting for age, 
smoking, hypertension, cholesterol and diabetes, the relative risk for angina was increased 
among those who were obese (men 1.8, 95% Cl 1.3, 2.6; women 1.6 (1.2, 2.3)) relative to 
normal weight individuals. Whilst the age-adjusted relative risk for myocardial infarction 
was increased in obese women, there was no greater risk in obese men or women in the 
multivariable model (men 1.2 (0.8, 1.7); women 1.5 (0.9, 2.3)).
The Nurses’ Health Study^^^ cohort of 115,818 women aged 30-55, all without 
cardiovascular disease at study inception, was followed for 14 years. In a multivariable 
analysis (not controlling for diabetes, hypertension and hypercholesterolaemia) comparing 
women with a body mass index of >29kg/m^ to those with a body mass index of <21kg/nf 
the relative risk was 2.90 for coronaiy heart disease, 3.15 for non fatal myocardial 
infarction and 2.73 for fatal coronary heai't disease.
In the Manitoba Study^^^, of a cohort of 3,983 men with a mean age of 31 at entry, body 
mass index significantly predicted myocardial infarction and coronary heart disease during 
a 26 year follow-up, after adjusting for age and blood pressure.
In the Study of Men Born in 1913^“^  ^ a cohort of 792 men aged 54 years were screened in 
1967. There was no correlation between BMI and ischaemic heart disease during the 13 
year follow up period.
1.5.2.4 Heart failure
There has been debate as to whether obesity is an independent predictor of heart failure or 
whether the risk is mediated through other physiological and metabolic abnormalities.
In the Framingham study^ "^  ^ 5881 participants were followed up for 14 years. 496 subjects 
(258 women and 238 men) developed heart failure. The hazard ratio for obesity relative to
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normal weight was 2.12 (1.51, 2.97) for women and 1.90 (1.30, 2.79) for men. There was 
an increase in the risk of heart failure of 5% in men and 7% in women for each increment 
of 1 unit in body mass index. Models were adjusted for age, alcohol consumption, 
cholesterol, smoking, valve disease, hypertension, diabetes, electrocardiographic evidence 
of left ventricular hypertrophy and myocardial infarction. In NHANES I^ "^  ^ 1382 heart 
failure cases were documented during a follow-up of 19 years (13,643 individuals screened 
between 1971-1975) from medical records and death certificates. The relative risk of heart 
failure for overweight (BMI >27.8 kg/nf in men and >27.3 kg/m^ in women) was 1.24 
(1.01, 1.51) for men and 1.43 (1.19, 1.72) for women after adjusting for age, race and 
coronary heai't disease and 1.23 (1.00, 1.52) in men and 1.34 (1.10, 1.64) in women after 
adjusting for age, race, high school education, smoking, alcohol, physical activity, 
hypertension, cholesterol, diabetes, valvular heart disease and coronary heart disease. In 
the New Haven, Connecticut cohort of the Established Population for Epidemiologic 
Studies of the Elderly program^"^  ^ 1749 subjects aged 65 years and over were evaluated in 
1982 and 173 subjects developed incident heart failure (determined by chart review) during 
13,811 person-years of follow up. The hazai'd ratio for a BMI > 28 kg/m^ compared with 
<24 kg/m^ was 1.6 (1.0, 2.4) after adjusting for age, sex, diabetes, pulse pressure, hi the 
Multifactor Primary Prevention Study (Goteborg) 7495 men were examined at baseline 
in 1970-73 and followed for 27 years. During this time 937 men were hospitalised for heart 
failure. The relative risk for a BMI >27 kg/m^ compared to a BMI <23.99 kg/m^ was 1.50 
(1.26, 1.78) in a bivariable analysis. Body weight was also related to incident heart failure 
in 973 Swedish men born in 1913.''^ With the exception of the Framingham study these 
studies do not use conventional definitions of obesity.
There are a number of possible mechanisms given in these studies for the association 
between obesity and heart failure. Obesity is a recognised risk factor for coronary artery 
disease and coronary risk factors such as hypertension, hyperglycaemia, and 
hyperlipidaemia, which increase the risk of myocardial infarction and therefore heart 
failure. Elevated body mass index is also associated with altered left ventricular 
remodelling possibly due to increased haemodynamic load (i.e. increasing cardiac output 
and intravascular volume, thereby causing elevated left ventricular filling pressure and 
end-diastolic volume leading to subsequent cardiac dilation and left ventricular 
hypertrophy thereby increasing the risk for developing heart failure), increased oxidative 
stress and neurohumoral activation. There is also the possibility of a direct effect of
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obesity on the myocardium - cardiac steatosis and lipoapoptosis was recently demonstrated
2 4 4in an animal model of obesity.
1.5.2.5 Stroke
There have been conflicting results on the effect of obesity on stroke with some studies 
showing a positive association^^ '^^"^^"^^° and others showing no association^'^^’^ ’^'^ '^^ .
The risk of stroke related to obesity has been shown to be different in men and 
women.^^^’^ "^^
In the Physicians’ Health Study of 21,414 male physicians, the adjusted relative risk for 
stroke (not including hypertension, diabetes and cholesterol) was 2.00 (1.48, 2.71) in 
participants with BMI >30 kg/m^ compared to those with BMI <23 kg/m^ .^ "*^  They also 
evaluated BMI as a continuous variable and found that each unit increase in BMI was 
associated with a 6% increased risk of stroke and this reduced to 4% when diabetes, 
cholesterol and hypertension were included in the model, hi the Honolulu Heart 
Program^ "^ *^  1663 non-smoking Japanese-American men (55-68 years) (screened 1965-68) 
with no hypertension, diabetes or left ventricular hypertrophy were followed for 22 years. 
The risk of stroke after adjusting for age and other risk factors (including systolic BP, 
glucose and cholesterol) for the average body mass index in the top tertile (26.6 kg/m^) 
compared with that in the bottom tertile (20.3 kg/m^) was 2.1 (1.1, 4.1). In a prospective 
population study a total of 234,863 Korean men aged 40-64 years were screened in 1986 
and followed up between 1991 and 2000 for fatal and nonfatal stroke events. The 
hazard ratio after adjusting for age, alcohol, smoking, exercise and monthly salary level for 
a BMI >30 kg/m^ relative to a BMI 22-23.9 kg/m^ was 1.7 (1.4, 2.3) for all stroke, 1.4 (0.9, 
2.0) for ischaemic stroke and 2.6 (1.7, 4.0) for haemonhagic stroke. After full adjustment 
for confounders and variables potentially on causal pathway (i.e. blood pressure, glucose 
and cholesterol) the association between body mass index and stroke subtype was 
attenuated (1.2(1.0, 1.6) for all stroke, 1.0 (0.6, 1.4) for ischaemic stroke and 1.8 (1.1, 2.7) 
for haemorrhagic stroke). In the Whitehall study^^° in 17,753 male civil servants, aged 40 
to 64 years, there was a two fold increased risk of death from stroke among men with BMI 
>24 kg/m^ compared with those with BMI<24 k g /n f. In the Nurses’ Health Study^ "^  ^
116759 women screened in 1976 aged 30-55 years. During 16 years of follow-up for 
women with increased BMI (>32 kg/m^) the relative risk of ischaemic stroke was 2.37 
(1.60, 3.50) as compared with those with a BMI <21 kg/m^ after adjusting for age.
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smoking, postmenopausal hormone use, and menopausal status. The equivalent RR for 
haemorrhagic stroke was 0.73 (0.42, 1.26) and for total stroke was 1.59 (1.22, 2.08).
Dey et al^ "^  ^ looked at risk factors for stroke in 2,287 individuals aged 70 years old and 
examined between 1971-1981 in Sweden. In men the relative risk for stroke in the highest 
BMI quartile (>28) was 1.68 (1.12, 2.53) after adjusting for smoking, CHD, diabetes, 
cholesterol and SBP. There was no significant association between BMI and risk of stroke 
in women. In contrast in the Framingham study^^^ Metropolitan Relative Weight 
(percentage of desired weight) was positively and independently associated with stroke in 
women but not in men.
In a study of 28,643 US male health professionals, abdominal obesity, but not elevated 
body mass index (age adjusted relative risk 1.29 (0.73, 2.27)), predicted risk of stroke in 
men.^^^ In the Study of Men Born in 1913^^ ,^ 789 men aged 54 at baseline were followed 
for 18.5 years for the development of stroke. Increased waist circumference, but not body 
mass index, was independently associated with the risk of stroke.
In the Copenhagen City Heart Study^^^ 7,060 women, > 35 years, were initially 
investigated between 1976-1978, and followed up to 1988. There was no significant effect 
of BMI (1.02 (0.99, 1.05) per unit of BMI) on risk of cerebrovascular disease after 
adjusting for age, length of school education, household income, smoking, alcohol, daily 
consumption of tranquilizers and physical inactivity. In the British Regional Heart 
Study^^^, 7,735 men aged 40-59 years from 24 General practices in the UK were followed 
for eight years for the development of fatal and non-fatal strokes. There was no association 
between obesity and stroke. In the Chicago Stroke Study^^  ^ 3,141 subjects were screened 
between 1965-67 and followed up for a median of 32.1 months. They examined the 
association between adiposity (as measured by pondéral index and chest skinfold) and risk 
of stroke. Pondéral index was associated with risk of stroke in a race-age-sex stratification 
however on a multivariate analysis neither variable was significantly associated with 
stroke, hi the Finnmark study, 13,266 men and women aged 35-52 years were followed for 
14 y e a r s . T h e r e  were 241 first stroke events. BMI was a highly signifieant predictor of 
stroke in a univariate but not multivaiiate model. The model however included height as 
well as body mass index.
In a random sample of 41,837 women aged 55-69 years from Iowa, women who developed 
a stroke were 2.1 times more likely to be in the upper tertile of waste-hip circumference
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r a t i o . Multivaiiable adjustment including body mass index in the model reduced the risk 
ratio to 1.6 and including diabetes and hypertension reduced the risk ratio to 1.3 which was 
no longer significant. This suggests that abdominal obesity increases the risk of stroke, 
even after accounting for overall body mass index and that the association between 
abdominal obesity and the risk of stroke is in part related to the association of abdominal 
obesity with hypertension and diabetes.
The fact that the association between BMI and risk of stroke is attenuated by adjustment 
for cholesterol, glucose and blood pressure indicates that obesity may have its effeet on 
stroke in part through these mechanisms. Other possible reasons are an increase in 
prothrombic factors observed among overweight and obese ind iv iduals.h icreased  levels 
of C-reactive protein in overweight and obese individuals may also play a role since an 
association between increased levels of inflammatory markers and risk of ischaemic stroke 
has been previously documented.
1.5.2.6 Atrial fibrillation
Obesity increases the risk of arrhythmias and sudden death, even in the absence of cardiac 
dysfunction.^^^’^ ^^
In the Multifactor Primary prevention study the adjusted HR for atrial fibrillation was 1.07 
(1.04, 1.10) per unit of BMI.^ '^* hi the Framingham cohort^^^, 5,282 participants without 
baseline atrial fibrillation were followed for a mean of 13.7 years for the development of 
new onset atrial fibrillation. There was a 4% increase in atrial fibrillation risk per one unit 
increase in body mass index in men and women. The adjusted hazard ratio for atrial 
fibrillation associated with obesity was 1.52 in men and 1.46 in women.
1.5.2.7 Venous thromboembolic disease
The Longitudinal Investigation of Thromboembolism Aetiology was a prospective study of 
19,293 individuals in 6 US communities between 1987 and 1998.^ *^  ^ There were 215 
venous thromboembolic events during a median of 8 years of follow up. The age-, race- 
and sex-adjusted hazard ratio (relative to a BMI<25) was 2.27 (1.57, 3.28) for obesity and 
1.51 (1.06, 2.14) for overweight. Possible mechanisms suggested in this study include 
venous stasis and higher levels of prothrombotic factors, such as fibrinogen, plasminogen 
activator inhibitor I, and factor VII in obese individuals. In addition it is possible that obese
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individuals are more likely to be hospitalised (and therefore subject to precipitating factors 
such as surgery and immobilization).
Two other studies have looked at body mass index and risk of pulmonary embolism and 
one of these was confined to fatal events. The Framingham study showed that women but 
not men who had a fatal pulmonary embolism had higher Metropolitan relative weights 
(percentage of desirable weight) compared with participants who died of other causes.^* '^ In 
the Nurses’ Health Survey of 121,700 female nurses, a BMI of 29 or higher was an 
independent risk factor for pulmonary embolism (HR 3.0 [2.0, 4.7] relative to a BMI <21 
adjusted for age, oral contraceptive pill, post menopausal hormone use, parity, diabetes, 
high blood pressure, cholesterol, smoking and time p e r i o d ) . I n  an autopsy study, morbid 
obesity was an independent risk factor for death from pulmonary emboslism. '^^^
Another study found an association between abdominal circumference and venous 
thromboembolism. In the Study of Men Born in 1913, 855 men screened at 50 years old 
and followed for 30 years, abdominal obesity was an independent risk factor for venous 
thromboembolic events.
1.5.3 All-cause and cardiovascular mortality associated with obesity
1.5.3.1 All cause mortality
Many studies have reported on the association between obesity and mortality with most 
studies showing an increased risk of death associated with obesity.(Table 22) Using data 
from US life tables, NHANES III, NHANES follow-up study and NHANES II Mortality 
Study, Fontaine ei al estimated the expected number of years of life lost due to overweight 
and obes i t y . Yea r s  of life lost is defined as the difference between the number of years 
that one would be expected to live if one were not obese and life expectancy if one were 
obese. They showed that obesity reduces life expectancy substantially especially among 
younger adults. Even a moderate amount of excess weight confers a noticeable diminution 
in life expectancy.
The Cancer Prevention Study 11^ ^^  was a prospective study of more than 1 million adults in 
the US who completed a questionnaire in 1982. Families were enrolled if at least one 
household member was >45 years and all household members >30 years were included.
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There was an increased risk of death associated with obesity and a gradient of increasing 
risk associated with increasing BMI above the normal range. For example among non­
smoking men who had no history of disease the relative risk of death compared to those 
with a BMI between 23.5 and 24.9, increased from 1.09 in men with a BMI 26.5-27.9 to 
1.32 in those with a BMI 30.0-31.9 to 2.58 in men with a BMI >40 (the equivalent RR for 
women 1.10 (1.30, 2.00)). Over 750,000 adults participated in an earlier study, the Cancer 
Prevention Study which had similar methodology. The relative weight was
calculated by dividing the person’s weight by the average weight for his or her group and 
multiplying by 100. Men and women who were more than 40% overweight had a mortality 
rate nearly twice as high as average weight people. In another analysis of Cancer 
Prevention Study I^ ^^  the association between BMI and death was examined in different 
age groups. The increase in risk of death from all causes associated with a higher body- 
mass index tended to be greater among younger subjects.
In the NHANES I Epidemiologic Follow-up Study^^^ there was an increased mortality risk 
associated with the highest 15th percentile of the BMI distribution which only reached 
statistical significance in white women. In another paper, data from the NHANES I 
Epidemiologic Follow-up study was compared to another national representative sample of 
the US population, the National Health Interview Survey^^*. hi the National Health 
Interview Survey each week a probability sample of households in the US was interviewed 
by trained personnel of the US Bureau of census to obtain information about health. There 
was a U shaped mortality curve associated with obesity. In both these studies the shape of 
the BMI mortality curves in men and women were similar in blacks and whites.
In the Adventist Health Study, the relationship between BMI and mortality was examined 
in a cohort of 20,346 non-Hispanic white, Seventh-day Adventist men and women aged 
25-84 years who never s m o k e d . T h e  cohort was screened in 1976 by mailed 
questionnaire and followed prospectively for 12 years. There was an increased risk of 
death associated with obesity in middle aged (25-54 years) and older aged (55-84 years) 
men and women both during earlier follow-up (1-6 years) and longer follow-up (7-12 
years). The Adventist Mortality Study was an earlier study in which Californian Seventh- 
day Adventists aged 30-74 years were screened in 1960 and followed for 26 years, hi the 
cohort of 12,576 women^^^ during the later years of follow-up (years 15-26) there was an 
elevated risk of mortality, in those with a BMI >27.4 compared to those with a BMI <
21.3. In 5,062 men^ "^^  there was also an increased risk of all-cause death in those with a
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BMI > 27.5 compared to those with a BMI 22.6-27.4 however this was only significant in 
younger (30-54 years) men.
An association between obesity and mortality was also shown in the Harvard Alumni 
Health Study^^^. 21,582 Harvard University male Alumni responded to a mailed 
questionnaire in 1962 or 1966 and were followed until 1988. Men with a BMI > 26 had 
nearly a 20% increased risk of death relative to those with a BMI <22.5. There was also an 
excess mortality in participants of the Honolulu Heart Study^^^ who were in the highest 
BMI quintile.
The relationship between BMI and mortality was also examined in a prospective 
population study from the Social Insurance Institution of F i n l a n d . I n  22,995 men 
aged 25 years and over there was a 1.5 fold increased risk of death for those with a 
BMI>34.0 as compai'ed with men of normal weight.^^^ In a separate analysis of 17,519 
Finnish women aged 25-79 years, the population was divided into quintiles of BMI by 10- 
year age groups. In those women aged 25-64 years there was an increased risk of death in 
the top quintile compared to the 2"  ^quintile (RR=1.5).^^^ However, among women over 65 
years of age BMI was not an important predictor of mortality. Data from compulsory army 
medical examinations of 78,612 Dutch men aged 18 yeai's, were linked to death 
registration data over a follow-up period of 32 years.^^^ An elevated BMI at aged 18 was 
associated with an increased risk of death.
In the Cardiovascular Health Study^^^ the relationship of body mass index to 5-year 
mortality was examined in a cohort of 4,317 non-smoking men and women aged >65 
years. There was no association between higher body mass index and mortality in this 
cohort of older adults. Likewise in the Established Populations for Epidemiologic Studies 
of the Elderly study^^  ^ there was no excess risk of death associated with obesity in a cohort 
of 6,387 whites aged 70 years or older during the period 1982-1987. In contrast in the 
Framingham Heart Study^^^there was an increased risk of mortality for non-smoking men 
and women at age 65 years in relationship to body mass index. After adjusting for 
cholesterol and glucose levels, systolic blood pressure and prior cardiovascular disease this 
excess risk however was only significant in women. The Longitudinal Study of Ageing^^^ 
examined the relationship between BMI and mortality in a large nationally representative 
sample of 7,260 US adults aged >70 years. Individuals were initially interviewed in 1984 
and were followed through to 1990. Using Cox proportional hazard model and adjusting 
for age, sex, education and several health related questions they found that the relationship
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between BMI and mortality was U-shaped for both men and women. The minimum 
mortality in this elderly cohort occurred at a BMI of 31.7 for women and 28.8 for men. In 
the Whitehall Study^ "^  ^the relationship between mortality and BMI in middle aged men 
differed within age bands, hr the 40-49 year age group mortality increased with increasing 
quintile of BMI, however the excess risk of death for the heaviest quintile disappeared with 
advancing age.
The association between BMI and overall mortality was examined in a cohort of 115,195 
U.S. women aged 30-55 years who were enrolled in the prospective Nurses' Health Study 
in 1976 and followed for 16 yeai's.^^  ^When women who had never smoked were examined 
separately, there was a direct association between BMI and obesity (p for trend < 0.001). In 
women who had never smoked and had recently had stable weight, mortality among obese 
women (BMI>29 kg/m^) was more than twice that among leanest women. Mortality did 
not increase substantially until BMI reached 27.6 kg/m^. A weight gain of 10 kg (22 lb) or 
more since the age of 18 was associated with increased mortality in middle adulthood. The 
relationship between BMI and mortality in women was also investigated in the Iowa 
Women's Health S t u d y . A  mailed questionnaire was completed in 1986 by 31,702 Iowa 
women aged 55 to 69 years who were free of cancer, diabetes or heart disease and who 
held a valid Iowa driver’s licence. Over a 12 year follow-up BMI showed a U-shaped 
association with all-cause mortality in the age-adjusted models. However after adjustment 
for other risk factors, there was no association between BMI and mortality (RR for fifth 
versus first quintiles 0.91 (95% Cl, 0.8, 1.0)).
Several studies have failed to show an association between BMI and death. In the Study of 
Men Born in 1913^ '^ '^ , 792 men aged 54 years, were screened in 1967. There was no 
significant difference in mean BMI between those who died and those who remained alive 
over the 13 year follow-up period. In another study from Goteborg, Sweden 1,462 women 
aged 38, 46, 50, 54 or 60 years were screened in 1968-69 and followed for 20 years.
There was no correlation between BMI and death. In both these studies Pitman’s 
permutation test was used for correlation and multivariable modelling was not performed. 
In a study from eastern Finland the risk of death from all causes was examined in 3,786 
men and 4,120 women aged 30-59 at outset in 1972 and followed for 9 y e a r s . I n  a 
multivariable analysis adjusting for age and smoking, BMI was not an independent 
predictor of the risk of death from all causes in men or women. In the Seven Countries 
study"^  ^ all cause mortality was not related to BMI.
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1.5.3.2 Cardiovascular mortality
As discussed earlier there is debate as to whether obesity exerts its affect on cardiovascular 
disease through its influence on established cardiovasculai' risk factors or whether obesity 
is an independent risk factor for cardiovascular disease. There are three potential 
methodological problems that can distort studies investigating the relationship between 
obesity and the risk of cardiovascular m orta lity .F irs tly , reverse causation, which is the 
effect of patients losing weight during chronic illnesses that are ultimately fatal, there by 
creating the appearance that persons with a lower weight have an increased mortality. 
Secondly, the issue of confounding variables such as not adjusting for smoking because 
smokers weigh less and have a higher mortality than non smokers. Thirdly, statistical 
adjustments for conditions related to obesity in the study population, for example 
hypertension and diabetes, which remove some of the adverse effects of obesity and give a 
false impression that the effect of obesity on the risk of death is neutral.
In the Cancer Prevention Study I, excess body weight increases the risk of death from 
cardiovascular disease in adults between 30 and 74 years of age.^ *^  ^The relative risk 
associated with greater body weight was higher among younger subjects. In another 
analysis of data from the Cancer Prevention Study I, men and women who were more than 
40% overweight had a coronary heart disease mortality rate nearly twice as high as average 
weight people (men 1.95; women 2.01)?^’'^ ^^  In the Cancer Prevention Study II, 
significantly increased risks of death from cardiovascular disease were found with a BMI 
of more than 25 in women and 26.5 in men.^ *^ ^
In the Nurses Health Study^^^, rates of death due to cardiovascular disease among obese 
women (BMI >29 kg/nf ) were four times higher than those among the leanest women. The
risk of coronary heart disease mortality was also increased with increasing BMI (p for 
trend <0.001). In the Iowa Women’s Health Study^'^ BMI was associated positively with 
coronary heart disease related mortality (multivariable adjusted RR for the fifth versus first 
quintiles of 1.7). In the Honolulu Heait Study^^^ most of the excess deaths in the fifth 
quintile of BMI were due to coronary heart disease.
In the Whitehall Study, a 2-fold increase in risk of stroke mortality was observed among 
men with BMI > 24kg/m2 compared with those with BMI<24kg/m2.^^°
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Obesity was also shown to increase the risk of premature coronary heart disease mortality 
in 84,910 men discharged from the US Army in 1946-47 and followed for 23 years?^^ In 
the Soeial Insurance histitution of Finland population survey, men aged >25 years, with a 
BMI >34, had a 1.8 times (p<0.001) increased risk of death from cardiovascular disease 
compared to men with a normal BMI (22.0-24.9) over a 12 year median fo llo w -u p .In  
non-smoking women, aged 25-64 years, there was also an increased risk of mortality from 
cardiovascular diseases in the highest BMI quintile relative to the second quintile of BMI 
(RR 1.6, 95% Cl 1.1-2.3).^^^ However, there was no excess cardiovascular mortality in 
older obese women.
There was a correlation between BMI and cardiovascular death in the study of 1462 
women from Goteborg, Sweden who were screened in 1968-69 and followed for 20 years 
after adjusting for age.^ ®*^
In the Seventh-day Adventist study^^°, 12,576 women who had never smoked completed a 
questionnaire in I960. There was an increased risk of death from cardiovascular causes in 
women with a BMI >27.4 relative to those with a BMI 21.3-27.4 between 9 and 26 years 
of follow-up.
1.5.3.3 Mortality from heart failure
Obese people with heart failure seem to have a more favourable prognosis and this is 
referred to as the ‘obesity paradox’. The role of obesity in the prognosis of patients
with heart failure was examined in 1,203 patients with advanced heart failure followed in a 
comprehensive heart failure management program.^^^ In this study obesity was associated 
with a better five-year survival rate in patients with advanced heart failure and in 
multivariable analysis there was an inverse association between body mass index and 
mortality. In a UK study of 525 non-cachectic patients with chronic heart failure increasing 
body mass index was not an adverse prognostic factor.^^^ In 522 patients with a history and 
clinical findings of heart failure referred to two Veteran Affairs Medical Centres in 
California, a lower body mass index was an independent predictor of death over a six-year 
follow-up period.^^^ In a study of 181 patients with heart failure from The Netherlands a 
higher body mass index was an independent predictor of a more favourable prognosis. 
Higher body mass index was also associated with better survival in a study of 209 patients 
with mostly class II and III heart failure who were followed at the Cardiomyopathy and 
Heart Transplant Centre in New O r le a n s .I n  the Systolic Hypertension in the Elderly
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Program study, overweight status was associated with a decreased stroke risk and reduced 
total mortality, as compared with lean subjects with heart fa ilu re .In c reasin g  body mass 
index was also associated with a lower mortality in a study of 4,700 patients hospitalised 
with heart failure.^^^ Compared with normal weight, and adjusted for age and sex, the risk 
ratio for obese was 0.77 (0.70, 0.86). In the Digitalis Investigation Group trial^^^, in 7,767 
patients with stable heart failure, overweight and obese patients were at lower risk for 
death (Hazard Ratio 0.88 and 0.81 respectively), compared with patients at a healthy 
weight.
In summary, the prevalence of obesity is growing and obesity is associated with many 
adverse outcomes. Although clearly a risk factor, the evidence surrounding the mechanism 
and magnitude of associated risks is not consistent and appears to vary according to the 
outcome studied.
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2 AIMS
To describe the epidemiology of cardiovascular' disease (including angina, AMI, acute 
coronary syndromes, heart failure, atrial fibrillation and obesity) in Scotland using 
routinely available sources of data as well as data available from the MIDSPAN study.
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3 METHODS
For this thesis I used data from primary care (Continuous Morbidity Recording in General 
Practice Scheme), secondary care (Linked Scottish Morbidity Recording Scheme) and a 
prospective cohort study (the Renfrew Paisley study). For each of these I will describe the 
source of the data and the quality, organisation and extraction of the data. In addition I will 
describe the specific data extracted and statistical analysis performed for each of the 
studies in chapters 4-11.
3.1 Continuous Morbidity Recording (CMR) in General Practice 
Scheme
3.1.1 Data sources
Primai'y care morbidity statistics from a sample of General Practices in Scotland were 
collected using the Continuous Morbidity Recording (CMR) scheme. Since April 2003, 
CMR has been superseded by Practice Team Information (PTI). CMR collected data on 
General medical Practitioner contacts only. PTI includes data recording by the broader 
practice team (general practitioners, practice nurses, district nurses and health visitors). 
Currently 44 practices contribute full Practice Team Information to PTI, covering ai'ound 5 
per cent of the Scottish population. In April 1998 CMR was included as part of the national 
dataset. Any computerised General Practice could volunteer to take part in CMR.
Practices were weighted to form a national sample that is broadly representative of the 
Scottish population as a whole in terms of age, sex, deprivation and rural/urban mix.
All individuals resident in Scotland (including children) are registered with primary care, 
which is free at the point of contact and manages the treatment of patients once they are 
discharged from hospital. Access to secondary care is usually obtained through a General 
Practitioner (GP) based within a primary care practice.
1 0 2
General Practices partipating in the CMR scheme collected data from every face-to-face 
patient contact with a OF. hi 1999, 53 practices participated in CMR covering 6% of the 
Scottish population. This increased to 55 General Practices contributing in 2001 (7% of the 
Scottish population). All contacts with practice patients (including temporary residents) 
were captured and recorded by every doctor (including locums and co-operative doctors). 
Data was collected from face-to-face doctor patient contacts only and not from telephone 
contacts or hospital episodes.
For each doctor-patient contact the following information is recorded; patient identifier, 
date of birth, sex, postcode, diagnosis, modifier, date of consultation, type of encounter and 
clinician I.D. These will be discussed in more detail below. The patient identifier is 
generated by General Practice Administration System for Scotland (GPASS) software, is 
practice specific and allows analysis of the data at the individual level. The diagnosis is the 
underlying morbidity the patient has presented with. It can be a diagnosis, or if the 
diagnosis is not clear, a symptom or sign. As patients can present with multiple problems, 
information is collected on the index condition and up to ten concomitant medical 
problems. General practitioners are asked to only record a problem if the patient presented 
with that condition or if the consultation was relevant to the condition in question (e.g. 
involving a change of medication for the condition). Each diagnosis is given a Read code. 
Read codes are the recommended national standard coding system in General Practice and 
can be mapped onto other coding systems including ICD-9, ICD-10 and British National 
Formulary (BNF) formulary. Read codes are arranged hierarchically, with the level of 
detail increasing down the hierarchy. For example G .... refers to circulatory system 
disease, G 3 ... ischaemic heart disease, G30.. acute myocardial infarction, G301. acute 
myocardial infarction not otherwise specified, G3011 acute anteroseptal infarction. Each 
diagnosis is also given an appropriate modifier of “first”, “recurrence” or “persistent”. A 
‘first’ modifier is defined by the first ever occurrence in primary care of a newly diagnosed 
condition or symptom for this patients with any doctor. A ‘recurrence’ modifier refers to a 
new occurrence of an illness or symptom, which has been previously diagnosed for that 
patient but has been inactive. ‘Recurrence’ also includes an acute exacerbation of an on­
going morbidity. A ‘persistent’ modifier is defined as a follow-up, review or other 
consultation of an on-going symptom or condition. Modifiers allow calculation of 
incidence and prevalence of conditions. The type of encounter identifies what type of 
contact took place such as a home visit, out of hours contact or a surgery or clinic contact.
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The data are entered onto the practice GPASS system and an extract is sent every month to 
the Information and Statistics division of the National Health Service in Scotland (ISD 
Scotland) for analysis. Data from all CMR practices is combined to form a national 
sample. The Primary Care Clinical Informatics Research Unit (PCCIU-R) based at the 
University of Aberdeen collates the prescribing and morbidity data.
CMR practices are located throughout Scotland with the highest concentration of practices 
in the more densely populated central areas of Scotland. (Figure 1) CMR practices are 
recruited on a continual basis so that the dataset is representative by age and sex of the 
Scottish population. The age distribution in the CMR practice population is comparable to 
the general Scottish population. The proportion of men and women in different age groups 
in the CMR practice population and in the Scottish population in the years ending March 
2000 and March 2002 is shown in Figure 2. The CMR practice population is based on 
CMR practices which returned complete GP data for the years ending March 2000 and 
2002 respectively. The source of the CMR practice population figures is the General 
Medical Practitioner Database (as at 1 October 1999 and 2001), while the source of the 
Scottish population figures is the General Register's Office, Scotland (mid year population 
estimates for 1999 and 2001). The overall proportion of men was slightly higher in the 
CMR population compared to the Scottish population in both time periods (1999-2000 
49.4% versus 48.6% and 2001-2002 49.6% versus 48.1%). This was due to a higher ratio 
of younger men to women in the CMR population compared to the Scottish population.
Figure 3 gives the CMR practice population and the Scottish population stratified by 
Scottish Index of Multiple Deprivation (SIMD) quintiles for the years 1999-2000 and 
2001-2002. The source of the CMR practice population and the Scottish population is the 
Community Health Index (CHI) record (as at 30 Sept 1999 and 2001). The SIMD is based 
on 37 indicators in seven domains: current income, employment, health, education skills 
and training, geographic access to services (including public transport travel times for the 
first time), housing and a crime domain. The SIMD is presented at data zone level, and the 
data zones have a median population size of 769. The first quintile is the least deprived and 
the fifth quintile is the most deprived. As can be seen from Figure 3 a disproportionate 
number of individuals in the CMR practice population are in SIMD quintiles 1 and 2.
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Figure IThe location of CMR practices in Scotland
C oB tim oQ s M oib id i*y  Rmcordm g P n c t ic a s
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Figure 2 The proportion of men and women stratified by age group in the CMR practice population 
and in the Scottish population in the years ending March 2000 and March 2002
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Figure 3 The proportion of the CMR practice population and the Scottish population* in the year 
ending March 2000 and March 2002 stratified by deprivation quintiles based on the Scottish Index of 
Multiple Deprivation
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3.1.2 Quality of the data
ISD administers the CMR project and operates a continuous quality assurance system for 
completeness and accuracy of entry. This involves a rolling programme of practice visits to 
compare CMR data with practice held records. Completeness is measured by comparing 
the number of contacts on the CMR database in a complete week with the number of 
contacts seen by the practice during that week. Accuracy is assessed by comparing clinical 
notes with the Read Codes held on the CMR database for a random sample of 80 contacts 
in each practice. Data from practices with less than 90% accuracy and 92.5% completeness 
are not included in the national sample. In 1999-2000 the completeness of capture of 
contacts was 91% and the accuracy of Read coding was 91%. The long-term nature of the 
database and its clinieal focus ensures that initially uncertain events are confirmed or 
refuted over time and the diagnostic codes amended appropriately.
3.1.3 Organisation and extraction of data
Information is extracted from CMR practices by the EQ software programme and stored in
Rich Text Format. This information is then converted and stored in Microsoft SQL server
software. Microsoft SQL server software uses Standard Query Language (SQL) to extract
data from long lists of information (‘base’ tables). Several ‘basic’ tables exist which can be
used for investigation. The ‘Patient’ table includes information on the patient’s date of
birth, sex, postcode sector, Cai’stairs deprivation category and the type of registration
(temporary or full). The ‘Clinical Events’ table includes information on every diagnosis
coded using Read codes, diagnosis name and diagnosis date along with a modifier code
(first, recurrent or persistent). The ‘Registration’ table includes date of registration, date of
deregistration and date of death. The ‘Prescribing’ table contains the names, BNF code,
quantity, dose and frequency of drugs prescribed, the start and finish date of the
prescription and whether the drug was prescribed as a repeat or acute script. All tables
contain unique practice and patient identifier numbers. The number of patients that are live
and registered in CMR stratified by age and sex is used as a measure of the population at
risk to calculate age and sex specific rates. Using the database language Transact SQL
queries are written to extract information from these basic tables so that a specified doctor
diagnosis that any patient has received (e.g. angina, heart failure or atrial fibrillation) can
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be viewed and amalgamated with patients given the same diagnosis. A single database can 
be created containing all patients with a specific illness and relevant demographic, clinical 
and prescribing information.
3.1.4 Data extracted for the present studies
CMR data was analysed to examine:
1. Prevalence, incidence, primaiy care burden and medical treatment of angina in 
Scotland (Chapter 4)
2. Prevalence, incidence, primary care burden and medical treatment of heart failure 
in Scotland (Chapter 5)
3. Prevalence, incidence, primary care burden and medical treatment of atrial 
fibrillation in Scotland (Chapter 6)
All study protoeols were approved by the Scientific Advisory Group of the Primary Care 
Clinical Informatics Unit -  Research (PCCIU-R).
3.1.4.1 Angina
For the year April 2001 to 31'^  ^March 2002 prescribing and morbidity data from 55 
General Practices with a total practice population of 362,155 fully registered patients (7% 
of the Scottish population) were obtained from the Primaiy Care Clinical Informatics 
Research Unit (PCCIU-R) based at the University of Aberdeen. All patients who had been 
labelled as ever having angina (includes stable and unstable angina) were included.
The following Read Codes for angina were included -  G33 (angina pectoris), G3111 
(unstable angina), G3112 (angina at rest), G3113 (refractory angina), G3114 (worsening 
angina).
Each patient record contained information on age, sex, GP practice, number of GP contacts 
in the yeai’ and an incidence marker. Information on medications included aspirin, 
clopidogrel, warfarin, statins, betablockers, nicorandil, calcium channel blockers, nitrates, 
ACE inhibitors and angiotensin receptor blockers, hi addition the following comorbidities 
were included; hypertension, back pain, chest infection, upper respiratory tract infection, 
chronic obstructive pulmonary disease, dyspepsia, diabetes, depression, pain in limb, heart 
failure, ischaemic heart disease and atrial fibrillation. Postcode sectors were used to derive 
Carstairs socio-economic deprivation scores, which were used to categorise patients into
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deprivation c a te g o rie sR e s id en t postcodes were used to assign a Carstairs deprivation 
category from one (least deprived) to five (most deprived) to each individual. These 
categories are derived from 1991 census data on four variables: the proportion of persons 
in households without a car; the proportion of economically active males who are 
unemployed; proportion of persons in private households with a density of more than one 
person per room; the proportion of persons in households with an economically active head 
of household in social class 4 or 5.
3.1.4.2 Atrial fibrillation
Atrial fibrillation data for the year April 2001 to March 2002 was obtained from 
PCCIU-R. Morbidity and prescription information was available for 55 General Practices 
with a total practice population of 362,155 fully registered patients (7% of the Scottish 
population). All patients who had been labelled as ever having atrial fibrillation were 
included. The following Read codes for atrial fibrillation were used; 3272 (ECG: atrial 
fibrillation), 3273 (ECG: atrial flutter), G573 (atrial fibrillation and flutter), G5730 (atrial 
fibrillation), G5731 (atrial flutter), G5732 (paroxysmal atrial fibrillation), G573z (atrial 
fibrillation and flutter NOS).
Each patient record contained information on age, sex, GP practice, number of GP contacts 
in the yeai’ for atrial fibrillation, an incidence marker and comorbidities. Prescribing 
information on the following medications were included; aspirin, clopidogrel, warfarin, 
verapamil, diltiazem, betablockers, sotolol, digoxin, propafenone, disopyramide, quinidine, 
flecainide and amiodarone.
3.1.4.3 Heart failure
Heart failure data, from 53 practices participated in CMR between 1"^  ^April 1999 and 31'^  ^
March 2000 was obtained from ISD. These practices had a total registered practice 
population of 307,741 patients representing 6% of the total Scottish population.
Prescribing information was available from the PCCIU-R for 22 of the CMR practices with 
a combined list size of 140,246 patients (2.6% of the Scottish population). All patients who 
had a consultation generating a heart failure related Read code during the year ending 31 
March 2000 were included in the analysis. The Read codes uses were; G58.. (heart failure), 
G580. (congestive heait failure), G5800 (acute congestive heart failure), G5801 
(chroncongestive heart failure), G5802 (decompensated cardiac failure), G5803
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(compensated cardiac failure), G581 (left ventricular failure), G5810 (acute left ventricular 
failure), G582 (acute heart failure) and G58z (heart failure not otherwise specified).
Repeat prescription data were obtained for a representative subset of the “period 
prevalence” group, in order to describe which medications these patients took on a regular 
basis. This information was obtained from the PCCIU-R based at the University of 
Aberdeen. It included prescribing information from 22 CMR practices with a combined list 
size of 140,246 patients (2.6% of the Scottish population). The age range, sex distribution 
and level of deprivation in these patients were comparable to those in the total Scottish 
population. Newly started medication (i.e. where a second prescription had not been 
issued) was not accounted for. The prescription rates reported may, therefore, slightly 
underestimate the true rate of use of the drugs concerned.
3.1.5 Statistical analysis
All tests of statistical significance were two tailed. All analyses were undertaken using the 
Statistical Package for Social Scientists (SPSS hie. Version 11.5, Chicago, Illinois 60611), 
Confidence Interval Analysis for Windows (CIA, 1998) and Centres for Disease Control 
and Prevention’s statistical package Epi Info (2002, Revision 2).
3.1.5.1 Descriptive analysis 
Prevalence
The prevalence of a disease is the proportion of a population that have the condition at a 
point in time (also referred to as point prevalence). Period prevalence refers to the 
proportion of the population that are cases within a designated period of time (for instance 
per annum). Prevalence per 1000 population was calculated using the following formula: 
Prevalence- (number of existing cases/ population at risk) X 1000 
The denominator used in these studies to calculate prevalence was the total registered 
practice population for the year studied. For the atrial fibrillation and angina analyses 
prevalence was calculated by estimating the proportion of total registered practice 
population who ever had a diagnosis of atrial fibrillation or angina. For heart failure period 
prevalence was estimated by including all patients who had a consultation generating a
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heart failure related Read code from in the 12 month period from L* April 1999 to 31"^  
March 2000, Any patient who died or moved away from the practice prior to 31 March 
2000 was excluded. Patients not attending their GP during the year of the study were also 
not accounted for. While this may have led to an underestimate of prevalence, it is 
unlikely that many patients with heart failure will not attend their GP within a 12 month 
period.
Incidence
The incidence of disease is the rate at which new cases occur in a population during a 
specified period ie the number of patients during the period of study who present with an 
illness for the first time. Incidence was calculated by including all patients with a Read 
code for the disease being studied which had a modifier of “first” for the year studied. 
Incidence per 1000 population per annum was calculated using the following formula: 
Incidence = number of new cases / (population at risk x time during which the cases were 
ascertained) X 1000
The population at risk was the total registered practice population for the year studied. 
Contact rates and number of contacts per patient
Contact rates (total number of consultations/attendances for the year where that condition 
was indicated as relevant to the visit) were also calculated using the following formula: 
Contact rate= (number of contacts/ population at risk) X 1000
The population at risk was the total registered practice population. The average number of 
contacts per patient was calculated by dividing the number of contacts relevant to the 
condition in one year by the number of patients with that condition.
As the CMR practices are age and sex representative of the Scottish population, the CMR 
data were used to estimate prevalence, incidence and contact rates for the whole Scottish 
population (5.1 million) on an age and sex specific basis, derived from the 2001 census.
Chi-squai'e tests and chi-square tests for trend were used to compare prevalence, incidence, 
contact rates and prescribing data between different age groups and deprivation categories. 
Indirect standardisation was used to adjust incidence, prevalence and contact rates for age 
and sex differences in the practice population in each deprivation category. Indirect 
standardisation was performed by applying age and sex specific prevalence, incidence and
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contact rates to the CMR population in deprivation categories 1-5 to get an expected 
number of events. The ratio of observed to expected events was then applied to the average 
event rate to get age and sex standardised rates.
For comparative purposes, contact rates for other common cardiovasculai' conditions are 
also described and we examined where each condition ranks amongst all reasons for 
consultation with a GP. Prescription rates stratified by sex, age and deprivation category 
are also described.
3.1.5.2 Logistic regression
Using the drug of interest as the dependent variable, multivaiiable logistic regression was 
performed to examine the independent effects of age, sex, deprivation category and general 
practitioner on prescribing of different medications. The odds ratios were adjusted for 
potential prognostic factors including sex, age, deprivation category, general practitioner. 
Co-morbidity (including conditions which may influence prescribing of angina 
medications such as prior myocardial infarction, hypertension, heart failure, stroke, atrial 
fibrillation and chronic obstructive lung disease) was also adjusted for in the angina 
analysis.
3.2 Linked Scottish Morbidity Recording Scheme (SMR)
3.2.1 Data sources
3.2.1.1 Scottish morbidity records
Healthcare data for individual patients in Scotland is collected as a series of Scottish 
Morbidity Records (SMR). The record type denotes the general type of healthcare received 
during an episode and/or the nature or status of the patient. The hospital activity SMRs are 
outpatient attendances (SMROO), all dischai’ges from acute hospitals (SMROl), maternity 
units (SMR02), psychiatric units (SMR04), neonatal units (SMRl 1) and geriatric long stay 
inpatients (SMR50). Analysis of SMROl data was used for this study. An SMROl is an 
episode-based patient record relating to all inpatients or day cases discharged from non- 
obstetric and non-psychiatric specialties. Fleetive and emergency admissions aie included.
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An SMROl is generated when a patient is discharged home from hospital, transferred to 
another clinician (either at the same or a different hospital), changes specialty (either under 
the same or a different clinician), or dies. Data collected includes patient identifiable and 
demographic information as well as episode management details (such as length of stay) 
and general clinieal information. Each patient is given a principal diagnosis and up to five 
secondary diagnoses and up to four operative procedures. These secondary diagnoses or 
comorbidities are recorded if they affect the management of the patient or are associated 
with the main condition or are chronic conditions. Diagnosis at discharge is coded using 
the World Health Organisation (WHO) International Classification of Diseases (ICD) 
sy stem .D iseases  were coded using the ninth revision (ICD-9) up to March 31st 1996 
and the tenth revision (ICD-10) thereafter. The data is abstracted from ease notes and then 
transcribed onto an SMROl form. The Information and Statistics Division (ISD) of the 
Common Services Agency (CSA) collates the data at National level.
3.2.1.2 Death certificate data
The General Register Office for Scotland records the causes of death for all Scottish 
residents. The codes used to classify deaths are allocated using the WHO International 
Classification of Diseases. ICD9 was used between 1979 and 1999 and ICD 10 has been 
used since 1st January 2000. Classification of the cause of death is based on information 
collected on the medical certificate of cause of death which contains information on the 
underlying cause of death and up to three other causes considered to have contributed to 
death.
3.2.1.3 Linked Database
Computerised hospital records (Scottish Morbidity Records), cancer registration records, 
mental health records and death registration records belonging to the same patient in 
Scotland are linked together in the Scottish Record Linkage System. Record linkages 
have been carried out in Scotland since the early seventies. Initially it was a slow and 
laborious process. A joint project between ISD and the CSA started in May 1989 and led to 
the development of permanent linked data sets of Scottish health related data. The linked 
data set holds hospital discharge records for non-psychiatric, non-obstetric specialties 
(SMROl) together with Cancer Registry records (SMR6) and Registrar General’s death 
records from 1981 until the present day. Ad hoc linkages can also be earned out dating 
back to 1968.
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3.2.1.4 Methods of linking
Records from individual hospital episodes from different SMR schemes together with 
records from the Registrar General are pulled together using probability matching record 
linkage to provide profiles for each patient. Howard Newcombe from Canada was the 
pioneer and founder of probability matching techniques in the 1950s. Over the last thirty 
years, methods of probability matching have been developed and refined in Oxford, 
Scotland and Canada and are used by the Record Linkage System to allow for inaccuracies 
in the identifying information. When records are linked, two records are compared 
using identifying items such as surname, first initial, sex, year, month and day of birth and 
postcode and a decision is made as to whether they belong to the same individual.
Surnames are changed to coded format in order to avoid the effects of differences in 
spelling. A computer algorithm calculates a score for each pair of records that is 
proportional to the likelihood that they belong to the same person. The huge volume of 
data would mean it is be impossible to carry out probability matching on all pairs of 
records involved in the linkage and blocking is used to cut down the number of 
comparisons required. Only those records that have a minimum level of agreement in 
identifying items are compaied. Probability matching then allows mathematically precise 
assessment of the implications of the levels of agreement and disagreement between 
records.
3.2.2 Quality of the data
The linkage process is largely automatic as a threshold score based on probability
matching dictates the decision as to whether the records belong together. Clerical checking
has shown that the accuracy of probability matching is 98-99%.^°^
The Quality Assessment and Accreditation (QAA) Unit of ISD monitors the quality of
SMR data, by assessing accuracy, completeness, consistency and fitness for pui-pose. It
cai'ries out routine validation of a sample of SMROl records where data held on the
sampled records are compared with information contained in the medical case notes. An
assessment of the accuracy of SMROl data, carried out between 2000 and 2002, on a 2%
sample of SMROl data found the accuracy for recording of clinical data at the three-digit
level was 88% for the main diagnosis falling to 81% at the four-digit level.'*^  ^The accuracy
of the main diagnosis was 89% from the 1997/98 audit. Coding of secondary diagnosis was
less accurate at 77% and the most frequently observed omissions from secondary diagnosis
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included chronic ischaemic heart disease, hypertension, asthma, diabetes and angina. The 
accuracy for main procedure/ operation was 91 % accurate and other procedures/ operations 
92% accurate. The accuracy for non-clinical data items was 97%. The accuracy of AMI, 
angina and chest pain coded as a principal diagnosis was shown to be 86%, 88% and 93% 
respectively. The accuracy of AMI coded as a principal diagnosis had been shown to be 
97% in the 1996/97 audit.
3.2.3 Organisation and extraction of data
The linked data is stored as a conventional flat file of records. The records for each 
individual are stored adjacently in chronological order and marked with a unique personal 
identifier. Different types of record are stored in their original unlinked format and are 
preceded by several fields of linkage information. The dataset is complex and requires 
tailored FORTRAN programs to access the data. The staff in ISD use FORTAN 
programming to produce specific datasets. In collaboration with staff at ISD, data specs 
were written which detailed the nature of the data required for these studies.
3.2.4 Data extracted for present studies
All study protocols were approved by the Privacy Advisory Committee which is an 
independent body set up in 1990 to provide advice on requests for the release of data by 
ISD.
SMR data was used to examine:
1. Trends in hospital discharge rates for suspected acute coronary syndromes in 
Scotland between 1990 and 2000 (Chapter 7)
2. Short-term and long-term outcomes in patients admitted with suspected acute 
coronary syndromes in Scotland between 1990 and 2000 (Chapter 8)
3. Between-hospital variation in short-term survival following an acute myocardial 
infarction (Chapter 9)
3.2.4.1 Suspected acute coronary syndromes 1990-2000
All adults (16 years and over) with a ‘firs t’ emergency hospitalisations with a “principal”
discharge diagnosis (coded in the first position) of AMI (ICD 9: 410, ICD 10:121 or 122),
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“hospitalised angina” (ICD 9: 411 or 413, ICD 10:120 or 124.9) or “other chest pain” (ICD 
9: 786.5, ICD 10: R07) in Scotland between January 1990 and December 2000 were 
identified. In addition all subsequent deaths occurring in these individuals up until 3C  ^
December 2001 were also identified. This allowed patients to be followed up for a 
minimum of one year to the end of the study (31st December 2001). A “first” 
hospitalisation was defined as one occuning in a patient with no previous discharge 
diagnosis of coronary heart disease or chest pain (ICD 9: 410-414, 786.5, ICD 10 120-125, 
R07) in the principal coding position, in the previous 10 yeais. This means there was an 
equal look back for all patients avoiding double counting and bias.
During a continuous inpatient stay, individuals may be coded with a number of different 
diagnostic codes. In the current study the principal diagnosis was based on the last 
cai'diovascular diagnosis in this continuous inpatient stay. Therefore, individuals who are 
diagnosed as chest pain or angina, before a definitive diagnosis of AMI is made, are 
included in the study as AMI. Individuals hospitalised with an AMI who are subsequently 
transferred with a diagnosis of angina are included in the study as angina. Individuals, 
who have a non-caidiovascular diagnosis at any point during their admission, are also 
included in the analysis. This avoids double counting of patients as each individual can be 
given only one diagnosis during their inpatient stay. Each patient record contains 
information on the dates of admission and discharge, age, sex, postcode of residence and 
date of death, if it occurred. Postcode sectors were used to allocate Carstairs deprivation 
categories on the basis of four variables from the 1991 census, namely male 
unemployment, overcrowding, social class and car ownership as described previously.^^^ 
Secondary diagnoses in positions two to six were examined in order to determine the most 
frequent concomitant diagnoses. These were then recoded into categorical variables.
Using the record linkage system, all prior hospitalisations occurring within five years of 
the index hospitalisation, were identified and coded according to the principal diagnosis 
recorded at discharge. Co-morbidity was defined as any concomitant diagnosis or as any 
principle diagnosis in a prior admission within five years of the index admission, 
categorised as: diabetes; (ICD9 code 250); respiratory disease (480-496); cancer (140- 
208); cerebrovascular disease (430-438); peripheral vascular disease (440-443); 
hypertension (401); renal disease (463); or atrial fibrillation, (427.3) [ICD 10 codes ElO- 
E14, J10-J18, J 40-J47, C00-C99,160-169, G 45,170-178,110-113, N17-N19, and 148 
respectively]. All 32 acute hospitals in Scotland were included in the analysis, of which 
eight were university hospitals and six had cardiac catheterisation facilities. Following the 
first index admission, all subsequent admissions for non-fatal events were identified.
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These included non-fatal acute myocaidial infarction, stroke, heart failure, angina and 
revascularisation (coronary artery bypass surgery and coronary angioplasty). Primary cause 
of death was categorised by ICD code.
3.2.4.2 Acute myocardial infarction
All patients discharged (alive or dead) from Scottish hospitals during two periods of time; 
i) between October 1988 and September 1991 and ii) between October 1998 and 
September 2001 with a principal diagnosis of AMI (ICD 9 410, ICD 10 121 and 122) were 
identified. Only discharges for a “first” AMI were analysed. A “first” AMI was defined as 
one where the patient had no prior hospital discharge for AMI. Only hospitals admitting 
patients with emergency medical problems during both study periods (n=26) were 
compared in this analysis.
Each patient record provided information on age, sex, postcode sector, date of discharge, 
hospital discharged from, previous discharges and date of death if it occurred. As discussed 
previously postcodes of residence were used to assign a Carstairs deprivation category 
ranging from one (least deprived) to five (most deprived) to each in d iv id u a l.T h ere  is a 
strong concordance between Carstairs scores for postcode sectors in 1991 and 2001 
(Pearson’s correlation coefficient 1-0.955). All prior discharges within five years were 
identified using retrospective linkage. Secondary conditions on the index admission 
allowed the identification of up to five co-morbidities.
3.2.5 Statistical analysis
All tests of statistical significance were two tailed. All analyses were undertaken using the 
Statistical Package for Social Scientists (SPSS Ine, Version 11.5, Chicago, Illinois 60611) 
and Confidence Interval Analysis for Windows (CIA, 1998).
3.2.5.1 Suspected acute coronary syndromes 1990-2000
The suspected acute coronary syndrome database was used to look at
1. Trends in hospital discharge rates for suspected acute coronary syndromes in 
Scotland between 1990 and 2000 (Chapter 7)
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2. Short-term and long-term outcomes in patients admitted with suspected acute 
coronary syndromes in Scotland between 1990 and 2000 (Chapter 8)
3.2.5.1.1 Descriptive statistics
Baseline data were compared using chi square tests and ehi square tests for trend for 
categorieal data and t tests for continuous data. Population denominator data were used to 
derive population-based discharge rates per 100,000 stratified by sex, age and year of 
admission. Rates were calculated using official age and sex specific population estimates 
obtained from the General Registrar for Scotland for each year between 1990 and 2000. 
Linear regression was used to test the significance of the observed trends in population 
discharge rates and numbers. Age and sex-specific rates for non-fatal events (non-fatal 
acute myocardial infarction, stroke, heart failure, angina and revascularisation) were 
calculated for individuals following the index suspected acute coronary syndrome 
admission.
3.2.5.1.2 Survival analysis
Crude case-fatality rates at 30 days and five years were compared in men and women who 
were categorized into five age groups. Survival time was calculated as the time from first 
admission for suspected acute coronary syndrome, to death from any cause; or eensored at 
31/12/2001. Age and sex specific survival rates were calculated for the follow up periods 
using the actuarial life table method. This takes account of admission dates and periods of 
follow-up, which differ between patients.
Kaplan-Meier survival curves were drawn in order to graphically illustrate the probability 
of fatal or non-fatal event in men and women following an AMI or angina admission. The 
log rank test was used to test the null hypothesis that these two groups are samples from 
the same population as regards survival experience. This involves calculating the observed 
and expected number of deaths in both groups at separate time intervals and summing 
these.
Cox’s proportional hazards
Cox’s proportional hazards models were then used to determine whether sex, age, socio­
economic deprivation, comorbidity and year of admission were independently associated
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with survival at five years excluding those deaths that occurred during the first 30 days 
following admission. The Cox’s proportional hazards model compares the hazard functions 
for each level of the model. This was carried out using an enter model. Cox proportional 
hazard models were also used to adjust for the effects of age, sex, year of admission, 
deprivation and co-morbidity on the risk of each subsequent non-fatal event in the two 
groups. All variables were entered simultaneously. For each variable entered into a model, 
the lowest class was set at unity. After fitting the final model, the assumptions were 
checked. The assumptions underlying a Cox’s proportional hazards model are
• Proportional hazards, the ratio of hazard functions for two individuals with 
different covariâtes does not vary with time.
• Linearity, the relationship between the covariates and the hazard function 
should be linear in the log space.
• Survival times should be independent and the mechanisms giving rise to 
censoring of individual subjects should not be related to the probability of an 
event occurring.
These were checked by looking at a log-log plot for each categorical covariate in the 
model, which should demonstrate parallel lines if the hazards are proportional.
Logistic regression
Multiple logistic regression was used to calculate the adjusted odds ratio for the probability 
of death within 30 days following an admission with a suspected acute coronary syndrome 
and to quantify the independent effects on survival of: age, sex, socioeconomic 
deprivation, year of admission and comorbidity (including respiratory disease, diabetes, 
cancer, cerebrovascular disease, peripheral arterial disease, hypertension, heart failure, 
atrial fibrillation, and renal failure). Men and women were considered separately in the 
models, because sex was a significant predictor of outcome and because of an interaction 
previously seen between age and sex in short term outcome following an acute myocardial 
in farction.^A ll variables were entered simultaneously into the models. For each variable 
entered into a model, the lowest class was set at unity. Adequacy of fit was assessed using 
the Hosmer Lemeshow Goodness-of Fit-Test and all were statistically non-significant.
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3.2.S.2 Acute myocardial infarction
The acute myocardial infarction database was used to examine
1. Between-hospital variation in short-term survival following an acute myocardial 
infarction (Chapter 9)
3.2.5.2.1 Descriptive statistics
Baseline eharacteristics of patients admitted to hospital within the two time periods were 
compared using chi-square test for discrete variables and Student t-test for continuously 
distributed variables. Crude 30 day survival was calculated for each hospital and for 
Scotland as a whole by use of the actuarial life table method. Indirect standardisation was 
then used to adjust hospital-specific 30 day survival rates for age and sex differences 
between the hospital population and the whole Scottish population.
3.2.5.2.2 Survival analysis
Multiple logistic regression models were used to determine the independent effect of 
hospital on 30 day case fatality after adjusting for the effects of age, sex, deprivation 
category and prior and eo-morbidity. The hospitals were entered into the logistic models as 
one categorical variable. The ‘index’ hospital was set as that with a case fatality nearest the 
Scottish crude case fatality for that time period. All variables were entered simultaneously 
into the models. Each model was subject to the Hosmer-Lemeshow goodness-of-fit test, 
and all were statistically non-significant.
3.3Renfrew-PaisIey Study
3.3.1 Data sources
3.3.1.1 Midspan studies
The Midspan studies are four separate occupational and general population cohort studies 
based in Scotland; the Main and Tiree study (an industrial group of 3931 individuals from 
13 factories in the central belt of Scotland), the Collaborative study (an occupational group
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of 7028 individuals from 27 workplaces in the central belt of Scotland), the Renfrew- 
Paisley study (a general population cohort from Renfrew and Paisley in the outskirts of 
Glasgow) and the Family study (2238 offspring of married couples in the Renfrew-Paisley 
study). The use of large-scale epidemiological studies for public health research was 
pioneered in Scotland by Victor Hawthorne in the 1960s. The Midspan studies originated 
in the post war drive to control pulmonary tuberculosis using mass miniature radiography. 
This effective screening method of examining large numbers of appai'ently healthy 
volunteers was extended in the Midspan studies to detect and control cardiorespiratory 
risks and diseases in addition to improving the detection and control of tuberculosis. For 
this thesis data from the Renfrew-Paisley study was used and will be discussed in more 
detail.
3.3.1.2 Sample and Baseline Data
The Renfrew-Paisley study is a general population study of 7048 men and 8354 women 
living in the industrialised towns of Renfrew and Paisley, near Glasgow in the west of 
Scotland.^Eligibility for the Renfrew-Paisley study was established by a door-to-door 
census of all households in the two towns in 1972. Between 1972 and 1976, all persons 
aged 45-64 years who met residency criteria were invited to complete a questionnaire and 
attend for a screening examination at one of twelve nearby temporary screening centers. 
78.8% of the target population in Renfrew and 77.9% of Paisley residents was examined. 
Approximately 60% of the cohort re-attended for repeat screening between 1977 and 1979.
The target population in the Renfrew-Paisley study was from a large urban area with high 
levels of socioeconomic deprivation and high mortality rates. In 1980-85 standardised 
mortality rates in Renfrew-Paisley for all cause death was higher than the Scottish average 
and Renfrew ranked 6^ '^  for ischaemic heart disease deaths and 10*^*^ for cerebrovascular 
deaths in Scotland out of 56 other local government d is tric ts .T w e lv e  of the 16 postcode 
sectors in Paisley and Renfrew were in Carstairs’ deprivation categories 4-7. One sector 
had the highest deprivation score in Scotland. In the 1981 census 63% of households in 
these two towns rented their accommodation from the local authority. Thirty per cent of 
households were overcrowded, 44% had no car, 13% of men were unemployed and 25% of 
heads of households were in social class 4 or 5.^ "^^
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Each subject’s demographic profile and cardiorespiratory health status were documented. 
Table 23 shows the study data recorded at the screening visit. Social class was determined 
by occupation according to the Registrar General’s classification, except for housewives 
and retired women whose husbands’ or fathers’ occupations were used instead.^R esident 
postcodes were used to assign a Carstairs deprivation category from one (least deprived) to 
five (most deprived) to each individual as described p rev io u sly .A n g in a  pectoris 
(identified by the Rose angina questionnaire), possible myocardial infarction (identified by 
a separate question on Rose questionnaire as having ever experienced a severe pain across 
the front of chest lasting for half an hour or more) and chronic bronchitis (determined by 
the Medical Research Council’s chronic bronchitis questionnaire) were n o t e d . P a s t  and 
current medical history and risk factors for caidiorespiratory disease were documented. A 
smoking history was recorded including average number of cigarettes smoked per day 
(never smoked, 1-14, 15-24, 25-34, 35 or more), ex-smoker (less than 5 years or 5 years or 
more) or pipe or cigar smoker. Blood pressure was recorded as the mean of two 
measurements taken in the seated position and diastolic pressure was recorded at the 
disappearance of the fifth Korotkoff sound. Height and weight were recorded and used to 
calculate body mass index in kg/m^ (weight in kg divided by height in meters squared). 
Forced expiratory volume in 1 second (FEVO was m e a s u r e d .^ A n  adjusted FEV, was 
calculated as a percentage of the “expected” FEV] (derived from a linear regression 
equation of age and height for men and women separately from a healthy subset of the 
sample who were nonsmokers and had no respiratory symptoms) and the actual FEV ]. The 
cardiothoracic ratio was based on a chest radiograph and cardiomegaly was defined as a 
cai'diothoracic ratio > 0.55. Plasma cholesterol and glucose concentrations were measured 
in a 10ml non-fasting blood sample. Glucose concentration was not measured during the 
whole screening period and was, therefore, only available for 69% of the total cohort. A 
six-lead electrocardiogram (ECG) was also obtained (leads I, II, III, aVR, aVL and aVF) 
and coded using the Minnesota coding system.^
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Table 23 Renfrew-Paisley study data recorded at screening
Questionnaire data Clinical measurements Derived data
Sex Blood pressure Social class
Marital status Height Deprivation category
Date of birth Weight Body mass index
Oecupation Sputum
Exercise Tine test
Bronchitis Chest X-ray
Weather effect on breathing Cardiothoracic ratio
Detailed questions on 
smoking habit
Respiratory funetion, EEV1, 
FVC
Rose angina questionnaire ECG (Minnesota code)
Severe chest pain Plasma cholesterol
Diabetes Blood sugar*
Past history of hospital 
admissions
S odium *1%
Stroke symptoms Potassium*
Asthma / hayfever Oxygen saturation*
Years in present homef Haemoglobin*
Carboxyhaemoglobin*
* Only available on some subjects 
t  Renfrew only
124
3.3.1.3 Study follow-up
Electronic linkage to hospital and death records is possible for all residents of Scotland, as 
previously described. The Scottish Morbidity Record Scheme was used to retrieve details 
of all hospital dischai'ges (according to the eighth [a small number of initial episodes] and 
ninth revisions of the World Health Organisation International Classification of Diseases) 
over the 20 years after initial screening (i.e., surviving subjects were aged 65 to 84 
y e a r s ) .T h e  occurrence and timing of admissions for acute myocardial infarction (ICD9 
410), coronary heart disease (ICD9 410-414), heart failure (ICD9 425.4, 425.5, 428, 402), 
deep venous thrombosis (ICD9 451.1) and pulmonary embolism (ICD9 415) (collectively 
referred to as venous thromboembolism), aortic aneurysm (ICD9 441), atrial fibrillation 
(ICD9 427.3) and stroke (ICD9 430-438) was noted. These diagnoses, in combination with 
a number of other less commonly recorded diagnoses are collectively called cardiovascular 
hospitalisations (ICD9 390-459). Emergency, transfers and elective admissions were 
included in total hospital admissions. Deaths and their certified cause were obtained from 
the General Register office for the same period.
3.3.2 Quality of the data
The self-completed health questionnaire at baseline screening was checked by experieneed 
interviewers at the screening examination. As discussed previously SMR data are 
approximately 90% accurate in identifying the correct discharge diagnosis.^^^ Death 
certificate data has been shown previously to be virtually complete with no discrepancies 
in coding comparisons of causes of death by the Registrar and by independent 
physicians.^
3.3.3 Organisation and extraction of the data
The Renfrew-Paisley study is centred at the Public Health and Health Policy Division in 
University of Glasgow. Data pertaining to the initial and follow-up screening visits is held 
in SPSS file format. A copy of original questionnaires and screening visit results for each 
patient is also held. The eohort is updated for mortality on a three monthly basis ineluding 
full checks on the status (dead/alive) of the oldest participants. At the time of this study
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subsequent hospital admission data for the cohort were available for 20 years of follow-up 
however this has subsequently been extended. In collaboration with Midspan staff a 
dataspec was written which detailed the nature of the baseline and follow-up data required 
for the studies in this thesis.
3.3.4 Data extracted for present studies
Written consent was given at the time of the studies in the 1970s for hospital records to be 
looked at. Ethical permission was obtained from MREC and Argyll & Clyde LREC for 
linkage with the Scottish Morbidity Records system. The Midspan Steering Committee 
approved the studies. Permission was given by the Privacy Advisory Committee of ISD to 
use the linked data.
Eaeh patient record contained all information available from the baseline questionnaire 
(Table 23). Date of death and cause of death until 30^ *^  June 2001 were also included. In 
addition the date of all hospitalisations and cause of all hospitalisations were also available 
up until 30^ ’’ December 1995. Because of the different lengths of follow-up for death and 
hospitalisations, all individuals were followed up until date of death or censorship. Date of 
censorship was 20 years from the date of each person’s initial screening visit.
Using the Renfrew-Paisley data I carried out two studies for this thesis.
1. A population study of the long-term consequences of angina: 20 year follow-up of 
the Renfrew-Paisley study (Chapter 10)
2. Long-term cardiovascular consequences of obesity: 20 year follow-up of more than
15,000 middle aged men and women (the Renfrew-Paisley study) (Chapter 11)
Rose angina criteria
The standard Rose angina classification was used.^ *^  The validity of the Rose angina 
questionnaire has been tested in studies comparing it to a clinical diagnosis of angina, 
electrocardiogram abnormality, thallium scanning and as a predictor of coronary artery 
disease m o r t a l i t y . I n  this classification, Grade I angina is defined as pain or discomfort 
when walking uphill or hurrying. Angina is classified as Grade II angina when the subject 
also reports chest pain or discomfort when walking at an ordinary pace on the level.
Angina is further classified as “definite” if, in addition, the pain is sited in the sternum or 
the left chest and arm, causes the subject to stop or slow down and resolves within 10
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minutes of the subject stopping or slowing down. If these additional criteria are not 
satisfied, angina is classified as “possible”. For the purpose of this study, “angina” was 
defined as Rose grade I and II “definite” angina and was not confirmed by further work up 
or evaluation. Possible myocardial infarction (identified by a separate question on Rose 
questionnaire as having ever experienced a severe pain across the front of chest lasting for 
half an hour or more) was noted. The Rose angina questionnaire is shown in Figure 4.
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Figure 4 The complete Rose angina questionnaire
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Ischaemic ECG criteria
The following Minnesota codes were considered to represent ECG evidence of 
“ischaemia”, 1.1-1.3 (Q waves), 4.1-4.3 (ST junction and segment depression), 5.1-5.3 (T 
wave abnormalities) and 7.1 (left bundle branch block).^'^
Overweight and obesity criteria
According to baseline body mass index (BMI), subjects in the Renfrew/Paisley Study were 
categorised into underweight (BMI < 18.5 kg/m^), normal (BMI 18.5-24.9 kg/nf ), 
overweight (BMI 25.0-29.9 kg/nf) and obese (BMI > 30 kg/m^). Only the data for 
normal, overweight and obese are presented.
3.3.5 Statistical analysis
All tests of statistical significance were two tailed. All analyses were undertaken using the 
Statistical Package for Social Scientists (SPSS Inc, Version 11.5, Chicago, Illinois 60611). 
Data were missing for social class in 409 (2.7%) cases and cholesterol in 124 (0.8%) cases. 
Missing values for social class were replaced with the most common social class in each 
sex and missing values for cholesterol were replaced with the sex specific mean 
cholesterol. Data were missing in a small number of cases for systolic blood pressure (n=7) 
and adjusted FEYl (n=l 1) however the availability of other variables was complete.
3.3.5.1 Angina
3.3.5.1.1 Descriptive statistics
Men and women were analyzed separately and compared. Those with angina were 
compared to those without angina. Because an abnormal ECG is recognised to be of 
prognostic importance, subjects with ischaemic ECGs were analyzed separately from those 
without ischaemic ECGs and the groups were compared.^^^ Therefore for men and women 
there were four groups examined -  i) angina and an ischaemic ECG, ii) angina and no 
evidence of ischaemia on ECG, iii) no angina and an ischaemic ECG and iv) no angina and
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no evidence of ischaemia on ECG. Categorical variables were compared using chi-square 
test and continuous variables were compared using Student t-test.
33.5.1.2 Survival analysis
Case-fatality and event rates were calculated over the 20-year follow up period using the 
actuarial life table method. 17 (0.1%) patients were excluded from the survival analyses as 
they had emigrated and their vital status was unknown.
3.3.5.1.3 Cox’s proportional hazards
Cox proportional-hazards regression models were used to examine the relation between 
Rose-positive angina (with and without an ischaemic ECG) and outcome. Outcome 
included all-cause death, death from cardiovascular causes, cardiovascular hospitalisations, 
cardiovascular death or hospitalisation. Age, blood pressure, cholesterol, prior history of 
diabetes, number of cigarettes smoked per day (with an additional 0/1 variable for ex­
smoker), Rose myocardial infarction, adjusted FEVl and social class were adjusted for. 
The adjusted risk of fatal and non-fatal outcomes in women with angina compared to men 
with angina was also examined. These were adjusted for age, ischaemic ECG, cholesterol, 
systolic blood pressure, adjusted FEVi, smoking, social class, Rose myocardial infarction 
and prior history of diabetes.
3.3.5.2 Obesity
3.3.5.2.1 Descriptive statistics
Baseline characteristics in different weight categories were compared using chi-square 
tests for trend for categorical data and one-way analysis of variance for continuous data. 
The expected number of hospital admissions or cardiovascular deaths in the overweight 
and obese groups was calculated by applying the mean admission rate or cardiovascular 
case-fatality rate per person in the normal weight group to the obese and overweight group. 
The projected burden of obesity was estimated by applying age and sex specific rates of 
cardiovascular events to the obese Scottish population in 1998 using the prevalence of 
obesity as estimated from the 1998 Scottish Health S u rv ey .P o p u la tio n  rates were 
calculated using official age and sex specific population estimates for 1972 and 1998.^^^
3.3.5.2.2 Survival analysis
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Case-fatality and event rates were calculated over the 20-year follow up period using the 
actuarial life table method.
33.5.2.3 Cox’s proportional hazards
Cox proportional-hazards regression models were used to examine the relation between 
body mass index and outcome. BMI was modelled both as a continuous and a categorical 
variable. The assumption of proportional hazai'ds was tested by inspection of the log minus 
log survival plots and this was satisfied. The linearity assumption for BMI as a continuous 
variable was assessed by fitting the models with added quadratic terms. Quadratic terms 
were significant for death. In all other cases the lineality assumption was satisfied. As 
elevated body mass index can mediate its effect on cardiovascular risk by promoting 
atherogenic traits such as hypertension, diabetes and dyslipidaemia therefore two separate 
multivariable analysis were run, the first adjusting for age, sex, adjusted FEVj, number of 
cigarettes smoked per day, social class and the second in addition also adjusting for 
systolic blood pressure, past history of diabetes and cholesterol. 17 (0.1%) patients (1 
subject in the obese category) were excluded from the survival analyses as they had 
emigrated and their vital status was unknown.
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4 PREVALENCE, INCIDENCE, PRIMARY CARE BURDEN 
AND MEDICAL TREATMENT OF ANGINA IN 
SCOTLAND: AGE, SEX AND SOCIOECONOMIC 
DISPARITIES
4,1 Introduction
Angina is an important clinical manifestation of coronary heart disease. In addition in 
patients with angina, the risk of future cai'diovascular events can be reduced with 
aggressive secondary prevention.^^^’^ ^^  Despite this, both the contemporary epidemiology 
and primai'y care burden of this condition aie remarkably poorly described. As evident 
from chapter 1 most existing studies were conducted at least a decade ago. In addition the 
majority examined selected cohorts (e.g. male civil servants, with resultant under­
representation of women and the elderly) and used patient questionnaires to diagnose 
angina.^"^’^ ’^^ ’^*^ ’^ ’^^ ’^^  ^One study, cairied out in 1984, used nitrate prescriptions as a proxy 
for the diagnosis of angina.^^ Another study, conducted by the Northern Region Faculty of 
the Royal College of General Practitioners, did try and identify patients with a physician 
reported diagnosis of an g in a .T h is  survey, however, which took place in 1979 and 
involved 51 general practitioners in the Newcastle region in England, focussed only on 
subjects aged 30-59 years.
Not only is the contemporaiy public health burden of angina poorly described but so is its
TOO • TO Ttreatment. With the emergence of new evidence-based treatments, ’ publication of 
guidelines and government directed national health-improvement programmes in 
coronary heart disease^^^, the analysis of current prescribing patterns for angina is relevant 
and topical. The CMR in General Practice scheme was used to give a more contemporary 
picture of the epidemiology, primary care burden and treatment of angina than existing 
studies.
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4.2 Methods
The CMR angina database was used as described in chapter 3.
4.3 Results
4.3.1 Prevalence
The overall prevalence of angina was 28 per 1000 in men and 25 per 1000 in women. The 
prevalence of angina was lower in women than men at all ages (p<0.05). hr men the 
prevalence was extremely low in those under 45 (1 per 1,000) increasing to 141 per 1,000 
in those over 75 years. In women the prevalence of angina was 108 per 1,000 in those over 
75 years. The highest prevalence in both sexes was in the age range 75-84 years. Though 
the prevalence was higher in men than women, the greater number of elderly women in the 
population meant that more women than men aged 75 years or above had angina and that, 
overall, almost as many women as men suffered from angina. (Table 24)
The prevalence of angina increased with increasing socioeconomic deprivation from 18 per
1,000 in the least deprived group to 31 per 1,000 in the most deprived group i.e. socio­
economically deprived individuals had a 72% higher prevalence of angina than affluent 
individuals (p<0.001 for trend). Similar significant trends were seen in men and women. 
(Table 25)
Extrapolating from the CMR practices to the whole of Scotland, the estimated number of 
Scots with angina in 2001 was 133,131 (67,867 men), 68% of whom were 65 years and 
over and 32% of whom were 75 years and over.
4.3.2 Incidence
The overall incidence of angina for the year 2001/2002 was 1.6 per 1,000. The incidence 
was higher in men (1.8 per 1,000) than in women (1.4 per 1,000). As with prevalence, the
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incidence of angina markedly increased with age from 0.1 per 1,000 in men less than 45 
years, to 6.5 per 1,000 in men aged 65-74 years, and thereafter declined by 50% to 3.1 per
1.000 in men over 85 years. In women the incidence of angina also increased with age, 
although it peaked in the 75-84 year age group (5.8 per 1,000) and thereafter declined to
3.2 per 1,000 in those over 85 years. In those over 65 year's, the incidence of angina was
6.1 per 1,000 in men and 4.7 per 1,000 in women. (Table 24)
The incidence of angina increased with increasing socioeconomic deprivation from 0.8 per
1,000 in the least deprived stratum to 2.2 per 1,000 in the most deprived stratum (p<0.001 
for trend) i.e. socio-economically deprived men were twice as likely to develop angina and 
socio-economically deprived women were three times more likely to develop angina 
compared to affluent men and women. (Table 25)
The estimated number of Scots presenting with angina for the first time in the year 2001 
was, therefore, 8,099 (4,378 men), 53% of whom were aged 65 years or older and 23% of 
whom were 75 years or older.
4.3.3 Contact rates
One year contact rates for angina were higher in men (15.7 per 1,000) than in women (12.3 
per 1,000). Contact rates increased with age. These were extremely low in those under 45 
years, increased 48-fold in men and 44-fold in women from less than 45 years to 45-64 
years and more than doubled again between 45-64 years and 65 years or older. Contact 
rates per 1000 population were highest in both sexes in the age group 75-84 years. (Table 
24) Men and women with angina had about 3 times as many GP contacts per year as those 
without angina and, for men and women with angina, contacts for angina (as opposed to 
other reasons) accounted for approximately 1 in 20 of all GP contacts made.
On average, patients with angina saw their general practitioner 0.5 times per annum.
For both men and women, the highest number of contacts per patient with angina was in 
the 45-54 year age band (0.8 in men and 0.7 in women), and after this, in contrast with 
prevalence and incidence, the number of contacts declined with age. Women aged 45-64 
years and over 85 years had less contacts per patient per year than men (p<0.05).
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The number of contacts per patient with angina declined with increasing socio-economic 
deprivation so that patients in the most deprived group were 33% less likely to see their 
general practitioner on an ongoing basis compared to affluent patients. (Table 25)
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4.3.4 Concomitant medical conditions
The top ten concomitant medical problems in patients consulting with angina are shown in 
Table 26. hi both sexes, upper respiratory tract infection was the commonest reason for 
general practitioner consultation and the most common concomitant diagnostic coding in 
patients with angina (39% of men and 49% of women). Hypertension was the second most 
frequently coded, reported in 34% of men and 42% of women. After adjusting for age, 
women were more likely than men to have concomitant respiratory problems (upper 
respiratory tract infection p<0.001, chest infection p<0.001, chronic obstructive airways 
disease p=0.035), hypertension (p<0.001), backache (p<0.001), dyspepsia (p<0.001) and 
depression (p<0.001) and men were more likely than women to have diabetes (p=0.003), 
pain in limb (p<0.001) and myocardial infarction (p<0.001).
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4.3.5 Pharmacological treatment
Table 27 shows the medications prescribed for patients with angina, stratified by age and 
sex. A P"blocker was prescribed for 49%, a calcium channel blocker for 43%, a nitrate for 
56%, an ACE inhibitor, an angiotensin receptor blocker or both for 33%, a statin for 50% 
and an antiplatelet agent for 71%.
There were significant sex differences in prescribing. Of men, 52% were prescribed a p- 
blocker, 44% a calcium channel blockers, 72% aspirin, 54% a statin, 36% an ACE 
inhibitor or an angiotensin receptor blocker and 20% “optimal evidence-based medication” 
(i.e. all of an antiplatelet medication, statin and an ACE inhibitor). The corresponding 
prescription rates for women were 46% (p<0.001), 41% (p=0.02), 69% (p<0.001), 45% 
(p<0.001), 30% (p<0.001) and 14% (p<0,001). The prescription rates were lower if prior 
history of myocardial infarction was excluded with 17.3% of men and 12.0% of women 
receiving optimal evidence-based medication, compared to 35.8% (36.5% men and 34.5% 
women) with a previous myocardial infarction. On multivariable analysis after adjusting 
for age, deprivation, GP practice and co-morbidity, compared to men, women were less 
likely to be prescribed a P-blocker (OR 0.86 95%CI 0.78, 0.93), a calcium channel blocker 
(OR 0.85 95%CI 0.78, 0.93), an antiplatelet agent (OR 0.82 95%CI 0.74, 0.90), a statin 
(OR 0.83 95%CI 0.76, 0.91), an ACE inhibitor and/or angiotensin receptor blocker (OR 
0.69 95%CI 0.63, 0.76) and optimal evidence based medications (OR 0.68 95%CI 0.60, 
0.76).
There were also significant age-related differences in prescribing. A p-blocker was 
prescribed for 52% of those less than 75 years compared to 42% of those aged 75 years 
and over (p<0.001). Similarly, younger patients were more likely to be prescribed a statin 
(58% <75 years compared to 31% >75 years, p<0.001) and optimal evidence-based 
treatment (19% <75 years compared to 12% >75 years, p<0.001). Older patients were 
more likely to be prescribed a nitrate (61%) and warfarin (8%) compared to younger 
patients (54% [p<0.001] and 5% [p<0.001], respectively). On multivariate analysis, men,
75 years and over were less likely to be prescribed a P-blocker (OR 0.67 95%CI 0.59,
0.78), a statin (OR 0.30 95%CI 0.26, 0.34), an ACEI and/or angiotensin receptor blocker 
(OR 0.76 95%CI 0.65-0.89) and optimal evidence based treatment (OR 0.51 95%CI 0.42,
0.62) and were more likely to be prescribed a nitrate (OR 1.42 95%CI 1.23, 1.62).
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Women, 75 years and over were also less likely to be prescribed a p-blocker (OR 0.71 
95%CI 0.62, 0.81), a statin (OR 0.33 95%CI 0.29, 0.38) an ACEI and/or angiotensin 
receptor blocker (OR 0.78 95%CI 0.66, 0.91) and were also more likely to be prescribed a 
nitrate (OR 1.24 95%CI 1.08, 1.41).
With increasing socioeconomic deprivation, patients were less likely to be prescribed a p- 
blocker (p for trend = 0.018) and more likely to be prescribed a nitrate (p for trend =0.006) 
and an ACE inhibitor (p for trend = 0.02). On multivaiiate analysis, patients in the most 
deprived stratum were 25% more likely to be prescribed a nitrate or a calcium channel 
blocker, 51% more likely to be prescribed an ACE inhibitor and/or angiotensin receptor 
blocker and 81% more likely to be prescribed warfarin compared to patients in the least 
deprived stratum. However, there were no differences in prescribing of statins (OR 0.92 
95%CI 0.77, 1.10) or antiplatelet medications (OR 1.08 95%CI 0.89, 1.32) according to 
socioeconomic deprivation. Socioeconomically deprived individuals with angina were 
64% more likely to be prescribed optimal evidence-based medications.
141
c5
ot.E■s
I
I«
I0
1 I
s
MIU
1cu
ONvdom ommoo mI o oCN3 <Nmoo<N
OO
S
ooooodmONcn00 om(N
O n CNooooo
00m<N ON
o
oo»n
(N
ON
m
(N
OO
(NO mrf)oo
mm
ooo omoo 3 o(NOOm tN(Nm
oNOs qo mON(N mm omoomm oo m(N00mcn
o
NOm
fSooNO m
o
o
om
o ooo00m m 00 oo
Tj-
OO
owS NOO n(Nm
i00m>noo>r) moom oo(N .OIE
(N m o
$
00m
<NmOm00CN
<N O
o 00oom( N
%o
00
( N
OO
NO
( N CN
CN 3CN NO>n
0£
o m
oom
a.m
CN 3CN OVOo mo
■BU ±u  a < « 
II .a -il*o u < oU S
■get
'T
I3O
«OuE82n
>0
1
EI
■g3
S
ISio
I
z
H
I
 ^ I I IS "OC/3
î î
aî
*©
I5Ti
6
«- ts
t
u
(N
Od
0£ OO O
dod d ooo
oo (N q
(N
00
(N
O(NS o <NO o
oCN
S 8
d
o
d oo o o
o
s
d d
o 'O
d
ON
d o o
o CN >o
dooo o
8
d
8
d
o 8CNNO O
s ON s
d
ÿ
d
JSo
NOCN
d
S
d
On ON
d
11odCNONOd W)do o
CN8 8 o 8
d
8
d
o
doo
S ON
d
ON
d
ONON O
oo 00
o o
NO00 §
d
ONCN NOOO
do o o
il u  < < < << * *w- *
4.4 Discussion
111 Scotland, in 2001/2002, the overall prevalence of angina was 2.6 per cent (6.4 per cent 
in individuals > 45 yeai's and 11.3 per cent in those > 65 years). Both prevalence and 
incidence were higher in men than in women and increased steeply with age. The 
prevalence and incidence of angina also increased with increasing socioeconomic 
deprivation though deprived individuals were less likely to see their general practitioner on 
an ongoing basis. Women and older patients were less likely to receive evidence-based 
therapy.
The estimates of prevalence (and incidence) were based on general practitioner reported 
diagnosis. This approach has strengths and weaknesses compai'ed to the more commonly 
used alternative of administration of a questionnaire (usually the Rose one).* There has 
been concerns that the questionnaire approach may overestimate the prevalence of angina, 
especially in women. The positive predictive value of the Rose angina questionnaire in 
compaiison to exercise thallium testing has been reported to be 67%  ^and as low as 25% 
in w om en.C onversely , reliance on a medical diagnosis may underestimate prevalence as 
individuals with unrecognised angina or very mild symptoms might not attend (or be 
correctly identified by) their general practitioner. In the Whitehall II study 70% of those 
who developed angina were undiagnosed at the time of their initial report.^^
I found an overall prevalenee of angina of 2.8% in men (7.1 per cent in subjects > 45 years 
and 13.1 per cent in those > 65 years) and 2.5% in women (5.8 per cent in subjects > 45 
years and 9.9 per cent in those > 65 years). These findings, therefore, give a somewhat 
higher prevalence than the 7.1% prevalence in men over 65 years of age in the Nottingham 
nitrate study carried out 1984-85 and a slightly lower prevalence than the 8.3% 
prevalence in individuals over 45 years reported in a more recent study of 48 general 
practices in the Wakefield region of northern England which used a similai" investigative 
approach to the Nottingham study. Another study, using data from the 1998 Health 
Survey for England, gave a self-reported prevalence of angina (recall of a doctors 
diagnosis) of approximately 3% in men and women 16 years or above.^^^ Indeed, the only 
inconsistent study was the Newcastle General Practice survey, carried out in 1979, which 
reported a prevalence of 1.1% in subjects aged 30-59 yea r s .T he  survey was conducted by
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51 general praetitioners and identified 338 patients; I am, however uncertain about the 
completeness of case-ascertainment in this study.
The prevalence of angina in CMR is also comparable to that reported in some studies using 
a questionnaire-based approach^^’^ ,^ but lower than in others of this type.*^’^** Why the 
prevalence of angina in my study is lower than in those latter studies, is not entirely 
certain. Apail from the methodological difference discussed above, many of the other 
surveys were condueted in selected cohorts and up to 25 years earlier than the current 
study (during which time the incidence of coronary disease is known to have been 
declining). However, even the more recent questionnaire-based studies have reported a 
higher prevalence of angina than found in the eurrent study. For example, amongst the 
10,191 men and women aged 35-55 years enrolled in the Whitehall II study, the prevalence 
of Rose “definite” angina was 2.9%, compared to 1.8% in subjects aged 45-55 years in my 
s t u d y . I n  the British Regional Heart Study, the prevalence of ''possible” or “definite” 
angina on Rose angina questionnaire in 5,263 men aged 55-79 yeai's in 1996 was 13,8%. 
The prevalence of angina in men aged 55-84 years was 10% in the current s tu d y .T h e  
inclusion of "possible” angina in the former study, may, however, have inflated the 
prevalence rate compared to mine. The prevalence of “definite angina”, in 11,797 women 
(mean age 56 years) screened with the Rose angina questionnaire during 1994-1995 as part 
of the Royal College of General Practitioners’ Oral Contraception Study was 9.9% in those 
women over 65 years, which is the same as in the eurrent study. *"* CMR prevalence 
findings are also consistent with another recent report from Sweden.**
Prior studies frequently reported a higher prevalence of angina in women compared to 
men, a finding inconsistent with the epidemiology of acute coronary syndromes, coronary 
deaths and the protection from coronary heart disease enjoyed by pre-menopausal 
women.^'*^’*^ ’*^ ’^  ^This anomaly has been attributed to an increased tendency for women to 
score positive for angina on the Rose questionnaire. I did not find a female preponderance 
of angina; indeed, I saw the opposite, as have other studies based on a physician diagnosis 
or prescription of anti-angina treatment.^ '^^ '^^"*
As in all prior studies, I also found that the prevalence of angina increased with age though 
few have explored the full age range. *°* The majority of patients (59% of men and 69% of 
women) were aged 65 years or above and a substantial minority were 75 years or older 
(25% of men and 37% of women). This is in striking contrast to the typical age range of 
patients enrolled in clinical trials^^^ or undergoing coronary revascularisation (only
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approximately 6% of patients in Scotland undergoing revasculaiisation in 2002/3 were 
older than 75 years). Also of note, although the overall prevalence of angina was lower in 
women than in men, prevalence in older women approached that of men and, because of 
the greater number of older women than men in the population generally, there were more 
women than men aged 75 years or above with angina.
In contrast to prevalence studies, there ai*e very few prior surveys of the incidence of 
angina and most of these date from the 1970’s.'*^ ’"*^’''^  In one more recent study, comparing 
coronary heart disease rates in France and Northern Feland, the incidence of angina in 
French men aged 50-59 years was 2.6 per 1000 compared to 5.4 per 1000 in Fish men; in 
Scotland it was 3.5 per 1000 in men aged 45-64 yeai's."*** By contrast, an earlier study from 
Southampton, Fngland reported an incidence of only 0.8 per 1000 in men and women aged 
31-70 years (compared to 2.9 per 1000 in Scotland in individuals aged 45-64 years).
While the standardised mortality ratio (SMR) for coronary heart disease is higher in 
Northern Feland and Scotland than in southern Fngland, the Southampton incidence figure 
seems unusually low (and lower than in France) and probably reflects the methods 
employed in that study. Patient identification required referral to a special chest pain clinic, 
patients with any prior evidence of coronary heart disease were excluded and, where 
possible, patients underwent exercise electrocai’diography. A rigorous definition of angina 
was applied. Of the 467 individuals referred, 110 (0.8 per 1000 population) had definite 
angina and another 63 had possible angina.
Consultation rates, refleeting the primai'y care burden of angina were relatively low with 
less than one visit per patient per year. This low rate of contact is in striking contrast to at 
least one other cardiac disorder, heart failure, where we have reported 2 to 3 contacts per 
a n n u m . A l s o  in contrast to heart failure, where the number of contacts per patient per 
year increased with age, the annual number of consultations per patient per year for angina 
decreased with increasing age. Women also had a lower number of contacts per patient per 
year than men, at all ages. The reason for this is not cleai', especially as women, in general, 
have more contacts with primary care physicians than men (approximately twice as many)
i.e. more opportunities for angina to be recorded at a contact. There is some evidence that 
women may seek help for angina less often than men. It is also possible that primary 
care physicians may record angina (as one of a number of problems) less often in women 
than in men (the general practitioner decided which medical problems were recorded as 
clinically important during “contacts”); there is evidence that physicians regard chest pain 
in women as less clinically significant than in men.
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The co-morbidities recorded in patients with angina are not unexpected. Respiratory 
problems aie the commonest reason for a primary cai'e consultation and dyspepsia and 
depression are also known to be common reasons for consultation. The higher proportion 
of co-morbidities in the angina group compai'ed to the general population may be related to 
their older age and more frequent general praetitioner contact. Hypertension, diabetes and 
myocardial infarction reflect the known relationships between these problems and angina. 
The prevalence of these co-morbidities is similar to that reported in other primary care 
studies and large angina trials. Interestingly, I found that patients with angina were 
more likely to have depression than the general population. An association between a 
history of depression and a higher frequency of angina attacks has been shown 
previously .Although patients with angina might be expected to have more comorbidily 
than those without, the difference may have been exaggerated because patients with angina 
have more frequent contact with their GP and therefore more opportunity for comorbidities 
to be recorded.
This study gives one of the most representative and up to date descriptions of treatment of 
patients with angina. The use of evidence-based secondary preventive treatments is higher 
than in most prior studies^ ^ '^^ ^*^  and similai' to that found in the Euro Heart Survey of Stable 
Angina which focused on newly diagnosed angina presenting to a cardiologist^^^.
Although only 73% of patients with angina in CMR were recorded as treated with anti­
platelet therapy others may be using “over the counter”, self-purchased aspirin. However, 
only about half of patients were prescribed a statin and less than a third an ACE inhibitor 
when the most recent evidence supports the use of these drugs in all patients who can 
tolerate them.^^^’^ ^^ ’^ ^^ . Drugs which modify lipids or reduce the risk of thrombosis 
substantially reduce the risk of myocardial infarction and death. " ACE inhibitors can 
also significantly improve outcome in patients with stable coronary artery disease.^^^ I 
found that female sex and older age were associated with under-nsQ of one or more 
guideline-recommended treatments (particularly beta-blockers and statins), even after 
multivariate adjustment. This reflects patterns previously described in the use of coronary 
revascularisation procedures, in the management of acute coronary syndromes and, 
recently, in the treatment of coronary heart disease (myocardial infarction and angina 
combined) in primary care. 2^8.333,336 j know of prior data on angina alone (as
opposed to coronary heart disease); this is an important distinction as patients with prior 
myocardial infarction are more likely to be prescribed these treatments than those with 
angina. 228,336,340 h might be argued that the under-preseribing in this study might,
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in part, reflect the lower number of consultations per patient per year in females and the 
elderly, this is not supported by examination of the pattern of prescribing in socio­
economically deprived patients who appeared to suffer less under-treatment despite lower 
contact rates (see below).
I found a quite strong relationship between socioeconomic deprivation and the prevalence 
and incidence of angina, in keeping with previous reports of higher levels of a number of 
different manifestations of coronary heart disease in these disadvantaged individuals. 
Socioeconomically deprived individuals with angina had a lower rate of contacts per 
patient per year. Despite this lower contact rate, deprived patients were less obviously 
under-treated than women or older individuals. Indeed, deprived patients were more likely 
to be treated with ACE inhibitors, perhaps reflecting greater contact with secondary care 
where these drugs are more likely to be used. Another recent UK study has also found that, 
after multivariable adjustment, social deprivation was not associated with under-use of 
either medical treatments or cardiac procedures.
A limitation to my study is that only patients who attend a physician with angina are 
included and it is known that there is a significant proportion of individuals with 
undiagnosed angina in the community Another limitation is that the diagnosis of angina 
is a GP diagnosis and not necessarily substantiated by definitive investigations. The CMR 
practices tend to be larger partnerships and are more likely to be training practices 
therefore the prescribing rates for whole of Scotland may be even lower than that presented 
here in CMR.
In summary, I have described the substantial burden of angina in primary care. It is a 
common condition affecting 3% of the population, with the prevalence rising to 12% in 
those 75 yeai'S and older. Although the incidence and prevalence of angina increases with 
increasing socioeconomic deprivation, deprived individuals with angina have less frequent 
follow-up with their general praetitioner. Although, overall, the use of evidence-based 
treatments is better than in prior studies, there is scope for further improvement in 
prescribing. The overall sub-optimal use of treatments may, in part, reflect the marked age 
and sex discrepancies in prescribing of evidence-based treatments, with the elderly and 
women receiving less guideline-recommended treatment therapy. These discrepancies 
warrant further investigation.
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5 PREVALENCE, INCIDENCE, PRIMARY CARE BURDEN 
AND MEDICAL TREATMENT OF HEART FAILURE IN 
SCOTLAND: AGE, SEX AND SOCIOECONOMIC 
DISPARITIES
5.1 Introduction
Though heart failure is perceived to be one of the most common, disabling, costly and 
deadly cardiovascular disorders encountered in clinical practice, its epidemiology and the 
burden which it places on health care systems aie still poorly defined, especially in primary 
c a r e . I n  particular, as outlined in chapter 1, incidence studies are lacking. Similarly, 
the other problems with which patients with heart failure consult a GP have not been 
reported. There are also no comparisons of the community burden of heart failure and 
other common cardiovascular disorders. In addition, there are few contemporary data on 
the treatment of heai't failure in primary caie across a whole country.
Socioeconomic deprivation is associated with higher rates of admission to hospital and 
case fatality in heai't failure but the mechanisms aie unclear- indeed, this excess risk seems 
to be independent of age, sex, comorbidities, disease severity, and even medication 
a d h e r e n c e . I t  may be intriguing to speculate about socioeconomic gradients in 
access to general practitioners and outpatient pharmacotherapy being the key causative 
factors, but there is paucity of high quality research on heart failure in primary care.^ "*^
This question is important as heait failure accounts for almost a quarter of all admissions to 
hospital for cai'diovascular events, has a high mortality rate (median survival around 18 
months), and places a great burden on all health care systems (estimated direct costs of 
£905 million in the United Kingdom in 2000, 2% of total NHS expenditure)/  ^ J  43;349 
I have therefore used the Scottish CMR scheme, to give a more comprehensive picture of 
the national epidemiology and primary care burden, of heart failure than existing studies.
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5.2 Methods
The CMR heart failure database was used as described in chapter 3.
5.3 Results
5.3.1 Heart failure Read codes used
Contacts were coded as congestive heart failure (51.0%), left ventricular failure (23.6%), 
heart failure -  not otherwise specified (10.0%), heart failure (6.7%), acute left ventricular 
failure (4.1%), acute congestive heart failure (3.7%), chronic congestive heart failure 
(1.2%), compensated cardiac failure (0.5%) or acute heart failure (0.1%).
5.3.2 Prevalence of heart failure
The one-year CMR prevalence for men and women of differing ages with heart failure is 
shown in Table 29. Prevalence was extremely low in persons aged <45 years, increased 6- 
fold between the age ranges 45-64 years and 65-74 years and more than doubled again 
between the age ranges 65-74 years and 75-84 years. The prevalence of heart failure was 
higher in women (7.8/1000) than in men (6.4/1000). Extrapolating from the CMR 
practices to the whole of the country, the estimated number of Scots with heart failure in 
2000 was, therefore, 37,305 (16,216 men), 87% of whom were aged 65 years or older and 
60% of whom were 75 yeai’s or older (Table 30). The prevalence of heart failure differed 
between deprivation categories (Table, p<0.0001), with a non-significant 13% trend 
towards higher age and sex standardised prevalence rates in the more deprived groups. 
Table 31
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5.3.3 Incidence of heart failure
The one-yeai* incidence for men and women of differing ages with heart failure is shown in 
Table 29. This was extremely low in persons aged <45 years, increased 4 - 5  fold 
between the age ranges 45-64 years and 65-74 years and increased again 2 - 3  fold 
between the age ranges 65-74 years and 75-84 years. The incidence of heart failure was 
higher in women (2.2/1000) than in men (1.8/1000). The estimated number of Scots 
presenting with heart failure for the first time in the year 2000 was, therefore, 10,375 
(4,504 men), 84% of whom were aged 65 years or older and 58% of whom were 75 years 
or older (Table 30). The incidence of heart failure significantly increased with increasing 
social deprivation (Table 31): socioeconomically deprived patients were 44% more likely 
to develop heart failure than affluent patients.
5.3.4 Contact rates for heart failure
The one-year contact rate was extremely low in persons aged <45 yeai's, increased almost 
7-fold between the age ranges 45-64 years and 65-74 years and nearly trebled again 
between the age ranges 65-74 yeai's and 75-84 years (Table 29). The contact rate for heart 
failure was higher in women (17.9/1000) than in men (16.5/1000).
Overall, contact rates were approximately 2-3 times higher than prevalence in both men 
and women. The average number of contacts per patient with heai't failure was 2.6 in men 
and 2.3 in women. The average number of contacts per patient doubled between the 
youngest and oldest subgroups in men (from 1.4 in those <45 years to 2.8 in those 85 years 
or older) and almost doubled in women (1.4 versus 2.5).
hr contrast to prevalence and incidence, the association between socioeconomic 
deprivation and contacts/consultations was in the opposite direction: patients in the most 
deprived groups had 23% less follow-up visits per annum with their general practitioner 
(Table 31). Although the age and sex standai'dised contact rates differed significantly 
between the 5 strata (p<0.00001), the p value for trend was not significant (p=0.07) as 
there was little appreciable difference between categories 1, 2, 3, and 4. However, the 
most deprived subgroup had significantly lower standardised contact rates compared to 
deprivation categories 1 (OR 0.81, 95% Cl 0.72, 0.90, p=0.0002), 2 (OR 0.72, 95% Cl 
0.65, 0.81, p<0.0001), 3 (OR 0.72, 95% Cl 0.65, 0.81, p<0.0001), and 4 (OR 0.79, 95% Cl 
0.70, 0.90, p=0.0003). Contact rates did not differ across age groups or by sex.
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5.3.5 GP contact rates for heart failure compared to hypertension, 
angina and other conditions
For comparison, contact rates for hypertension and angina were 96.2/1000 and 21.2/1000, 
respectively, for men and 133.9/1000 and 19.2/1000, respectively, for women. Figure 5 
shows age-specific contact rates for males and Figure 6 shows age-specific contact rates 
for females for hypertension, angina and heart failure. In older age groups, consultation 
rates for heart failure equalled or exceeded those for both hypertension and, especially, 
angina. Table 32 shows the most common conditions leading to contact with a GP in men 
and women in different age groups. Heart failure was one of the top five reasons for 
consultation in men aged 75 yeai's or older and in women 85 years or older.
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Figure 5 Age stratified GP consultation rates per 1000 population for heart failure, angina and 
hypertension in men
Angina Hypertension Heart Failure
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Figure 6 Age stratified GP consultation rates per 1000 population for heart failure, angina and 
hypertension in women
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Table 32 The five most common reasons for consulting a general practitioner in Scotland by sex and 
age group in year 2000*
Men Women
45-64 65-74 75-84 85-1- 45-64 65-74 75-84 85-1-
Hypertension 1(229) 1 (445) 1(386) 4(155) 3(269) 1(572) 1 (565) 1 (242)
Back problems 2(148) - - - 4(177) 3(150) 4(169) -
Depression 3(125) - - - 2(275) 4(148) - -
Lower RTI 4(88) 2(175) 2(216) 1 (290) - 2(189) 2(216) 2 (240)
Anxiety 5(73) - - - 5(160) - - -
Coronary heart 
disease - 3(156) 5(125) - - - -
COPD - 4(147) 3(198) 3(160) - - - -
Diabetes mellitus - 5(143) - - - - - -
HEART FAILURE - - 4 ( 136) 2 (248) - - - 5 ( 169)
Menopause - - - - 1 (313) - - -
Osteoarthritis - - - - - 5(143) 3(186) -
Urinary tract 
infection - - - - - - 5(147) -
Dementia - - - - - - - 3(215)
General
miscellaneous - - - 5(154) - - - 4(185)
COPD= chronic obstructive pulmonary disease; RTI= respiratory tract infection
*Year ending December 2000; rank (1-5) and consultation rate per 1,000 population (brackets).
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5.3.6 Concomitant diagnoses in patients with heart failure
The top ten concomitant diagnostic codings in patients consulting with heart failure are 
shown in Table 33. In both sexes, lower respiratory tract infection was the most common 
concomitant diagnostic coding (in 28% of men and women). Coronary or ischaemic heart 
disease was the second most frequently coded, reported in 22% of men and 13% of 
women. 14% of men and 16% of women had a concomitant coding for hypertension 
recorded and 12% of and 10% of women had a coding for atrial fibrillation (atrial 
fibrillation was not one of the top 10 concomitantly coded conditions in women with heart 
failure). The frequency of other diagnoses was generally similar in men and women.
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Table 33 Proportion of heart failure patients seen with specified condition/illness; April 1999-March 
2000*
Condition/illness Men
(n=973)
Women
(n=1213)
Lower Respiratory Tract Infection 273 (28 .0 338 (273^
Coronary Heart Disease -  Miscellaneous 216(22.2) 159(13.1)
Breathlessness 201 (20.7) 247 (20.4)
Angina 144(14.8) 141 (11.6)
Chronic Obstructive Airways Disease 142(14.6) -
Upper Respiratory Tract Infection 
(excluding sore throat)
141 (14.5) 176(14.5)
Hypertension 134(13.8) 196(16.2)
Atrial Flutter/Fibrillation 114(11.7) -
Oedema 111 (11.4) 177(14.6)
Miscellaneous 108(11.1) 144(11.9)
Back Problems - 153 (12.6)
Osteoarthritis - 143(11.8)
* number (per cent)
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5.3.7 Medications taken by patients with heart failure
Prescribing information was available from 22 CMR practices with a combined list size of 
140,246 patients (2.6% of the Scottish population). The age range, sex distribution and 
level of deprivation in these patients were comparable to those in the total Scottish 
population. Table 34, 35Table 36 shows the medications prescribed for patients with heart 
failure, stratified by sex and age. Diuretics were prescribed for 81% of these patients, ACE 
inhibitors for 39%, beta-blockers for 21%, digoxin for 21%, and spironolactone for 9%. 
Only 11% of these patients were prescribed both an ACE inhibitor and a beta-blocker, and 
1% was prescribed the combination of ACE inhibitor, beta-blocker, and spironolactone.
There were significant sex differences in prescribing. Eighty per cent of men were 
prescribed a diuretic, 46% an ACE inhibitor, 23% a (3-Blocker, 11% spironolactone and 
24% digoxin. The corresponding figures for women were 81% (p=0.87), 34% (p<0.001), 
20% (p=0.29), 7% (p-0.02) and 18% (p=0.02), respectively (p values for women vs. men). 
There were also significant age differences, with fifty per cent of patients < 75 years, but 
only 33% of patients > 75, prescribed an ACE inhibitor (p<0.001). Twenty six per cent of 
patients < 75 and 19% of patients > 75 years were prescribed a (3-Blocker (p=0.Q4). These 
proportions for spironolactone were 19% and 9%, respectively (p=0.04). There was no 
difference in the rate of use of digoxin.
There was a clear association between age and sex (older patients were more often women) 
and multivariable analyses revealed that age was the most important factor influencing 
prescribing patterns. Indeed, sex was only significantly associated with ACE inhibitor 
prescribing (men were 42% more likely [p=0.009] to be prescribed an ACE inhibitor than 
women, even after adjusting for age). The multivariable analyses revealed that, compared 
to patients younger than 65 years, older patients were less likely to be prescribed ACE 
inhibitors (odds ratios [OR] 0.60 for patients aged 75-84 years [p<0.001] and OR 0.39 for 
patients older than 85 years [p<0.001]) or the combination of ACE inhibitors plus beta- 
blockers (OR 0.60 for patients aged 75-84 years [p=0.03] and OR 0.32 for patients older 
than 85 years [p=0.001]).
161
Prescribing patterns did not vary by deprivation category on bivariate (Figure 7) or 
multivariable analyses. There were wide discrepancies in prescribing between general 
practitioners; however, these discrepancies disappeared after adjusting for differences in 
patient demographics. For example, the variables associated with ACE inhibitor 
prescribing on multivariable analysis were sex (Odds Ratio [OR] 1.42 for males compared 
to females, p=0.009) and age (OR 0.60 for patients aged 75-84 yeai'S [p=0.004] and OR 
0.39 for patients older than 85 years [p<0.001] compared to patients younger than 65 
years). Deprivation category (p=0.31) and general practitioner (p=0.79) were not 
independently associated with prescriptions for ACE inhibitor.
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Table 34 Pharmacological treatment of men with heart failure in Scotland between April 1999-March 
2000
Treatment Age group
45-64 65-74 75-84 85+ <75 yrs ^75 yrs all ages
n= 64 132 164 74 201 238 439
Frusemide 36
(56.3)
80
(60.3)
114
(69.5)
49
(66.2)
119
(59.2)
163
(68.5)
282
(64.2)
Any diuretic 47
(73.4)
105
(79.6)
139
(84.8)
58
(78A)
155
(77.1)
197
(82.8)
352
(80.2)
ACE Inhibitor 39
(60.9)
71
(53.8)
69
(42.1)
21
(28.4)
111
(55.2)
90
(37.8)
201
(45.8)
Angiotensin 
receptor blocker
4
(6.3)
5
(3.8)
8
619)
1
(1.4)
9
6L5)
9
(3.8)
18
(4.1)
P-Blocker 20
(31.3)
34
(25.8)
33
(20.1)
14
(18.9)
55
(27.4)
47
(19.8)
102
(23.2)
Spironolactone 12
(18.8)
16
(12.1)
16
C9.8)
4
(5.4)
28
(13.9)
20
(8 /0
48
(10.9)
Digoxin 17
(26.6)
30
(22.7)
43
(26.2)
15
(20.3)
47
(23.4)
58
(24.4)
105
(23.9)
Any HF 
treatment
57
(89.1)
114
(86.4)
149
(90.9)
61
(82/n
175
(87.1)
210
(88.2)
385
(87.7)
HF = heart failure
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Table 35 Pharmacological treatment of women with heart failure in Scotland between April 1999- 
March 20(10
Treatment Age group
45-64 65-74 75-84 >85 <75 yrs >75 yrs All
ages
n= 56 116 227 166 176 393 569
Frusemide 30
(53.6)
66
(56.9)
124
(54.6)
97
(58 /0
97
(55.1)
221
(56.2)
318
(55.9)
Any diuretic 42
(75.0)
95
(81.9)
190
(83.7)
132
(79.5)
138
(78 /0
322
(8130
460
(80.8)
ACE Inhibitor 24
(42.9)
53
(45.7)
76
(33.5)
41
(24.7)
77
(43.8)
117
(29.8)
194
(34.1)
Angiotensin 
receptor blocker
5
(830
5
6L3)
14
(6.2)
6
(3.6)
10
(5.7)
20
(5.1)
30
(5.3)
P-Blocker 14
(2530
27
(23.3)
51
(22.5)
22
(13.3)
41
(23.3)
73
(18.6)
114
(20.0)
Spironolactone 3
(5.4)
10
(8.6)
13
(5.7)
12
C7.2)
13
(7.4)
25
(6 /0
38
(6.7)
Digoxin 6
(10.7)
18
(15.5)
43
(18.9)
35
(2L1)
25
(14.2)
78
(19.8)
103 
(18.1)
Any HF 
treatment
49
(87.5)
102
(87.9)
206
(90.7)
139
(83.7)
153
(86.9)
345
(87.8)
498
(87.5)
HF = heart failure
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Table 36 Pharmacological treatment of heart failure in Scotland between April 1999-March 2000 (men 
and women combined)
Treatment Age group
45-64 65-74 75-84 >85 <75 yrs >75 yrs All
ages
n= 120 248 391 240 377 631 1008
Frusemide 66
(55.0)
146
(58.9)
238
(60.9)
146
(60.8)
216
(57.3)
384
(60.9)
600
(59.5)
Any diuretic 89
(74.2)
200
(80.7)
329
(844)
190
(79.2)
293
(77.7)
519
(82.3)
812
(80.6)
ACE Inhibitor 63
(52.5)
124
(50.0)
145
(37.1)
62
(25.8)
188
(49.9)
207
(32.8)
395
(39.2)
Angiotensin
receptor
blocker
9
(7.5)
10
(4.0)
22
(5.6)
7
(230
19
(530
29
0L6)
48
018)
P-Blocker 34
(28.3)
61
(24.6)
84
(21.5)
36
(15D)
96
(25.5)
120
(1930
216
(21.4)
Spironolactone 15
(12.5)
26
(10.5)
29
(7.4)
16
(630
41
(10.9)
45
(7.1)
86
(8.5)
Digoxin 23
(19.2)
48
(19.40
86
(22.0)
50
(20.8)
72
(19.1)
136
(21.6)
208
(20.6)
Any HF 
treatment
106
(88.3)
216
(87.1)
355
(90.8)
200
(83.3)
328
(87.0)
555
(87.9)
883
(87.6)
HF = heart failure
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Figure 7 Prescribing patterns in patients with heart failure, stratified by socioeconomic status
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5.4 Discussion
This study has a number of important strengths. Not only does it describe the prevalence 
and incidence of heart failure across a whole country but it also describes overall contact 
rates with general practitioners. Furthermore, compaiative contact rates for other common 
cardiovascular (and non-cardiovascular) conditions are reported. Finally, the 
contemporary pharmacological treatment of heart failure in primary care is also described.
A number of recent prevalence studies in the United Kingdom have focused on the 
presence of echocardiographic left ventricular systolic dysfunction and not a clinical 
diagnosis of heart failure per The first of these, from Glasgow, was limited in
concentrating on a relatively young age group (1640 persons aged 45-74), when heart 
failure is known to be uncommon before the age of 70 years (as confirmed in the present 
s t u d y ) . T h e  second report from Poole in England examined 817 subjects aged 70-84 
years. Another more recent survey examined 3960 patients > 45 years, but, like the 
former studies, was limited to a single urban area (the West Midlands of England). Other 
studies in the United Kingdom have usually involved only a small number (one to three) of 
General Practices and/or relied on diuretic prescription as a surrogate for heart failure.
Recording of concomitant medical problems, concomitant drug therapy and the 
frequency and nature of contacts (surgery or office visits, home visits, out of hours visits) 
has been limited or absent.
It is difficult to precisely compare my findings to prior studies as many of these did not 
include men and women and/or the whole population age range. Nevertheless, looking at 
men aged 0-74 years, the prevalence rate (0.32%) was very close to that found in the 
Rochester epidemiology project (0.33%).*°'^’’°'^  The proportions for females were 0.28% in 
Scotland and 0.21% in Rochester. The National Health and Nutrition Examination Survey 
(NHANES) investigators reported a prevalence of 1.1% in men and 1.0% in women aged 
25-74 years in the USA.^^^ The prevalence in men aged 45-74 years in the current study 
was 0.92% and 0.78% in women. I also had reasonably close agreement with another 
north European study, the Rotterdam study, which reported a prevalence of 3.4% in 
persons aged 65-84 years ' ' * (compared to 3.6% in the same age group in my study). On 
the other hand, a study from Copenhagen reported the prevalence of heart failure signs and 
symptoms in 3 GP practices was 6.4% in patients over 50 years. This is much higher than
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the prevalence in CMR (1.8% in patients over 45 y e a r s ) . Ano t he r  national primary care 
survey from southern Europe also reported discrepant findings. The Epidemiologia da 
Insuficiencia Cardiaca a Aprendizagen (EPICA) investigators reported a prevalence of 
heart failure in men aged >25 years of 4.33%. The prevalence in women was 4.38%.'^°
The deficiencies in existing epidemiological investigations of heart failure are even more 
apparent when it comes to incidence studies with only one Finnish, two U.K. and one US 
study reported until r e c e n t l y . T h e  Finnish and American studies were confined 
to a limited geographical area (four rural communities in eastern Finland and Olmsted 
County in Minnesota). Of the two UK studies, one was hospital based, was
limited to part of London, and adopted an unusually broad definition of heart failure 
(including heart failure arising as a complication during hospitalisation with an acute 
coronary s y n d r o me ) . T h e  second UK study used data from the UK General Practice 
Research Database to describe the incidence of newly diagnosed heart failure during 
1996.'^*  ^That study did not, however, describe pharmacological treatment. The incidence 
rate of heart failure in the Scottish population was 1.8/1000 in males and 2.2 per 1000 in 
females, and this figure is in keeping with the previous estimates from the UK (1.4 and 
1.2/1000)*^^ Finland (1.0 and 4.0/1000)^^^ and the USA (3.4 and 2.4/1000)'^^
What appears to be different at first sight between this study and previous studies is the 
higher overall prevalence and incidence of heart failure in women compared to men. This, 
however, is likely to reflect the wider age range included in my study, compared to most 
others, and the predominance of women over men with heart failure in the very elderly 
segment of the population.^^^’^ ^^
The lack of information on contact rates in primary care has been a surprising gap in the 
literature on heart failure. I found that the contact rate is 2-3 times the prevalence, that 
is, patients average 2-3 heait failure related contacts, per yeai', with their GP. This rate was 
remarkably consistent between men and women and across all age groups.
Not only are there few data on the rates of consultation with GPs but there is also little 
information on the reasons for c o n s u l t a t i o n . I  found that lower respiratory tract 
infection was the single most common problem recorded by GPs in both men and women 
with heart failure. The potential importance of this is suggested by the knowledge that 
pulmonary infection is a commonly recorded precipitant of heart failure 
h o s p i t a l i s a t i o n . T h e s e  two observations underscore the importance of influenza and
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pneumococcal immunisations in patients with heart f a i l u r e . T h e  other major co­
morbidities reflect the most common causes of heart failure (coronary artery disease and 
hypertension), other smoking related illnesses (such as COPD) and degenerative diseases 
of ageing (back problems, osteoaithritis).
Another gap in our knowledge has been how the primary care burden of heart failure 
compares to that of other cardiovascular and non-cardiovascular conditions.
Consultation rates for heart failure were much lower than those for angina and, especially, 
hypertension in patients < 75 years. Thereafter heart failure consultation rates exceeded 
those for angina and by the age of 85 or above exceeded those for hypertension also. It is 
interesting to speculate that the falling prevalence and consultation rates for hypertension 
and angina, relative to heart failure, in the older age groups may reflect the natural history 
of coronary heart disease and hypertension progressing to heart failure over time.
Another important feature of this study is the description of the contemporary 
pharmacological management of heart failure in primary care across a whole country. 
Though, as expected, most patients had been prescribed a diuretic, there was a striking age 
differential in the prescription of evidenced-based therapies: older patients were 
significantly less likely to be prescribed ACE inhibitors, beta-blockers and/or 
spironolactone. There are a number of possible explanations for these observations. The 
above treatments are indicated when left ventriculai' systolic function is reduced and not 
when it is preserved. Heart failure in the elderly is more often associated with preserved 
left ventricular systolic function.^^^ Digoxin, however, was used at least as commonly in 
the elderly, yet is also only indicated when left ventricular' systolic function is reduced. 
Perhaps ACE inhibitors, beta blockers and spironolactone have a perceived or real 
contraindication more frequently in the elderly or are not as well tolerated by the elderly.^^^ 
The other possibility is that these treatments are not offered to the elderly as often they are 
to younger patients, as has been reported in other c o n d i t i o n s . T h e  concern that older 
patients with heart failure might be inappropriately denied treatments proven to reduce 
morbidity and mortality is worthy of further investigation. Women also received less 
evidence-based therapy and this was not wholly explained by the generally older average 
age of women. Preserved left ventricular systolic function is also more common in women 
and this could explain at least part of the sex difference in treatment.^^*’^ ^^  Women may 
also tolerate these other treatments less well and there is some evidence that this is true for 
ACE i n h i b i t o r s . C u r i o u s l y ,  however, the greatest sex difference in evidence based 
prescribing was for spironolactone which should be better tolerated by women than men.
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This, again, raises the concern, as in other disease areas, that women are under-treated 
compai'ed to men.^^^
In addition in this study socioeconomically deprived individuals were significantly more 
likely to develop heart failure, but were significantly less likely to see their general 
practitioner on an ongoing basis. Contrary to speculation, there was no relationship 
between general practitioner prescribing practices and socioeconomic status.
Although the finding of an increased incidence of heart failure in socioeconomically 
deprived individuals has not previously been reported, a study from the United States did 
demonstrate an inverse association between heart failure incidence and educational 
a t t a inment .However ,  my finding is not unexpected given data showing increased heart 
failure hospitalisations in deprived patients.^'^^’^ ‘^^ Furthermore, as the risk factors for heart 
failure (which are similar to those for coronary artery disease) are more prevalent in 
socioeconomically deprived groups,’ it is entirely plausible that heart failure incidence 
would be higher in these groups. Despite the mai'ked gradient in incidence, there was only 
a trend towards differences in prevalence across the deprivation categories. This is not 
unexpected given that deprived patients have higher case fatality rates and shorter survival 
times when they do develop heart failure as demonstrated in this study and another Scottish 
study which examined survival in 66 547 patients hospitalized with heart failure between 
1986 and 1995.’"’^  The finding that socially deprived individuals with heart failure have 
less ongoing contact with their general practitioners is novel and worrying, particularly 
since the limited data in this field suggest that socially deprived patients with heart failure 
have a worse functional s t a t u s . T h e  obvious questions raised by this novel example 
of Tudor Hart’s inverse care relationship are twofold; (1) why does this occur, and (2) what 
consequences might ensue? There are several potential factors that may contribute to these 
lower consultation rates. Firstly, illness behaviour is substantially different in deprived 
groups, fatalism is more common, and individuals often consult non-professionals for 
health care adv i ce . Second l y ,  socially deprived patients may seek care in hospital 
emergency rooms rather than attend their primaiy care physicians - indeed, this pattern has 
been observed for other cardiovascular and respiratory illnesses chaiacterized by 
intermittent acute e x a c e r b a t i o n s . T h i r d l y ,  their general practitioners may fail to offer 
regular follow-up care. However, the comparable rates of prescribing across the social 
class spectrum argue against this. Although we do not know what consequences may ensue 
from less frequent follow-up with general practitioners for socioeconomically deprived 
heart failure patients, other studies suggest that this lack of contact may have important 
consequences for patients with chronic diseases. For example, patients with heart failure
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or asthma who are not seen regularly after hospital discharge are more likely to be re- 
admitted.^"’^ '^ ^^  Moreover, a retrospective analysis of administrative data from Canada 
found improved survival rates in heart failure patients who were regulaiiy followed by a 
physician compared to those without ongoing contact (P. Kaul, personal communication). 
Finally, there is a wealth of evidence that closer follow-up of heart failure patients (either 
by physicians or by specially trained nurses) does lead to better outcomes.^^^ It is thus 
intriguing to speculate whether disease management programs specifically targeting more 
deprived individuals with heait failure would improve their prognosis- this is an important 
hypothesis that needs to be tested. I did not find any evidence of socioeconomic bias in 
these general practitioners’ prescribing patterns. Although there was no information on 
patient adherence, an earlier study in Scotland did not find any differences in diuretic 
compliance between deprived and affluent heart failure patients.
As in any study of this type, there are limitations. One is the lack of information on cardiac 
structure and function, which did not allow differentiation between patients with reduced 
and preserved left ventricular systolic function. Nevertheless, I have been able to provide 
information on the community burden of the syndrome of heart failure, rather than left 
ventricular systolic dysfunction which has been the main focus of most other 
epidemiological studies. Second, the diagnosis of heart failure was not confirmed 
independently nor was there data on disease severity.
In summary, this study confirms that heart failure is predominantly a problem of the 
elderly. When the full age spectrum is accounted for, there aie more women than men with 
heart failure in the population. In the elderly, heait failure is one of the commonest causes 
of consultation with a GP and is at least as common a cause of consultation as angina and 
hypertension. There is a marked age discrepancy in prescribing of evidence based 
treatment, with the elderly receiving less life saving therapy. There is also an independent 
sex effect with women also receiving less evidence based treatment. These discrepancies 
merit further investigation.
Although the incidence of heart failure diagnosed in General Practice is significantly 
higher in socioeconomically deprived individuals, the subsequent follow-up is significantly 
less frequent. My study has eliminated the prescribing bias hypotheses commonly cited as 
a potential explanation for the socioeconomic gradients in heart failure. Indeed, it raises 
another potentially important explanation, that socioeconomically deprived patients may 
have poorer outcomes because they have less ongoing contact with their general
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practitioner. Further studies are required to determine why such patients are followed less 
closely. Once the mechanisms behind these socioeconomic gradients in heart failure are 
better understood, programs can then be devised to ensure that outcomes ai*e optimized for 
all afflicted patients, irrespective of social class.
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6 PREVALENCE, INCIDENCE, PRIMARY CARE BURDEN 
AND MEDICAL TREATMENT OF ATRIAL 
FIBRILLATION IN SCOTLAND: AGE, SEX AND 
SOCIOECONOMIC DISPARITIES
6.1 Introduction
Atrial fibrillation is tlie commonest chronic arrhythmia.'^'' As outlined in the literature
review the prevalence and incidence of atrial fibrillation are believed to be increasing’^ ’ 
probably because population age is increasing^^’ and survival from conditions predisposing 
to atrial fibrillation (e.g. coronary heart disease) is i m p r o v i n g . A t r i a l  fibrillation is 
associated with significant morbidity and excess mortality, including heait failure and 
stroke, two of the most disabling and costly cardiovascular conditions k n o w n . T h e  
risk of stroke can be substantially reduced with warfarin.^^^ Two recent trials suggest that 
rate control and anticoagulation are at least as good as rhythm control and medical 
treatment is the preferred option for most patients with atrial fibrillation.
As outlined in the literature review there are many studies examining the prevalence and 
incidence of atrial fibrillation however only recently have studies which have analysed the 
prevalence of atrial fibrillation using data from general practices in the UK been 
published.’^^ ’’^ ’^’^’ In addition there is relatively little contemporary information about the 
primary care burden and treatment of atrial fibrillation in the community. CMR was 
analysed to accurately estimate the prevalence, incidence and consultation rates for atrial 
fibrillation in primaiy care and also to describe concomitant medical problems and drug 
therapy.
6.2 Methods
The CMR atrial fibrillation database was used as described in chapter 3.
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6.3 Results
6.3.1 Atrial fibrillation Read codes used
The vast majority (99.3%) of contacts were coded as atrial fibrillation (84.6%), atrial 
fibrillation /atrial flutter (9.8%), paroxysmal atrial fibrillation (3.5%) or atrial flutter 
(1.4%).
6.3.2 Prevalence of atrial fibrillation
The prevalence of atrial fibrillation was 8.7/1000 and was higher in men (9.4/1000) than 
women (7.9/1000). Prevalence increased with age from 0.3/1000 in <45 to 30.5/1000 in 
65-74 and more than doubling to 70.7/1000 in >85 years (Table 37). Age and sex 
standardised prevalence of atrial fibrillation decreased with increasing socioeconomic 
deprivation from 9.2 per 1,000 in the least deprived to 7.5 per 1,000 in the most deprived 
category (p for trend =0.02). Deprived individuals had an 18% lower prevalence than more 
affluent individuals (Table 38).
6.3.3 Incidence of atrial fibrillation
The incidence of atrial fibrillation was 0.9/1000 - 1.0/1000 in men and 0.8/1000 in women. 
Incidence in men increased with age from 0.1/1000 in <45, 3.8/1000 in 65-74 and 8.6/1000 
in those >85 yeai's. The corresponding rates for women were O.O/IOOO, 2.7/1000 and 
7.4/1000, respectively (Table 37). There was no difference in incidence of atrial fibrillation 
according to deprivation class (Table 38, p for trend =0.537), although the number of cases 
in each category was small.
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6.3.4 Contact-rates for atrial fibrillation
The one-year contact-rate was higher in men (9.9/1000) than women (7.6/1000), Table 37. 
The contact-rate vaiied with age, initially increasing from 0.2/1000 in <45, to 62.0/1000 in 
75-84 but fell to 50.9/1000 in >85 years. The average number of contacts per patient with 
newly diagnosed atrial fibrillation was highest in men <45 years (4.17) and women aged 
45-54 years (7.75).
The proportions of women consulting >65 years and >75 years were 86.1% and 57.6%, 
respectively (the corresponding proportions in men were 71.4% and 36.7%, respectively). 
Age and sex standardised contact-rates fell from 8.6 per 1,000 in the most affluent group to 
6.1 per 1,000 in the most deprived group (Table 38). Deprived individuals had a 29% 
lower contact-rate than more affluent individuals (p for trend =0.02).
Comparison with contact-rates for angina and heart failure.
The contact-rates for heart failure and angina in 2002 were 14.3/1000 and 17.0/1000, 
respectively, for men and 14.6/1000 and 13.5/1000, respectively, for women. Consultation 
rates for atrial fibrillation were lower than those for angina in younger individuals and 
similar to angina in those >75 years (Figure 8 and 9). Consultation rates for atrial 
fibrillation were considerably lower than those for heart failure in men and women >65 
years.
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Figure 8 Age stratified GP consultation rates per 1000 population for heart failure, angina and atrial 
fibrillation in men.
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Figure 9 Age stratified GP consultation rates per 1000 population for heart failure, angina and atrial 
fibrillation in women
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6.3.5 Top ten concomitant diagnoses in patients with atrial fibrillation
In both sexes, hypertension was the most common concomitant diagnostic coding (in 
24.8% of men and 27.1% of women, Table 39). Respiratory, infection, coronary heart 
disease and heart failure were the next most commonly coded conditions. Stroke was only 
recorded in 4.7% of men and women. Atrial fibrillation was the nineteenth most common 
reason for consulting a GP in men 65-74 years and the 21st most common reason in those 
>85. In women 65-74 years atrial fibrillation was in position 49 while in women >85 it was 
in position 31.
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Table 39 Proportion of atrial fibrillation patients seen witb specified condition/illness; April 2001 
March 2002
Condition/illness Men Women
Hypertension 24.8% 27J9&
Lower respiratory tract infection 16.5% 20.4%
Coronary heart disease -  
miscellaneous
16.2% 12.6%
Heart failure 15.3% 19.8%
Upper respiratory tract infection 
(excluding sore throat)
9.5% 11.1%
Chest pain 9.2% 9.1%
Miscellaneous 9.2% 9.4%
Breathlessness 9.2% 13.2%
Back problems 9.2% -
Diabetes &2% -
Urinary tract infection - 11.9%
Stroke 4.7% 4.7%
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6.3.6 Concomitant medication
71% of patients with atrial fibrillation received rate-controlling medication: beta-blocker 
28%, rate limiting calcium channel blocker 42% and digoxin 43%. Of men, (Table 40)
31% received one rate-limiting agent and 38% >2 drugs. The respective proportions for 
women (Table 41) were 39% and 35%. 19% of patients received an anti arrhythmic drug. 
42% of patients received warfarin, 44% aspirin and 78% >1 of these.
Sex, age and socioeconomic differences in prescribing
On multivariable modelling, after adjusting for deprivation, age and GP practice, women 
were 25% more likely to receive digoxin and 18% less likely to receive warfarin compared 
to men (Table 42). On multivariable modelling, men and women >75 years were more 
likely than those <75 years to receive digoxin (men OR 1.41 95%CI 1.14, 1.74; women 
OR 1.88, 95% Cl 1.50, 2.37) and aspirin (2.04 (1.66, 2.51); 1.79 (1.42, 2.25)) and less 
likely to receive an anti arrhythmic drug (0.62 (0.48, 0.81); 0.52 (0.39, 0.70)) or warfarin 
(0.74 (0.60, 0.91); 0.58 (0.46, 0.73)). After adjusting for age, sex and GP, there was no 
socioeconomic gradient in prescribing.
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Table 42 Relative risk of being prescribed various medication for atrial fibrillation for women 
compared to men*, for men and women aged over 75 years compared to under 75 yearst and for 
Carstairs deprivation category 5 compared to Carstairs deprivation category I f
Women versus 
men
>75 years versus < 75 years Carstairs 
deprivation 
category 
5 versus 1
Men Women
OR OR OR OR
P-blockers 0.92 (0.78, 1.09) 0.55 (0.44, 0.70) 0.89 (0.69, 1.16) 0.72 (0.43, 1.21)
Calcium channel blockers 
§
1.05 (0.91, 1.24) 0.51 (0.42, 0.64) 0.69 (0.55, 0.87) 0.73 (0.45, 1.19)
Digoxin 1.25 (1.07, 1.46) 1.41 (1.14, 1.74) 1.88 (1.50, 2.37) 1.00 (0.62, 1.63)
Class I antiarrhythmics t 1.34 (0.84, 2.13) 0.32 (0.15,0.67) 0.14(0.06, 0.32) 0.62 (0.14, 2.82)
Amiodarone 0.94 (0.74, 1.19) 0.73 (0.53, 1.01) 0.77 (0.54, 1.03) 1.10(0.49, 2.48)
Sotalol 1.11 (0.80, 1.54) 0.60 (0.38, 0.96) 0.48 (0.30, 0.79) 0.51 (0.18, 1.50)
Warfarin 0.82 (0.70, 0.96) 0.74 (0.60, 0.91) 0.58 (0.46, 0.73) 1.21 (0.75, 1.96)
Aspirin 0.93 (0.80, 1.08) 2.04 (1.66, 2.51) 1.79(1.42, 2.25) 0.78(0.48, 1.26)
Any antithrombotic ** 0.85 (0.70, 1.03) 1.81 (1.40, 2.35) 1.11 (0.85, 1.45) 1.11 (0.61,2.03)
Negative chronotropes t t 1.28 (1.08, 1.51) 0.90(0.72, 1.12) 1.33 (1.03, 1.72) 0.97 (0.56, 1.70)
Any antiarrhythmic 1.03 (0.85, 1.24) 0.62 (0.48,0.81) 0.52 (0.39, 0.70) 0.80(0.42, 1.50)
* Adjusted for practice, age, and deprivation category
t  Adjusted for practice and deprivation category
I  Adjusted for age, sex and practice
§ Excluding dihydropyridines
$ Includes quinidine, disopyramide, propafenone and flecainide
** Warfarin or aspirin or clopidogrel
t t  p-blocker or rate limiting calcium channel blocker or digoxin 
Class 1 antiarrhythmic or amiodarone or sotalol
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6.4 Discussion
The overall prevalence of atrial fibrillation in Scotland in 2001-2002 was 8.7/1000, was 
higher in men than women (and in the less compared to the more socioeconomically 
deprived) and increased strikingly with age (to 64/1000 in those >75 yeai's). Digoxin was 
used much less commonly, and rate-limiting CCBs and beta-blockers more commonly, 
when compared to results of older studies. Women and older individuals were, however, 
less likely to be prescribed warfarin and more likely to be prescribed digoxin than a beta- 
blocker or rate-limiting calcium channel blocker for rate control.
Prevalence
Other UK primary care studies have reported on the prevalence of atrial fibrillation.
A study of the records of 4,522 patients >50 years in two GPs in West Birmingham taking 
drugs relevant to the treatment of atrial fibrillation, showed that 111 (2.4%) had the 
arrhythmia, indicating a similar prevalence to that in those in CMR >45 years (2.1%).'^^ 
Electrocardiographic screening of 4,843 subjects in 26 GPs in Northumberland, England, 
revealed a 4.7% prevalence of atrial fibrillation in individuals > 65 years, comparable to 
the 4.6% prevalence in the same age group in CMR.^^^ The prevalence of atrial fibrillation 
was estimated from the computer records of 211 GPs in England and Wales 1994-1998, 
using the GP Research Database (GPRD).^^^ The prevalence of atrial fibrillation in 1994 
was very similar to that in CMR but the prevalence in 1998 was considerably higher e.g. 
9.5% in men and 7.2% in women 75-84 years, compared to 7.3% and 6.2%, respectively. 
The prevalence of Read-coded atrial fibrillation in 131 GPs included in the DDSf-LlNK 
database increased from 1994 to 2003 - from 0.84% to 1.49% in men and from 0.83% to 
1.29% in w o m e n . T h e  overall prevalence in the DIN-LINK database, as well as the only 
age-specific prevalence reported (13.2% in men and 11.0% in women >85 years in 2003 
compared to 8.4% and 6.6%, respectively, in my study), was considerably higher than in 
CMR, as well as the other UK studies. Even taking account of the increase in recorded 
prevalence that has occurred over time, the prevalence in CMR still seems lower than that 
found in the DIN-LINK database. One possible explanation is that my analysis only 
included patients consulting their GP (for any reason) during the year of study. 
Consequently, a patient with atrial fibrillation who did not have a GP contact for any 
reason in the period April 2001-March 2002 would not have been identified. On the other 
hand, the analyses of the epidemiology of heart failure and angina using CMR data as
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discussed in earlier chapters have given estimates very consistent with those from other 
parts of the UK and elsewhere. Geographical variation and, particularly, differences 
in socioeconomic status (see below) might also have accounted for some of the differences 
observed. The prevalence in Scotland was similar to that found in a primary care study in 
the Netherlands'*'^ and a report from the Kaiser Permanente system in Northern 
California
I found that the prevalence of atrial fibrillation fell with increasing socioeconomic 
deprivation, which has not been reported before and which contrasts with other 
cardiovascular disorders. Possible reasons for the higher recorded prevalence of atrial 
fibrillation in more affluent patients may be higher rates of certain types of contact with 
GPs leading to diagnosis (e.g. greater uptake of “health screening” and more recording of 
electrocardiograms) and reduced survival in more deprived patients with atiial fibrillation.
Incidence
There are few studies reporting the incidence of atrial fibrillation. The incidence of atrial 
fibrillation in patients 40-89 years was estimated to be 1.7 per 1000 person-years in the 
GPRD in 1996.'^' This was comparable to the 2 per 1000 per year incidence in patients 
aged 45-84 years in CMR. However, the Framingham Hear t Card i ovascu la r  Health 
(CHS)'^^ and Olmsted County s t u d i e s a l l  from the USA, reported much higher 
incidence rates than either CMR or the GPRD. This can be explained by methods of 
ascertainment. In the CMR study and in the GPRD analysis only patients who attend their 
GP with symptoms or who had an incidental finding of atrial fibrillation would have been 
identified. By contrast, in the studies from the USA, either regular examination (including 
recording of an EGG) of subjects or examination of hospital records and other physician 
records was conducted over a long period of follow-up.
Primary care burden
There is little information on the health care burden created by atrial fibrillation in general 
practice. Patients with atrial fibrillation have few contacts with their GP - approximately 
one per year -  and atrial fibrillation was not one of the common reasons for a patient to 
contact their GP. The consultation rate for atrial fibrillation was less than that for angina in 
subjects < 75 years but greater than for angina above that age; the contact rate for atrial 
fibrillation was much less than that for heart failure. These data, however, underestimate 
the complete community burden related to atrial fibrillation as many patients in Scotland at 
the time of this survey had anticoagulation monitoring in hospital-based clinics.
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Medication
The few prior reports on the pharmacological treatment of atrial fibrillation have focussed 
upon the use of antithrombotic therapy. Observations from this Scottish study confirm the 
finding of other recent studies from the UK that about 40% of patients receive 
w a r f a r i n , a  considerably higher proportion than reported in earlier studies.'*'*  ^
Although we do not know what proportion of patients should have been treated with 
warfarin (because we did not know which of our patients had an indication or 
contraindication to warfarin), other investigators have estimated that between 40-60% of 
patients might benefit from anticoagulation. Paradoxically, however, waifarin was 
less likely to be prescribed in women and in the elderly, both of which are at greater risk of 
stroke. This has been a consistent finding in both older and more recent studies and 
suggests that there is still an educational deficit in these respects.^^^
There is much less recent information on the use of other medications to treat atrial 
fibrillation in primary care. I found that 71% of patients were treated with an agent that 
controls ventricular rate: 43% digoxin, 42% a calcium channel blocker and 28% a beta- 
blocker. This is a quite different pattern than in older studies which showed that digoxin 
was the most common agent of this type used.'^*' As recently as 1996, digoxin was used in 
approximately 70% of cases in the GPRD.'^' Recent recommendations preferring calcium 
channel blockers and beta-blockers for rate control may, therefore, have influenced clinical 
practice.^^^ Older patients, however, were less likely to be treated with these more effective 
agents and were more likely to be treated with digoxin. Older individuals were also less 
likely to be prescribed antiarrhythmic agents. Duration of atrial fibrillation and differential 
referral to secondary care may explain some of the age related differences in prescribing.
It is interesting, however, to contrast prescribing in Scotland with the rest of Europe. A 
recent Euro Heart Survey, conducted 2003-2004, described the treatment of atrial 
fibrillation in secondaiy care in 35 countries. Twenty three per cent of patients with 
persistent and 50% of patients with permanent atrial fibrillation were prescribed digoxin.^^^ 
A beta-blocker (excluding sotalol), was used as an anti-arrhythmic or rate-controlling agent 
in 30% of patients with persistent or permanent atrial fibrillation, (which is similar to 
Scotland) but only 10% of these patients were prescribed a rate-limiting calcium channel 
blocker, a much lower rate than in Scotland.
Also of interest was the finding that, although prevalence and contact rates differed 
according to socioeconomic status, treatment did not. This is in keeping with prior findings
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in other disease areas and may relate to the greater use of secondary care by more deprived 
individuals.
Limitations
Atrial fibrillation is frequently asymptomatic^^*^ and cases may be missed if the patient is 
not examined or an ECG recorded e.g. atrial fibrillation was an incidental finding on 
electrocardiography in 12% of cases in the CHS'^^. Also, many cases are paroxysmal. 
Consequently, the findings in this study almost certainly underestimate the prevalence and 
incidence of all types of atrial fibrillation.
Summary
I have confirmed the higher prevalence and incidence of atrial fibrillation with increasing 
age and in men. I have made the novel observation that the prevalence of atrial fibrillation 
fell with increasing socioeconomic deprivation. This unexpected finding deserves further 
investigation as it probably reflects poorer detection, prognosis or both in more deprived 
individuals. I have shown that the rate of prescription of warfarin was higher than in past 
studies and that calcium channel blockers and beta-blockers are now more commonly (and 
digoxin less commonly) used for rate control that previously reported. Women and older 
individuals, however, were less likely to be prescribed warfarin and older subjects less 
likely to be prescribed more effective rate-controlling treatment with a calcium channel 
blocker or a beta-blocker. This suggests that there is still a need for education regarding the 
risks and benefits of the pharmacological treatments of atrial fibrillation in women and the 
elderly.
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7 TRENDS IN HOSPITAL DISCHARGE RATES FOR 
SUSPECTED ACUTE CORONARY SYNDROMES 
BETWEEN 1990 AND 2000: STEEP DECLINE IN ACUTE 
MYOCARDIAL INEARCTION AND MARKED 
INCREASES IN ANGINA AND OTHER CHEST PAIN
7.1 Introduction
As outlined in the literature review much has been written about the incidence of, and case- 
fatality related to, acute myocardial infarction (AMI), however there is little information on 
the clinical epidemiology of hospitalised angina and other types of chest pain.*' '^ 
64;66;70;72;77;80;8i;94;38];382 surprising. Many I'ecent cliiiical tiials have focused on
hospitalised angina yet the public health impact and cost of the resulting new treatments 
are impossible to assess without relevant epidemiological data.^^ '^^^  ^Similarly, while it is 
widely perceived that chest pain has been an important contributor to the increase in 
eiHergency medical adimssions documented in many “developed” countries over the past 
decade, hospital admissions rates for this problem, and associated resource utilisation, have 
not been documented.^*'^’^ *^'’^ '^ Recent trends in the population discharge rates for AMI, 
angina and chest pain (collectively referred to as “suspected acute coronar y syndromes”) 
over the period 1990 to 2000 was examined.
7.2 Methods
A retrospective cohort study of all hospital discharges in Scotland (population 5.1 million) 
between the January 1990 and December 2000 was carried out. The SMR acute coronary 
syndrome database was used as described in chapter 3.
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7.3 Results
7.3.1 Baseline characteristics
Table 43 shows the baseline characteristics of the 225,512 individuals hospitalised as an 
emergency with ^ first suspected acute coronary syndrome, between January 1990 and 
December 2000. The discharge diagnosis was AMI in 96,026 (43%) patients, angina in
37,403 (17%) and other chest pain in 92,083 (41%).
Patients with chest pain were younger than those with hospitalised angina or AMI. Patients 
with angina were an average of 11 years older (p<0.001), and those with AMI 13 years 
older, than patients with chest pain (p<0.001). A substantially higher proportion of patients 
with chest pain were aged less than 55 years (52%), compared to those hospitalised with 
angina (20%) or AMI (16%).
The proportions of men and women in the three diagnostic categories varied according to 
age. There were fewer women than men aiuongst those aged less than 55 years hospitalised 
with angina or with AMI. This sex imbalance was not as notable in patients hospitalised 
with chest pain. Conversely, there were proportionately more women aged over 75 years, 
across all three diagnostic categories.
Compared to patients with chest pain, patients with an AMI or angina were more likely to 
have a prior admission with diabetes, cerebrovascular disease, peripheral arterial disease, 
heart failure, hypertension, atrial fibrillation, renal failure or respiratory disease. For 
example patients with angina were nearly twice as likely to have a prior admission with 
stroke (OR 2.1; 95% Cl 1.9-2.2) or heart failure (OR 1.9; 95% Cl 1.7-2.0) and patients 
with AMI were 50% more likely to have a prior admission with diabetes (OR 1.5; 95% Cl 
1.5-1.6), than patients with chest pain.
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7.3.2 Trends in discharge rates, diagnostic mix and sex and age 
characteristics
Changes in discharge rates
Table 44 and Figure 10 show population discharge rates for all suspected acute coronary 
syndromes (AMI, angina and chest pain) between 1990 and 2000. Though this increased 
only modestly, by 25%, the overall change conceals important differences in the diagnostic 
mix, between men and women and in younger compared to older patients.
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Figure 10 Population discharge rates per 100,000 per year for AMI, angina and chest pain in Scotland, 
1990-2000.
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Changes in diagnostic mix
The population discharge rate for AMI fell by 33%, from 260 to 173 per 100,000 between 
1990 and 2000 (Figure 11) (p<0.001). hi contrast, the population discharge rates for angina 
increased by 79%, from 59 to 105 per 100,000 (p<0.001), during the same period. The 
increase in the discharge rate for other chest pain was even more striking at 110% (from 
114 to 296 per 100,000) (p<0.001).
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Figure 11 Trends in population admission rates of different diagnostic groups in men and women 
between 1990 and 2000
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Sex differences
There was a greater relative increase in the population discharge rate for all suspected 
acute coronary syndromes in women (+33%) than in men (+19%). This was explained, 
mainly, by a larger rise in the discharge rates for chest pain in women than in men. The 
relative change in discharge rates for AMI and angina were comparable in men and women 
overall (Table 44).
Age trends
The age of patients hospitalised with a possible acute coronary syndrome decreased from 
1990 to 2000 (from a median of 61 to 59 year's in men and from 68 to 65 years in women). 
This overall change again concealed important differences between diagnostic groups and 
between men and women. In patients with angina, the median age increased (from 62 to 65 
years in men and 67 to 70 years in women). The median age with AMI also increased from 
65 to 66 year's in men and from 73 to 75 year's in women. In contrast, the median age of 
patients with chest pain decreased (from 52 to 51 years in men and from 56 to 55 years in 
women).
Figure 12 andFigure 13 summarise how age, sex and diagnostic mix interacted to 
determine the overall temporal changes in discharge rates for suspected acute coronary 
syndromes. The greatest change, across all diagnostic sub-groups, occurred in the elderly. 
The absolute decline in AMI discharge rates was much greater in men than in women in 
both the younger and older age groups. The absolute increase in angina was slightly greater 
in men than in women in both the younger and older age groups. There was little 
difference in the absolute increase in discharge rates for chest pain between men and 
women in either age category.
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Figure 12 Changes in population rates per 100,000 between 1990 and 2000 by age, sex and diagnostic 
group.
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Figure 13 Population discharge rates per 100,000 per year for AMI, angina and chest pain in Scotland, 
1990-2000 according to age group.
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7.4 Discussion
This analysis of all discharges between 1990 and 2000 for suspected acute coronary 
syndromes reveals several interesting and important temporal trends.
Firstly, the overall number and rate of emergency hospitalisations has increased only 
modestly. There was, however, a very striking change in the proportion of patients in each 
of the diagnostic sub-categories.
The fall in rates of hospitalisation for AMI is in keeping with numerous other reports from 
many c o u n t r i e s ^ ^  This contrasts markedly with hospitalisation rates 
for angina which increased by around 80%. There is only one other report of this latter 
change. The Minnesota Heart Survey reported a 56% increase in the discharge rate for 
angina in men and a 30% increase in women between 1985 and 1995 (with a 20% decline 
in the discharge rate for AMI in both men and women).^® Though the Minnesota group 
looked at all and not j u s t ho s p i t a l i s a t i o n s ,  our findings are consistent.
What has caused this apparent shift from AMI to angina? Increased “survivorship” from 
previous acute coronary events, a possibility raised by the Minnesota investigators, seems 
unlikely given that only first admissions were included. Another possibility is that the 
natural history of coronary heart disease has changed. As the pathogenesis of “unstable” 
angina and AMI are both believed to involve coronary arterial plaque rupture, this 
hypothesis would require a change in the risk of progression to complete coronary 
occlusion. The more widespread use of aspirin and other anti-platelet agents could, in 
theory, account for this.^^  ^Increased use of early in-hospital anti-thrombotic therapy, 
aborting AMI, could also have played a role.^ ^^ "^ "^*
Less likely is better diagnostic exclusion of infarction, with a “transfer” of patients from 
the AMI category to the angina category. No major changes in the use of enzymatic or 
other diagnostic criteria or approaches took place in Scotland during the period of study 
(and those that have occurred more recently have tended to increase rather than decrease 
diagnosis of AMI).^^^ Similarly, there are no financial influences, relating to 
reimbursement, on coding in the NHS.
Alternatively, there may have been “threshold” changes for both admission and diagnosis 
over the period of study. Primary care practitioners may have become more aware of the
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clinical importance of unstable angina and the newer treatments available which reduce the 
risk of infarction and death. They may also have become less happy about excluding the 
possibility of infarction without a hospital assessment. This may have reduced their 
threshold for hospital referral and admission. Similar recognition may also have increased 
in-patient efforts to diagnose and treat angina (resulting in more cases of “chest pain” 
becoming cases of angina).
The other major and new finding of this study was the striking increase in discharges for 
chest pain which doubled between 1990 and 2000. There are no similar' reports of this 
change from elsewhere. What is the explanation for this change? Similar influences to 
those already discussed that may have increased discharges for angina, might also have led 
to an increase in discharges labelled “chest pain”. In other words, the importance of 
identifying and treating acute coronary events may have resulted in an increase in referrals 
to hospital and intensified diagnostic effort, leading to more patients having definite angina 
or AMI excluded. That the overall number of cases of “possible acute coronary 
syndromes” did not increase much (and that the major change was in the diagnostic label 
applied at discharge), suggests that the latter change (better diagnosis) had to be the more 
important one, if this analysis is correct. Of course, this may not be the case and the 
success of diagnostic triage is best measured by the long-term prognosis of patients with a 
discharge diagnosis of chest pain.
Whatever the explanation, I have clearly shown two new findings with important clinical 
implications. The increase in hospitalisations for angina has enormous resource and 
financial implications, given the proven benefits of certain pharmacological treatments and 
percutaneous coronary intervention in these patients.' Conversely, the potential public 
health benefits are also substantial as these treatments reduce the risk of progression to 
infarction (with all its consequences), recurrence of angina (and hospital readmission) and 
improve quality of life.
The large increase in hospitalisations for chest pain raises different issues. What exactly is 
wrong with these patients? Has coronary disease been properly excluded? What is their 
long-term prognosis? Clearly, if this is a benign syndrome, the need for hospital admission 
at all must be questioned. The substantial and increasing use of acute hospital beds 
certainly suggests that chest pain observation units are a potentially attractive alternative to 
the conventional approach to management of this growing problem.
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8 SHORT-TERM AND LONG-TERM OUTCOMES IN 
PATIENTS ADMITTED WITH UNSTABLE ANGINA OR 
MYOCARDIAL INFARCTION IN SCOTLAND 1990-2000
8.1 Introduction
Every year, hospitals admit large numbers of emergency patients with suspected acute 
coronary syndromes: about one million in the UK and two million in the pjg 397,399-401 ^his 
places a massive burden on the health service and such suspected acute coronary 
syndromes represent a high priority g r o u p . B y  time of discharge, most patients with 
acute coronary syndrome have a clear diagnosis of acute myocardial infarction or unstable 
angina. However, the subsequent management plan is crucially dependent on a sound 
assessment of the individual patient's prognosis."^ ^^ "'^^ ^
A few small population-based surveys in Australia, Iceland and the UK have suggested 
that, compared with myocardial infarction, long-term survival in middle aged men is 
apparently much better for angina, whether defined as BCG abnormalities or "Rose 
positive angina" on a Rose angina questionnaire with a normal e q q  3,20,54,404 
none of these studies specifically examined unstable angina. As discussed in the literature 
review long-term survival following acute myocardial infarction has been extensively 
studied, however much less is known about prognosis following emergency admission for 
unstable angina. In Canada, Chang et al^  ^ reported a five year' case-fatality rate of 19.5% 
in men and 21.6% in women following unstable angina, compared with 26.8% and 38.8% 
and respectively following acute myocardial infarction in a large administrative database. 
Longer term prognosis also reflected associated conditions including age, ventricular 
function and co-morbidity.^’^
Cardiology has seen a therapeutic revolution since the 1980s. In addition to CAB G 
surgery and angioplasty, a growing armamentarium of effective medical therapies now 
include thrombolysis, aspirin, beta blockers, glycoprotein receptor antagonists and 
statins.^^^’"’’” "’®^’'”’^  But has this evidence-based therapy actually benefited ordinary
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patients in the general population?^^’^  ^ In spite of the increasingly widespread use of these 
therapies, there are almost no recent UK data describing survival in unselected patients in a 
population context. This highlights the practical difficulties of long-term follow-up in 
large unselected patient cohorts. However, such studies ai'e now increasingly facilitated by 
the record linkage achieved in Britain and elsewhere.^"’"^’’^ ’'”’^ ’'”’^  In this present study, short 
and long-term outcome and prognostic factors have been analysed in this large population- 
based cohort of unselected patients with a first emergency hospitalisation for suspected 
acute coronary syndrome between 1990 and 2000 in Scotland.
8.2 Methods
The SMR acute coronary syndrome database was used as described in chapter 3.
8.3 Results
Between 1990 and 2000, 225,512 patients had a first emergency hospitalisation for 
suspected acute coronary syndrome: 96,026 with acute myocardial infarction (43%),
37,403 with angina (17%) and 92,083 with chest pain (41%). This chapter only considers 
the patients with an acute myocardial infarction and angina.
Angina patients were slightly younger than those with acute myocardial infarction. The 
median age of men with angina was 64 years compared to 65 years in men with acute 
myocardial infarction (women, 69 versus 73 years respectively).(Table 43)
8.3.1 Cause of death
Following a first hospitalisation with acute myocardial infarction 41.1% of patients died 
within five years. The principal causes of death were acute myocardial infai’ction (37.8%), 
other coronary disease (2.7%), other cardiovascular disease (40.6%), cancer (13.6%) and 
all other causes (5.3%). The proportions were similar in the 21.8% patients who died 
within five years of their first emergency admission with angina: acute myocardial 
infarction (28.4%), other coronary heart disease (4,3%), other cardiovascular disease 
(30.9%), cancer (17.7%) and all other causes (18.7%).
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8.3.2 Univariable analysis
8.3.2.1 Short-term case fatality
Crude short-term case-fatality within one month was high in patients with acute 
myocardial infarction (15.7% in men and 25.7% in women), but low for emergency 
admissions with angina (2.0% in men and 1.8% in women).
8.3.2.2 Longer-term case fatality
After excluding deaths within 30 days, longer-term crude case-fatality at one, five and ten 
years in men with angina, was 6.5%, 23.9%, and 39.8%, respectively (6.4%, 23.5% and 
41.5% in women). These are very similar to the 6.4%, 21.6% and 36.0% respectively seen 
in men after a first admission for acute myocardial infarction (and 8.9%, 26.0% and 40.6% 
respectively in women). Age-specific case-fatality rates were likewise very similar in 
patients following acute myocardial infarction or angina.
8.3.2.3 Death rates in acute myocardial infarction and angina groups compared with 
the general population
At five years 25.8% of men with angina and 37.3% with acute myocardial infarction had 
died. In comparison the five year case fatality rate for a 64 year old man in Scotland 
(mean age of angina group) was only 15.3%. Likewise in women the five year case fatality 
rate in the general population was lower (13.2% in a 68 year old and 17.9% in a 72 year 
old) than that of either angina (25.2%) or acute myocardial infarction (51.7%).
8.3.3 Multivariable analysis
8.3.3.1 Short-term case fatality: age, co-morbidity and sex effects
After adjustment for other factors using logistic regression, short-term case-fatality in both 
patient groups approximately doubled for each decade of increasing age, and increased by
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up to two-fold with a wide range of co-morbidities including cancer, respiratory disease, 
renal disease and peripheral vascular disease. (Table 45) Adjusted short-term case-fatality 
following acute myocardial infarction was 22% higher in women than in men, (95% 
confidence intervals 18%, 27%), but 29% (18%, 40%) lower in women than in men 
following an angina hospitalisation.
5.3.3.2 Longer-term case fatality: age, co-morbidity and sex effects
As for short term case fatality adjusted case-fatality over five years also doubled for each 
decade of increasing age, and increased almost two-fold with a wide range of 
comorbidities. (Table 45) Compared with men, adjusted case-fatality in women was 29% 
(95% confidence intervals 24%, 33%) lower following angina, but only 7% (4%, 10%) 
lower following acute myocardial infarction.
5.3.3.3 Socioeconomic effects
A modest 9% adverse socio-economic gradient was seen in short-term case-fatality 
following myocardial infarction but not angina (Table 45) The socioeconomic gradient 
increased over the longer-term rising to a 22% (16%, 29%) increase in the hazar d of death 
in the most deprived quintile compared with the most affluent following myocardial 
infarction, and a 14% (4%, 25%) increase in angina patients.
5.3.3.4 Comparison of survival after acute myocardial infarction and angina
After adjustment for other factors, short-term case-fatality in patients with angina was 92% 
lower than that seen in patients with acute myocardial infarction. (Table 46) However after 
excluding deaths in the first 30 days, longer-term case-fatality in male angina patients was 
only 8% lower than that of acute myocardial infarction patients. In women, however, 
longer-term case-fatality in angina patients was 24-28% lower than that in acute 
myocardial infarction patients.
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8.3.4 Subsequent non-fatal events
8.3.4.1 Post AMI
Within five years of the first admission with acute myocardial infarction, 15,406 (16.1%) 
of the surviving men experienced one or more non-fatal cardiovascular events. These 
comprised 9.9% acute myocai'dial infarction, 1.9% stroke, 3.2% heart failure, 7.2% CABG, 
and 3.1% angioplasty (and in women: 6.3%, 4.1%, 2.7%, 3.0%, and 1.9% respectively). 
These events were not mutually exclusive, and some patients experienced multiple events.
8.3.4.2 Post angina
Within five years of the first emergency angina admission, 6,715 (18.0%) of the surviving 
men experienced a non-fatal cardiovasculai' event within five years of the first admission: 
6.6% acute myocardial infarction, 4.7% stroke, 1.7% heart failure, 10.1% CABG, and 
5.1% angioplasty (and in women 5.1%, 5.1%, 1.8%, 4.2%, and 3.0% respectively.
8.3.4.3 Subsequent revascularisation
Men were approximately twice as likely as women to undergo a revascularisation 
procedure within 5 years of their index hospitalisation (3.6% in men versus 2.2% in 
women for CABG and 7.9% in men versus 3.4% in women for angioplasty). 
Revascularisation rates showed a substantial negative age gradient and a consistent sex 
inequality. Following an acute myocardial infarction, CABG surgery rates within five 
years decreased from 11.5% in men aged under 55 years, to 0.8% in those aged 75-84 
years (8.5% versus 0.2% in women; corresponding rates after angina decreasing from 
10.5% to 2.6% in men (3.5% to 0.9% respectively in women). A similar age gradient was 
seen for angioplasty within five years following acute myocardial infarction, decreasing 
from 7.0% in men aged less than 55 years, to 0.5% in men aged 75-84 years (8.1% to 0.3% 
respectively in women). Corresponding rates after angina decreased from 7.7% to 1.3% in 
men (5.0% to 0.6% respectively in women).
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8.3.5 Subsequent fatal and non-fatal events
Within five years of the first admission, almost half of all men experienced a fatal or non- 
fatal event: death, acute myocardial infarction, angina admission, stroke, heart failure, 
angioplasty or CABG surgery. Following acute myocardial infarction, age-adjusted event 
rates in women were as high as in men (52.6% versus 53.6%, Figure 14), and almost as 
high following angina (48.8% v. 56.3%, Figure 15).
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Figure 14 Probability of fatal or non-fatal event in men and women following a first admission for
acute myocardial infarction in Scotland 1990- 2000 (adjusted for age, excludes deaths up to 30 days)
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Figure 15 Probability of fatal or non-fatal event in men and women following a first admission for
angina in Scotland 1990- 2000 (adjusted for age, excludes deaths up to 30 days)
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8.3.5.1 Subsequent fatal and non-fatal events: multivariable analysis
After adjustment for age and other factors, the risk of fatal plus non-fatal event was 34% 
(95% Cl 31%, 37%) lower in women compared with men following a first hospitalisation 
for angina, but only 11% (95% Cl 8%, 13%) lower following an acute myocardial 
infarction hospitalisation (Table 47). After adjustment for other factors, the risk of fatal 
and non-fatal events were greatly increased by age, (three-fold following acute myocardial 
infarction and four-fold following angina, aged <55 versus aged 75-84 years). Risk was 
also increased up to 60% by different co-morbidities. However, socio-economic 
deprivation had an adverse effect of only 8% following angina and 15% following acute 
myocardial infarction.
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Table 47 Factors influencing fatal plus non fatal event rates from 30 days to five years following a first 
emergency admission for acute myocardial infarction or angina (multivariable analyses, excludes 
deaths at 30/7)*
Acute myocardial 
infarction
Angina
Risk of fatal plus non fatal event (95% confidence 
intervals)
Sex Men 1.00 1.00
Women 0.89 (0.87,0.92) 0.66 (0.63,0.69)
Age (years) <55 1.00 1.00
55-64 1.13(1.08,1.18) 1.59(1.47,1.72)
65-74 1.37(1.31,1.43) 1.99(1.85,2.15)
75-84 2.00(1.91,2.09) 2.74 (2.54,2.96)
>84 3.03 (2.86,3.21) 4.15(3.74,4.60)
Deprivation 1 (most aflluent) 1.00 1.00
2 1.04 (0.99,1.08) 1.04 (0.96,1.12)
3 1.04(1.00,1.09) 1.05 (0.98,1.14)
4 1.06(1.01,1.10) 1.02 (0.95,1.10)
5 (most deprived) 1.15 (1.10,1.20) 1.08(1.00,1.16)
Comorbidity Diabetes 1.32(1.26,1.38) 1.41 (1.30,1.53)
Cancer 1.48(1.39,1.56) 1.35 (1.24,1.47)
Respiratory 1.27 (1.21,1.32) 1.20(1.12,1.29)
Cardiovascular 1.52(1.45,1.60) 1.44 (1.32,1.57)
Peripheral 
vascular disease
1.27(1.21,1.34) 1.21 (1.12,1.31)
Hypertension 1.07(1.02,1.12) 1.01 (0.94,1.08)
Heart failure 1.51 (1.46,1.57) 1.42 (1.32,1.53)
Atrial fibrillation 1.22(1.16,1.29) 1.04(0.95,1.13)
Renal disease 1.62(1.48,1.77) 1.68(1.44,1.97)
*all the hazard values reported come from multivariate analyses using Logistic Regression and Cox 
models. The values are thus independent, being adjusted for all other variables.
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8.4 Discussion
This paper describes clinical outcomes in a large unselected cohort of patients after a first 
emergency admission with suspected acute coronary syndrome. Short-term case-fatality 
following a diagnosis of acute myocardial infarction was high, as reported 
elsewhere.^^’^ '^ ’"'^  ^However, short-term case-fatality was only 2% following an emergency 
hospitalisation with angina (the proxy for unstable angina using this database). These data 
therefore support the current clinical priority of rapidly triaging such p a t i e n t s . .402.405 
Following exclusion of initial deaths, longer-term case-fatality following a first emergency 
admission was almost as high for angina as for acute myocardial infarction, approximately 
4%-5% per year. These novel and important findings suggest that long-term risk is 
substantial in all emergency admissions with coronary heart disease, not just acute 
myocardial infarction survivors. Non-fatal event rates were also high. This highlights the 
importance of secondary preventative strategies for all patients with acute coronary 
syndromes.
Short-term and long-term case-fatality in all groups with suspected acute coronary 
syndromes approximately doubled with each increasing decade of age, and was further 
increased by a range of comorbid diagnoses. These findings are consistent with earlier 
studies^^’^ '^ ’'^ ^^  and endorse the recommended prioritisation of older and sicker 
patients.'":''«:"(^'
As in the smaller Canadian series^^, socioeconomic deprivation consistently increased 
longer-term case-fatality in all patient groups with suspected acute eoronary syndromes, 
with the risk of death increasing by approximately 20% from the most affluent to the most 
deprived quintile s. Although lower use of secondary prevention medications might partly 
explain this gradient, other factors may also be important, such as diet and 
smoking. '^ '^^^ '^^^  ^ These modest deprivation gradients contrast with the consistently 
reported threefold variations in disease incidence.
Risk o f subsequent non-fatal events
Within five years of their first admission, approximately one quarter of the surviving 
patients experienced a non-fatal cardiovascular event: (principally acute myocardial 
infarction, but also stroke, angina, heart failure or revascularisation). This is consistent 
with the 10%-15% rates reported after just 12 months in trial and registry patients.^^’^ ’^'^ ^^
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Interestingly, while a further, non-fatal myocardial infarction was more common in 
myocardial infarction survivors than in angina survivors, the opposite was seen for stroke. 
This merits further research. After adjustment for other factors, cardiovascular event rates 
increased three-fold with age, increased by up to 60% with different co-morbidities, and by 
up to 15% with increasing socioeconomic deprivation. This finding strengthens the case 
for equally aggressive secondary prevention, irrespective of age and class.
Inequalities in revascularisation after a first admission for acute coronary syndrome
Revascularisation rates were generally low, much as might be expected in the 1990s. 
Revascularisation was twice as likely in men as women of the same age. Clinical 
justification for this finding appears difficult. Revascularisation rates also showed a 
substantial age gradient. Following an acute myocardial infarction, CABG surgery within 
five years was approximately fifteen times less likely in men aged 75-84 years compared 
with men aged less than 55 years. Even larger age gradients were seen in women. These 
findings provide yet more evidence of the substantial age and sex biases reported in North 
America, Europe and e l s e w h e r e . T h e  probability of undergoing CABG surgery 
within five years of hospitalisation with AMI was approximately twice as high as for 
angioplasty between 1990 and 2000. However, this ratio is now close to unity.
My study captured essentially all hospital and fatal events in the Scottish population of 5.1 
million, and is thus cautiously generalisable to similar populations elsewhere. However, it 
has a number of potential limitations. While routine death certification of coronary heart 
disease in Britain appears reliable up to the age of 65, it may overestimate coronary heart 
disease in older age groups by up to 20%."^ *^  However, any such inflation is unlikely to 
have changed substantially between 1990 and 2000. The definition of a first admission, 
may have included some long-term survivors with a prior admission, albeit less than 
5 % 94,156 YPs proxy for unstable angina, "emergency admission with angina" may have 
resulted in milder cases of angina being included in this analysis. This may have resulted in 
an underestimation of the case-fatality of patients admitted with angina. However, this 
may have been balanced by some over-estimation of case fatality, because these data come 
from the “pre-troponin era” and probably include some patients with actual myocardial 
infarction. There were no data on severity of cardiovascular disease, so it was not possible 
to take this into account when looking at the potential effects of age, sex and socio­
economic status on variations in rates for deaths, events, or revascularisation.
Furthermore, some mis-classification is possible, for instance, some angina patients dying 
in hospital may have been re-coded as myocardial infarction. However, my findings are
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generally consistent with smaller series from clinical disease registers.^^’^ *^’'^ ^^ ’^ '^^  
Furthermore, coding is essentially complete and accuracy exceeds 9 0 % . It was only 
possible to identify those non-fatal events actually admitted to hospital. However, this is 
likely to have included the great majority of significant events. Furthermore, if the true 
total was even higher, this further emphasises the substantial event rates in these patients.
In conclusion, following a first emergency hospitalisation for acute coronary syndrome, the 
long-term prognosis is almost as poor for angina as it is for acute myocardial infarction. 
Within five yeai's, half of all patients will experience a future fatal or non-fatal event.
These data may strengthen the case for aggressive secondary prevention in all patients 
hospitalised with acute coronary syndrome.
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9 REDUCED BETWEEN-HOSPITAL VARIATION IN 
SHORT-TERM SURVIVAL FOLLOWING ACUTE 
MYOCARDIAL INFARCTION: THE RESULT OF 
IMPROVED CARDIAC CARE?
9.1 Introduction
In a study of the period 1988 to 1991, substantial variation in 30 day survival following 
admission with AMI was identified between hospitals in Scotland.* Since that study, at 
least one Cardiologist has been appointed in each Scottish hospital and acute medical care 
has been reorganised in most to ensure more rapid and appropriate care of patients 
suspected of this diagnosis.  ^I have re-examined variation in survival following admission 
with AMI, ten years after the initial study. The aim was to determine whether there has 
been a reduction in the variation in survival between Scottish hospitals in this more recent 
time period compai'ed to the eaiiier one.
9.2 Methods
The SMR AMI database 1988-91 and 1998-2001 was used as described in chapter 3.
9.3 Results
9.3.1 Baseline characteristics
Table 48 shows the baseline characteristics of the 61,484 individuals diseharged with a 
first AMI during the two time periods of study. 36,108 (58.7%) were admitted between 
1988 and 1991 and 25,376 (41.3%) were admitted between 1998 and 2001. The mean age 
of men and women increased between these time periods (p<0.001). In the period 1988-
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1991, 48.2% of men were aged 65 or over. This proportion rose to 50.5% in 1998-2001 
(p<0.001). The corresponding figures for women were 72.1% and 75.4% (p<0.001). 
Between 1988 and 1991, 39.4% of men and 45.3% of women had one or more co­
morbidities or prior admissions. This proportion rose to 46.9% in men and 52.9% in 
women in 1998-2001 (p<0.001).
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9.3.2 30 day survival following hospital admission
Improved crude and age and sex adjusted 30 day survival (Table 49)
Crude 30 day survival for first AMI increased from 11,1% in 1988-1991 to 80.9% in 1998- 
2001 in Scotland as a whole. The number of hospitals with a 30 day survival of less than 
75% decreased from 5 to 0 (and those with a survival of less than 80% from 18 to 7) 
between these two time periods.
Decreased variation in crude and age and sex adjusted 30 day survival (Table 49 and 
Figure 16)
Between 1988 and 1991 the median crude 30 day survival rate was 79.2% with a range 
from 72.1% to 85.1% across hospitals, a difference of 13.0%. After standardising for age 
and sex, there was still a difference of 12.1% in 30 day survival between hospitals. 
Between 1998 and 2001 the median crude 30 day survival rate was 81.6% with a range 
from 78.0% to 85.6%. This difference of 7.6% increased slightly to 8.8% after 
standardising for age and sex. Therefore the inter-hospital variability decreased between 
these two time periods after adjusting for age and sex differences. The hospitals with the 
worst survival in 1988-1991 had the most marked improvement in 1998-2001.
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Table 49 Crude and age and sex adjusted 30 day survival after admission with a first acute myocardial 
infarction in 1988-1991 and 1998-2001.
Crude 30 day survival (%) Age and sex adjusted 30 day survival (%)
1988-1991 1998-2001 1988-1991 1998-2001
number % number % difference % % difference
Scotland 36108 77.7 25376 80.9 3.2
I 1361 74.1 939 85.5 11.4 73.8 84.9 11.1
2 1209 76.8 1156 83.3 6.5 76.1 84.1 8
3 1095 78.2 685 84.7 6.5 78.4 84.1 5.7
4 2309 81.6 1651 83.4 1.8 80.1 82.5 2.4
5 2099 81.4 2000 83.1 1.7 80.0 83.3 3.3
6 919 82.8 714 85.6 2.8 81.7 83.7 2
7 922 83.8 730 81.4 -2.4 83.1 82.7 -0.4
8 1948 84.5 1365 82.8 -1.7 84.5 82.7 -1.8
9 601 80.5 504 81.0 0.5 81.3 81.9 0.6
10 957 72.9 586 81.4 8.5 73.7 82.5 8.8
11 912 76.9 605 82.5 5.6 75.8 82.3 6.5
12 1173 80.8 668 83.1 2.3 79.3 80.6 1.3
13 536 78.5 452 82.1 3.6 77.6 81.1 3.5
14 1314 82.0 1137 81.6 -0.4 79.0 81.7 2.7
15 706 78.5 861 81.7 3.2 77.0 80.7 3.7
16 664 73.6 688 81.1 7.5 73.9 80.7 6.8
17 1029 79.3 575 80.4 1.1 79.3 80.7 1.4
18 1013 77.7 582 81.6 3.9 77.7 80.3 2.6
19 1243 80.8 1093 80.1 -0.7 78.6 79.4 0.8
20 470 80.6 419 78.0 -2.6 82.1 80.6 -1.5
21 1188 72.1 837 80.1 8 72.4 78.9 6.5
22 598 85.1 761 82.4 -2.7 82.7 79.1 -3.6
23 839 79.0 815 80.5 1.5 76.5 78.5 2
24 1020 78.2 1106 81.0 2.8 74.0 78.2 4.2
25 1201 77.3 799 79.2 1.9 75.4 78.1 2.7
26 1455 80.8 805 78.5 -2.3 78.6 76.1 -2.5
Total* 28781 79.2 22533 81.6 2.4 78.6 80.9 2.3
* Total number and median survival for 26 hospitals
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Figure 16Age and sex standardised 30 day survival after admission with acute myocardial infarction 
between 1988-1991 and 1998-2001
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9.3.3 Multiple logistic regression
1988-1991: After adjusting for age, sex, deprivation category and prior (previous 
admissions) and co-morbidity (secondary discharge diagnoses), admission hospital was a 
highly significant predictor of outcome at 30 days (p<0.001). The odds ratio (OR) for death 
following admission with AMI, ranged from 0.71 (95% Cl 0.58, 0.88) to 1.50 (1.19, 1.89) 
between hospitals. The index hospital was hospital 18 which had the same crude survival 
as Scotland as a whole (Figure 17). The adjusted risk of death within 30 days following an 
admission with AMI was significantly higher than average in 9 (and better in 1) of 26 
hospitals.
1998-2001: Admission hospital remained an independent predictor of outcome at 30 days 
(p<0.001). The OR for death ranged from 0.82 (0.60, 1.13) to 1.46 (1.07, 1.99) between 
hospitals, relative to hospital 9 which had a similar crude survival as Scotland as a whole 
(Figure 18). Inter-hospital variation was less and the adjusted risk of death was 
significantly higher than average in only 2 hospitals.
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Figure 17 The adjusted probability of death* at 30 days post AMI between 1988-1991
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*Odds ratios and 95% confidence intervals are shown. 18 is the index hospital. 
Figure 18 The adjusted probability of death* at 30 days post AMI between 1998-2001
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*Odds ratios and 95% confidence intervals are shown. 9 is the index hospital.
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9.4 Discussion
There are two notable findings of this study. Firstly, despite an increase in age and 
documented co-morbidity, patients hospitalised with AMI had a higher 30 day survival in 
Scotland between 1998 and 2001 than in 1988 to 1991. Secondly, and most germane to the 
aims of this study, inter-hospital vaiiation declined substantially between 1988-1991 and 
1998-2001.
Though not the principal aim of this study, it was of interest to be able to confirm that there 
has been a fall in the incidence of AMI between the two study periods, a finding consistent 
with prior studies from Scotland and elsewhere. ^'^^This may be attributable to a variety of 
factors including better primary prevention, falling rates of smoking, a change in the 
natural history of coronary artery disease and better public and doctor awareness of the 
importance of potential caidiac symptoms. Similarly, the increase in 30 day survival 
following an AMI is also consistent with prior reports from Scotland and elsewhere.
Several factors, including those which may have contributed to the decline in incidence, 
may be important. Others include changing thresholds for referral (whereby patients 
with chest pain are more likely to be referred to hospital by primary caie practitioners) and 
admission (when referred more likely than previously to be admitted). Diagnostic 
thresholds may also have been lowered, with consequent changes in severity of infarction. 
New treatments may also have played an important part.
The second major finding of this study (and the one most pertinent to the aim of the study) 
is that inter-hospital variation declined substantially between 1988-1991 and 1998-2001. 
This is less easy to attribute to the factors mentioned above in connection with the decline 
in case fatality between these two periods. Indeed, the hypothesis was that greater input of 
Cardiology services and re-organisation of care should have led to reduced between 
hospital vaiiation in 30 day survival and the findings are consistent with this (these may 
also, of course, have contributed to the improvement in survival). The reduction in 
vaiiation between hospitals seemed to be due, largely, to a particularly notable 
improvement in survival in those hospitals which had the highest care fatality in the 1988- 
1991 study.
Though there was less variation between 1998 and 2001 than previously, inter-hospital 
variation persisted, with a 9% difference in adjusted survival. The reasons for this require
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further study as identification of conectahle factors (such as deficiencies in treatment) 
could lead to further improvements in outcome and reductions in variation. This highlights 
the major limitation of this study which is absence of information on treatment and on 
other factors such as measurement of ventricular function, which might allow better 
adjustment of case mix.
In summary, the appointment of Cardiologists and their involvement in the care of acute 
admissions to Scottish hospitals seems to be associated with an overall improvement (and 
less variation between hospitals) in survival following AMI.
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10 A POPULATION STUDY OF THE LONG-TERM 
CONSEQUENCES OF ANGINA: 20 YEAR FOLLOW-UP 
OF THE RENFREW-PAISLEY STUDY.
10.1 Introduction
Although the incidence of myocardial infarction is decreasing, the prevalence of angina 
pectoris has changed little and remains high."^ *^  As such, angina remains the most common 
manifestation of coronary heart disease and the most common symptomatic cardiac 
condition. As evident from chapter 1, relatively little is known about the long-term natural 
history of angina at a population level, especially in women.^^’"**’^ ’^^  ^As discussed 
previously most existing population-based studies have mainly or exclusively reported 
outcomes in Only a few described prognosis in women and those that did
have not usually compared their outcome to men in the same p o p u la tio n .F u rth erm o re , 
most existing studies which have reported clinical outcomes have focussed on death, 
myocardial infarction or both.^ '^^ '^^ '^^ '^^  ^Patients with angina are likely to be at increased 
risk of other complications of coronary heart disease (e.g. heart failure) and non-cardiac 
vascular events (e.g. s tro k e)S im ila rly , the true lifetime burden of angina is reflected not 
only in fatal but also in non-fatal events, especially those leading to hospital admission. 
Consequently, the aim of this study was to examine the long-term population risk of fatal 
and non-fatal cardiovascular events in both men and women with angina, during 20 yeai’ 
follow up of 15,402 initially middle-aged individuals (8,354 women) who were first 
screened between 1972 and 1976.
10.2Methods
The Renfrew-Paisley study database was used as described in chapter 3.
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10.3Results
10.3.1 Prevalence of angina
At baseline screening, 669(9.5%) men and 799(9.6%) women had Rose-positive angina. 
Of these, 22.7% of men and 14.8% of women had an ischaemic ECG. Conversely, 
697(9.9%) men and 712(8.5%) women had an ischaemic ECG. Of these, 21.8% of men 
and 16.6% of women had angina
10.3.2Baseline characteristics according to the presence or absence of 
angina at baseline
Compared to individuals with no angina and no ischaemic ECG changes, those with angina 
or an ischaemic ECG were older and more likely to have cardiovascular risk factors or 
prior cardiovascular disease (these findings were generally more marked for subjects with 
an abnormal ECG). (Table 50) This gradient was also seen for pulmonary disease. 
Compared to women, men with angina were significantly more likely to be current or ex­
smokers (p<0.001) (and to have a lower FEV] (p<0.001) and more likely to have chronic 
bronchitis (p=0.002)). Men were also more likely to have a history of Rose-myocardial 
infarction (p<0.001). Conversely, women had a higher total cholesterol (p<0.001), systolic 
blood pressure (p=0.005) and cardiothoracic ratio (p<0.001).
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10.3.3Survival over 20 years follow-up
A larger propoition of men than women died over the 20 year follow-up period, 
irrespective of whether or not they had angina (Figure 19 and Table 51). Men and women 
with angina were more likely to die than those without angina. 67.7% of men with angina 
died over the 20 years of follow-up, compared to 45.4% of men without angina (p<0.001). 
The corresponding figures for women were 43.3% and 30.4% respectively (p<0.001). Both 
angina and ischaemic ECG changes were associated with an increased risk of death. An 
ischaemic ECG was associated with a somewhat greater risk than that seen with angina 
alone (i.e. where there were no ischaemic ECG changes).
Subjects with angina and an abnormal ECG had the highest risk of death. 84.2% of men 
and 66.1% of women with angina and an ischaemic ECG died by 20 years, compared to 
62.9% and 39.4% of men and women with angina but without an abnormal ECG.
Angina was associated with an increase in the adjusted relative risk of death from all 
causes, cardiovascular causes and, especially, coronary causes. The adjusted relative risk 
of death from any cause was 1.38 (95% confidence interval 1.25, 1.53) in men and 1.24 
(95% confidence interval 1.11, 1.39) in women (compared to those without angina), 
whereas the relative risk of death from a coronary cause was 1.95 (1.68, 2.27) in men and 
1.50 (1.23, 1.82) in women.
Both angina and an ischaemic ECG were separately associated with increased risk, though 
the risk associated with an abnormal ECG was greater. Men with angina, but no ECG 
changes, had a 71% increase in the adjusted risk of dying from coronary heart disease 
(compared to individuals with neither angina nor ECG changes) while women had a 33% 
increased risk. The corresponding increases in individuals with an abnormal ECG but no 
angina were 108% in men and 81% in women.
The increase in relative risk was greatest in individuals with angina and an abnormal ECG, 
where men had a more than 4-fold and women a more than 3-fold increased risk of death 
from coronary heart disease, eompared to individuals without angina or an ischaemic ECG.
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Figure 19 Age-adjusted Cox survival curves for all cause death according to the presence or absence of 
angina or ischaemic ECG changes in men and women
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10.3.4Hospitalisation from cardiovascular causes
Men and women with angina were more likely than those without angina to experience a 
subsequent cardiovascular hospitalisation. 43.5% of men with angina experienced such an 
event over the 20 years of follow-up, compared to 32.7% of those without angina 
(p<0.001). The corresponding figures for women were 37.4% and 24.6%, respectively 
(p<0.001). 47.4% of men and 52.5% of women, with both angina and an abnormal ECG, 
experienced a cardiovasculai’ hospitalisation, compared to 42.4% of men and 34.8% of 
women with angina but a normal BCG (p<0.001). (Table 52)
The adjusted relative risk of admission to hospital for a cardiovascular reason was 
increased to a similai' extent as the risk of death from a cardiovascular cause. As with 
death, the increased risk of a major coronaiy event was even greater.
As with death alone, the risk of hospital admission for a cardiovascular reason was 
increased by both angina and an ischaemic ECG, separately. Unlike death, the increase in 
risk was not substantially greater with an abnormal ECG than with angina. However, as 
with death, the greatest risk was seen in subjects with angina and an abnormal ECG. In 
these individuals, the relative risk of a cardiovascular hospitalisation was increased 2.7- 
fold in men and 2.8-fold in women (compared to individuals with neither angina nor an 
ischaemic ECG).
Angina, an ischaemic ECG and, especially, both, were associated with an increased risk of 
hospitalisation due to heart failure and stroke (angina alone did not increase this latter risk 
in men).
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10.3.5Total hospitalisations for cardiovascular reasons
Both angina and an ischaemic ECG were associated with more subjects requiring at least 
one admission for a cardiovascular reason and also more admissions per patient. (Table 53) 
The high rate of death in patients with both angina and an abnormal ECG reduced the 
overall numbers and rate of admission in this sub-group.
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10.3.6Death or hospitalisation from cardiovascular causes
Men and women with angina were more likely than those without angina to experience a 
major non-fatal or fatal cardiovascular event. 61.6% of men with angina experienced such 
an event over the 20 years of follow-up, compared to 43.4% of those without angina 
(p<0.001). The corresponding figures for women were 45.9% and 30.9% respectively 
(p<0.001). 77.6% of men and 69.5% of women, with both angina and an abnormal ECG, 
experienced a major adverse cardiovascular' event, compared to 56.9% of men and 41.9% 
of women with angina but a normal ECG (p<0.001). (Figure 20 and Table 54)
The adjusted relative risk of a major fatal or non-fatal car'diovascular event was increased 
to the same extent as the risk of death from a cardiovascular cause in individuals with 
angina. As with death, the increased risk of a major coronary event was even greater. Men 
with angina had an increased risk of cardiovascular death or hospitalisation (HR1.62 
95%CI 1.46, 1.80), myocardial infarction (1.80 (1.56, 2.08)) and head failure (1.62 (1.19, 
2.19)) relative to men without angina. The corresponding hazai'd ratios for women were 
1.48 (1.32, 1.65), 1.67 (1.41, 1.98) and 2.05 (1.55, 2.71).
As with death alone, the risk of either a major fatal or non-fatal event was increased by 
both angina and an ischaemic ECG, separately. The increase in risk was greater with an 
abnormal ECG. However, even those with angina, but without an abnormal ECG, had 
substantial and significant increases in risk of cardiovascular' (40-50% increase) and 
coronary (70-80% increase) events, compared to individuals with neither angina nor an 
ischaemic ECG.
All of these risks were enhanced in subjects with angina and an abnormal ECG, in whom 
the relative risk of a major fatal or non-fatal coronary event was increased 4-fold in men 
and 3-fold in women (compared to individuals with neither angina nor an ischaemic ECG). 
Examination of composite fatal and non-fatal outcomes also showed that angina, an 
ischaemic ECG and, especially, both, were associated with an increased risk of death or 
hospitalisation due to heart failure and stroke (angina alone did not increase this latter risk 
in men).
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Figure 20 Age-adjusted Cox survival curves for cardiovascular (CV) death or hospital admission 
according to the presence or absence of angina or ischaemic ECG changes in men and women
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10.3.7Outcomes in men compared to women
The adjusted hazard for death from any cause in women with angina compared to men 
with angina was 0.51 (0.43, 0.60), p<0.001. Even after adjusting for the powerful effect of 
an ischaemic ECG (which was more commonly found in men), women had less than half 
the risk of men of any adverse cardiovascular outcome (Table 55). However, this 
difference was mainly explained by a lower risk of coronary events; the risk of stroke and 
heart failure was not lower in women.
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Table 55 Adjusted risk* of fatal and non-fatal outcomes over 20 years in women compared to men with 
angina.
Death Hospital
admission
Death or 
admission
HR (95% confidence interval)
Any cardiovascular 
cause
0.44 (0.35, 0.54) 0.60 (0.50, 0.73) 0.53 (0.45, 0.63)
Coronary heart disease 0.32 (0.25,0.41) 0.49 (0.36, 0.64) 0.41 (0.33, 0.50)
Myocardial infarction 0.37 (0.28, 0.50) 0.49 (0.36, 0.67) 0.43 (0.34, 0.54)
Heart failure 1.05 (0.32,3.44) 0.78 (0.50, 1.22) 0.80 (0.52, 1.22)
Atrial fibrillation - 0.78 (0.35, 1.78) 0.86 (0.39, 1.92)
Cerebrovascular
accident
1.49 (0.83, 2.69) 0.95 (0.61, 1.47) 1.11 (0.74, 1.65)
Aortic aneurysm 0.32 (0.02, 5.31) 0.18(0.03, 0.98) 0.23 (0.05, 1.04)
Venous
thromboembolism
- 0.54 (0.21, 1.41) 0.50 (0.20, 1.26)
* Adjusted for age, ischaemic ECG, cholesterol, systolic blood pressure, adjusted FEV|, smoking, 
social class, past history of diabetes.
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10,4Discussion
This population-based study describes, in a more complete way than previously, the 
mortality and morbidity burden associated with angina over a long period of follow-up. In 
particular, fatal and non-fatal outcomes are described in a large cohort of women who 
have, generally, been excluded from prior epidemiological studies of angina.
Although it has been suggested that angina is associated with a relatively good prognosis, 
the present analysis clearly shows otherwise."^Consideration of only fatal outcomes 
underestimates the adverse prognostic effect of an angina d i a g n o s i s . W h i l e  
approximately 40% of men and 25% of women reporting this symptom in middle-age died 
from a cardiovascular cause, almost half of women and two thirds of men went on to 
experience a major fatal or non-fatal cardiovasculai' event over the next two decades.
This study’s findings in men closely support those of prior studies such as the Reykjavik 
Study, the Gothenburg Primary Prevention Study and the British Regional Heart S t u d y . I  
found that women had a better prognosis than men, as noted in the few prior studies to 
include both s e x e s . T h i s  was especially true for coronary events (both fatal and non- 
fatal). Although men had a greater prevalence of certain adverse coronary prognostic 
factors (especially ECG evidence of ischaemia and infarction), women remained at lower 
risk after adjusting for these differences. Interestingly, however, women were less 
protected from non-coronary cardiovascular events including stroke, heart failure and atrial 
fibrillation. I do not know of any other reports of this discrepancy. Consequently, though 
women had only a 1 in 5 twenty-year risk of fatal or non-fatal myocardial infarction, 
compared to a 1 in 3 risk in men, the risks in women of stroke and heart failure were 1 in 8 
and 1 in 12, respectively, compared to 1 in 12 and 1 in 13, respectively, in men. These 
differences may reflect the significantly greater systolic blood pressure (a powerful risk 
factor for stroke) and cardiothoracic ratio (a powerful risk factor for heart failure and atrial 
fibrillation) in women at baseline.
Why do women have a better survival than men? One explanation is that a higher
proportion of women who are “Rose positive” for angina do not have cardiac
d i s e a s e . A l t e r n a t i v e l y ,  women with definite angina and coronary heart disease have
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better left ventricular systolic function than men (though they have as much heart 
failure)."^’^  Left ventriculai' systolic function is a very powerful predictor of death.
As described by others previously (and alluded to above), ischaemic changes on the ECG 
were found to be a powerful predictor of coronary death.^'^’^ ^^  In addition, these changes 
were also strong predictors of non-fatal coronary events and of other non-fatal and fatal 
cardiovascular events such as heart failure and stroke. Indeed, an abnormal ECG was a 
more powerful predictor of all these adverse outcomes than the symptom of angina alone 
(i.e. in the absence of ischaemic changes on the ECG). Individuals with both an abnormal 
ECG and angina had the worst outcome, with a risk in men of 1 in 2 for myocardial 
infarction and 1 in 10 for stroke and heart failure. For women these risks were 1 in 3, 1 in 
5 and 1 in 8, respectively. Indeed, more than three-quarters of men and more than two- 
thirds of women in this category experienced a major fatal or non-fatal cardiovascular 
event during follow-up.
It is, nevertheless, important to emphasise that angina without associated ECG changes 
(similar to “uncomplicated angina” in prior studies was still predictive of a poor
outcome, even in women. However, as in the overall cohort, the risk of a coronary death 
in these subjects was increased to a greater extent in men (-4-71%) than women (+33%), 
whereas this difference was less for death from cardiovascular causes (+46% in men and 
+31% in women). There was also much less difference between men and women when 
combined fatal and non-fatal outcomes were considered, with an approximately 70-80% 
increase in risk of coronary events and 40-50% increase in risk of cardiovascular events in 
both sexes in this category (i.e. those with angina but without ECG changes).
This study has a number of limitations. Angina was documented at only one time point and 
spontaneous variation is well r e c o g n i s e d . " ^ Th e  validity of the Rose questionnaire and 
which Rose categories should be included have been d e b a t e d . T h e  study was 
conducted in an area with a high prevalence of coronary heart disease.'^ Morbidity (e.g. 
symptoms, functional limitation) not associated with hospital admission were not 
measured."^Records of coronary revascularisation either as an outcome or a treatment or 
information on medical treatment was not available. The prevalence of angina increases 
with increasing age^^  ^however by design our study looks at outcome in a group of middle- 
aged individuals. There is a possible lack of generalisability to other populations, as this is 
a cohort from Scotland and also because the inception of the cohort occurred thirty years 
ago. By necessity, this is a historical cohort, demographics and risk factor profiles have
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changed in the time interval, and the cohort could not benefit from a number of recent 
treatments which are known to reduce morbidity and mortality in angina.^ ^^ '"^ ^^ '"^ "^' The 
mortality rate of individuals with angina in our study is higher than that reported in 
contemporary pharmaceutical trials. For example, the PEACE trial reported an 8.1% 
mortality rate at 5 years"^ ^^  and in the ACTION trial the mortality rate was 1.53 per 100 
patient years^^^ (Renfrew-Paisley angina cohort 5-year mortality rate 11.6% and 2.62 per 
100 patient years). The mean age of patients was higher in both these studies (approx 63 
years versus 56 years in our study). It is likely that contemporary phaiinacological 
treatments and revascularisation options have improved outcome in patients with angina.
In summary, angina, as identified by the Rose questionnaire, is common and is associated 
with substantial long-term mortality and morbidity in both men and women. Consideration 
of only death (or death and myocardial infarction) greatly underestimates the public health 
burden related to angina. Of middle-aged subjects with angina, almost two thirds of men 
and half of women will die or require hospital admission for a cardiovascular reason over 
the subsequent 20 years. If these individuals have an ischaemic ECG, the proportions rise 
to more than three quarters of men and two thirds of women. Vigorous efforts to identify 
and treat subjects with angina (many of which, especially w o m e n , a r e  not known to the 
health care system^^’"^ ^^ ) could lead to substantial reductions in the direct and indirect 
burden of cardiovascular disease."^^^’"^ ^^
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11 LONG-TERM CARDIOVASCULAR CONSEQUENCES 
OF OBESITY: 20 YEAR FOLLOW-UP OF MORE THAN 
15,000 MIDDLE AGED MEN AND WOMEN (THE 
RENFREW-PAISLEY STUDY).
ll.llntroduction
The prevalence of obesity has reached unprecedented proportions.^'** Nearly one third of 
Americans are obese.^"'^'^ It is estimated that there are up to 200 million obese citizens in
the recently expanded European Union. The obesity epidemic is also affecting developing 
count r i e s . Ther e  is appropriate concern that this alarming trend will have major public 
health consequences globally, with evidence linldng obesity to an increased risk of more 
than 30 medical conditions.
One of the first medical consequences of obesity to be recognised was coronary heart
• 224 235 237disease. ’ ' Obesity, however, carries a broader cardiovascular risk though this has
not been fully explored in any society. Neither the full range of cardiovascular problems 
related to obesity nor the complete burden, as measured by both fatal and non-fatal events, 
has been quantified in detail, hi particular, the whole spectrum of cardiovascular problems 
related to obesity has not been evaluated in a single population-based cohort in order to 
compare the relative effect of obesity on different outcomes.
Between 1972 and 1976, the Renfrew-Paisley Study enrolled 7,048 men and 8,354 women, 
representing 80 per cent of individuals aged 45-64 years residing in these two towns in the 
west of Scotland.^’ Because of the large number of events over 20 years (3,028 
cardiovasculai’ deaths and 11,028 hospital admissions), this cohort provides the opportunity 
to quantify the entire cardiovascular burden of obesity in the long-term. Furthermore, 
when combined with monitored trends in body mass index in Scotland^^', this information 
enables projection of the future cardiovascular consequences likely to result from recent 
increases in the population prevalence of obesity.
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11.2Methods
The Renfrew-Paisley study database was used as described in chapter 3
11.3Results
11.3.1 Baseline characteristics
The baseline characteristics of the Renfrew-Paisley cohort, divided into the different BMI 
categories, are shown in Table 56. Compared to individuals with a normal BMI, obese 
men and women had more risk factors for cardiovascular disease (with the notable 
exception of smoldng), more clinical evidence of cardiovascular disease and more ECG 
abnormalities. Of particular note, the prevalence of diabetes was two-fold higher in obese 
subjects and systolic blood pressure was an average of more than 15 mmHg higher. 
Individuals who were “overweight” had a profile intermediate between that of those who 
were obese and men and women with a normal BMI.
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11.3.2Death from any cause over 20-years of follow-up
51.2% of obese men died within 20 years of screening, compared to 48.9% of men with a 
normal BMI (p value for BMI as a continuous variable =0.285, Table 57). The 
corresponding figures for women were 39.2% and 29.8% respectively (p=0.015). The 
adjusted HR (95% Cl) of death (compared to those with a normal BMI) was 1.16 (1.03, 
1.30) in obese men and 1.23 (1.11, 1.37) in obese women. The proportion of “overweight” 
men who died was 45.5% (1.00 (0.93, 1.08)) and in women this proportion was 29.3% 
(0.95 (0.87, 1.04)). There was evidence of a quadratic trend for death in men (p value for 
BMI squared = 0.001) and women (p<0.001).
11.3.3Death from cardiovascular causes over 20 years of follow-up
Compared to individuals with a normal BMI, a significantly higher proportion of obese 
men and women died from a cardiovascular cause (men 35.6% compared to 23.2% 
p<0.001; women 25.5% compared to 15.6%, p<0.001) (Figure 21 and Table 57). The 
adjusted HR of cardiovascular death was 1.49 (1.28, 1.72) in obese men and 1.45 (1.25, 
1.67) in obese women, compared to individuals with a normal BMI. The risk of death 
from a cardiovascular cause was increased in men in the overweight category (1.14 (1.03, 
1.26)) but not in women (0,92 (0.81, 1.05)).
11.3.4Death from coronary heart disease over 20 years of follow-up
Obese men (HR 1.60 95% Cl 1.35, 1.90) and women (1.44 (1.19, 1.74)) were more likely 
to die from coronary heart disease. Again the risk of death from coronary heart disease was 
increased in men in the overweight category (1.19 (1.06, 1.35)) but not in women (0.99 
(0.83, 1.16)) (Table 57). Examination of deaths attributed to acute myocardial infarction 
showed similar findings.
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11.3.5 Death from non-coronary cardiovascular causes over 20 years of
follow-up
There were many fewer deaths from stroke than from coronary heart disease and only a 
small number of deaths from heart failure, venous thromboembolism and atrial fibrillation, 
making assessment of their risk related to obesity unreliable. Examination of combined 
fatal and non-fatal outcomes gives a more reliable estimate of risk (see below).
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Figure 21 Age adjusted event free survival in men and women for cardiovascular death
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11.3.6Hospitalisations for cardiovascular causes over 20 years of
follow-up
The excess risk of cardiovascular hospitalisations associated with obesity was broadly 
similar to the increased risk of cardiovasculai* death (Table 58). Table 59 shows the total 
number of hospitalisations for different cardiovascular reasons over 20 years of follow-up. 
Obesity was associated not only with more subjects requiring at least one admission for a 
cardiovasculai' reason but also more admissions per patient. Overweight patients were at 
intermediate risk. Obesity accounted for an “extra” 600 (95%CI 530, 670) admissions 
(difference between the observed and expected number of admissions) for caidiovascular 
reasons (an increase of 47%) amongst the 2,010 individuals in this BMI category i.e. 30 
per 100 extra admissions. Heart failure accounted for the greatest proportional increase 
(138%) in hospital episodes related to obesity (i.e. 139 (95%CI 119, 159) extra heart 
failure admissions).
This was because of a two fold increase in the rate of two admissions (p=0.001) and a four 
fold increase in the rate of three or more admissions (p<0.001) in obese compared to 
normal weight individuals.
The prevalence of “overweight” was much greater than that of obesity. Consequently, 
though the relative risk related to “overweight” was less, the absolute number of events 
attributable to overweight was greater. Overweight accounted for an additional 884 
(95%CI 759, 1009) cardiovascular hospitalisations (an increase of 22%) amongst the 6,493 
individuals in this BMI category i.e. 14 per 100 extra admissions.
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11.3.7Death or hospitalisation for cardiovascular causes over 20 years of
follow-up
58.6% of obese men died from, or were admitted to hospital for a cardiovascular reason 
compared to 47.9% of men in the normal BMI category (p<0.001) (Table 60 and Figure 
23). The risk for overweight men (50.6%) was intermediate. The adjusted HR was 1.44 
(1.29, 1.61) for obese men and 1.15 (1.06, 1.24) for overweight men. The picture for 
women was similar; 45.6% of obese women died or were admitted to hospital (HR 1.44, 
(1.30, 1.60)) compared to 34.0% of overweight women (HR 1.06 (0.97, 1.15)) and 32,0% 
of women with a normal BMI. The pattern for deaths and admissions related to coronary 
heart disease were similar.
Examination of the composite of hospital admission or death doubled the number of 
individuals experiencing a stroke (n=1288). The proportion of men and women admitted 
to hospital with a stroke was increased in obese subjects. The adjusted HR was 1.33 (1.03, 
1.73) for obese men and 1.47 (1.20, 1.80) for obese women.
The addition of hospital admissions to deaths increased the total number of patients 
experiencing a heart failure related event seven-fold (n=641). Obesity increased the 
adjusted risk of heart failure in men (2.61 (1.92, 3.56)) and women (1.70 (1.26, 2.30)). 
Obesity also increased the risk of fatal and non-fatal episodes of venous thromboembolism 
in men (1.89 (1.13, 3.17)) and women (2.91 (1.72, 4.94)). Patients in the overweight 
category had an intermediate risk. There was no increase in the adjusted risk of atrial 
fibrillation in men though this risk was increased in obese women (2.18 (1.31, 3.56))
(Table 60).
For every 1 kg/m^ increase in BMI there was a 4% increased risk of myocai'dial infarction 
(1.04 (1.03, 1.05)), a 3% increased risk of stroke (1.03 (1.01, 1.04)), a 6% increased risk of 
heart failure (1.06 (1.04, 1.08)), a 8% increased risk of venous thromboembolism (1.08 
(1.05, 1.11)) and a 5% increased risk of atrial fibrillation (1.05 (1.01, 1.08)).
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Figure 23 Age adjusted event free survival in men and women for cardiovascular death or hospital 
admission
Men
>>
S2
C L1
3in
1 '
1  .
?0)
<  0.0
o b ese
overweight
normal
0 2000 4000 6000 8000
Survival tim e in days
Women
12Ol
(DO
CO3 o b ese
6
<  0.0
overw eight
normal
0 2000 4000 6000 8000
Survival tim e in days
259
11.3.8Fully adjusted risk of death or hospitalisation for cardiovascular
causes over 20 years of follow-up
When we included diabetes, cholesterol and hypertension in the multivariable analysis 
obesity remained an independent risk factor for any cardiovascular hospitalisation or death 
in men (HR 1.21 (95% Cl 1.08, 1.36)) and women (1.22 (1.10, 1.36)) and for a coronary 
heart disease event in men (1.32 (1.14, 1.53)) and women (1.30 (1.11, 1.51)). Obesity also 
increased the risk of heart failure (men 2.16 (1.57, 2.97); women 1.37 (1.00, 1.88)), venous 
thromboembolism (men 1.92 (1.13, 3.26); women 2.90 (1.67, 5.01)) and atrial fibrillation 
in women (1.76 (1.04, 2.98)) although it was no longer an independent risk factor for 
stroke (men 1.04 (0.79, 1.35); women 1.17 (0.95, 1.44)).
11.3.9Potential consequences of increase in obesity
Using the above data it is possible to estimate the cardiovascular consequences of the 
increase in prevalence of obesity from the time of the initial Renfrew-Paisley study 
screening (1972-1976) and the present day. A recent survey showed that the prevalence of 
obesity in Scotland has risen to 28.8% in men and 26.0% in women aged 45-54 years and 
23% in men and 31.5% in women aged 55-64 years in 1998. We applied the rate of 
cardiovascular events seen in the Renfrew-Paisley cohort to the Scottish obese population 
in 1972 and 1998. The number of obese Scots aged 45-64 years in 1972 and 1998 was 
calculated using age specific population estimates and the obesity prevalence for each year. 
The difference between the numbers of obese men and women experiencing a 
cardiovascular event in both years was expressed per 100 men and women in Scotland in 
1998. Assuming the cardiovascular risk profile and outcomes associated with obesity have 
remained unchanged, the increase in prevalence of obesity between 1976 and 1998 is 
expected to lead to an additional 9 (95% Cl 8.7, 9.9) per 100 men and an additional 5 (5.5, 
6.2) per 100 women experiencing a cardiovascular event (death or hospital admission) 
between 1998 and 2018. The increase in obesity is also projected to lead to an extra 18 
(17.7, 18.6) hospital admissions for cardiovascular disease per 100 men and 10 (10.0, 10.6) 
per 100 women over this period.
260
The increased prevalence of men and women in the overweight category is expected to 
result in an additional 1 (1.0, 1.1) per 100 cardiovascular events and an additional 1.9 (1.9, 
1.9) per 100 cardiovascular hospital episodes in men (the corresponding figures for women 
would be 0.04 (0.04, 0.04) per 100 and 0.07 (0.07, 0.07) per 100).
11.4Discussion
I have been able to examine the association between obesity and a broad spectrum of 
cardiovascular events in a single, large, population-based cohort followed for 20 years and 
examine the rates and rankings of these outcomes. The principal finding of this study is 
that the harmful cardiovascular effects of obesity extend beyond coronary heart disease 
though, numerically, coronary events account for the greatest proportion of all 
cardiovascular events.
In the Renfrew-Paisley cohort, obesity was also associated with an increased, long-term, 
risk of fatal and non-fatal (and recurrent) heart failure, venous thromboembolism, atrial 
fibrillation (in women) and, probably, stroke. Consideration of only coronary events, only 
fatal events and only first events, therefore, greatly underestimates the cardiovascular 
burden of obesity.
Stroke and heart failure were, numerically, the two next most frequent adverse 
cardiovascular outcomes after coronary heart disease. The comparative risk of these two 
outcomes differed between men and women across the range of body mass index.
Heart failure was relatively more common in men but there was a clear association 
between obesity and an increased risk of heart failure in both sexes. Indeed, the relative 
risk of a heart failure event was greater than that for any other type of cardiovascular event, 
including coronary events, with the exception of the much less common problem of venous 
thromboembolism (see below). Obesity was also particularly associated with multiple 
hospital admissions for heart failure which is important given the huge symptom burden 
and cost related to heart failure.
Another equally dreaded and expensive cardiovascular complication is stroke. This was 
relatively more common in women but, unlike heart failure, the fully adjusted relative risk
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of this outcome was not statistically significantly increased, in relation to obesity. This 
finding is consistent with other studies which have also demonstrated no consistent 
relationship between obesity and stroke in prior s t u d i e s . T h e r e  seem to be a 
number of explanations for this. The risk of stroke related to obesity may be different in 
men and women and for ischaemic compared to haemonhagic s t r o k e . M o r e  
contentious is the completeness of adjustment for baseline co-variables. Two separate 
multivai'iable analyses are reported, one excluding and one including blood pressure, 
cholesterol and diabetes. There has been much debate as to whether these obesity related 
variables should be adjusted for when examining the independent effect of obesity on 
cardiovasculai' outcomes. Clearly, doing so attenuates the strength of the relationship 
between obesity and stroke (and other cardiovascular outcomes).
Venous thromboembolic events were infrequent compared to heart failure or stroke. 
However, the adjusted risk for thromboembolism was increased relatively more than for 
any other adverse cardiovascular outcome. Increased risk of thromboembolism has been 
reported before but no comparison with the rate and risk of other cardiovascular events has 
been provided.^^* "^^^^
Lastly, I also looked at the relationship between obesity and atrial fibrillation which was 
also infrequent and relatively more common in women. The adjusted relative risk for the 
composite of death or hospital admission was increased, significantly, in women but not in 
men though this apparent difference may not be real and may simply reflect low power due 
to small numbers. The few prior reports on the relation between obesity and atrial 
fibrillation have given inconsistent results.
Overall, obesity was associated with 9 additional cardiovascular deaths and 36 additional 
cardiovascular hospital admissions for every 100 affected middle-aged men over the 
subsequent 20 years; for women these numbers were 9 and 28, respectively. Clearly, the 
rise in the prevalence of obesity may result in a rise in cardiovascular events although the 
calculated number of these events given in the “Results” section may be excessive, as 
newer preventive treatments such as blood-pressure and cholesterol lowering, as well as a 
fall in smoking prevalence, are likely to have reduced the risk related to obesity in more 
recent times.
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This study has several limitations, A small proportion of individuals had heart disease at 
initial screening and this wasn’t adjusted for in the analysis. The main analysis did not 
adjust for cholesterol, diabetes and hypertension as it is impossible to disentangle the effect 
of these different factors from each other and they are important mediators in the risk 
between obesity and cardiovascular disease; these factors were however, included in a 
separate analysis to determine the independent effects of obesity. These figures have, of 
course, only quantified the cardiovascular burden of obesity as reflected by death and 
hospital admission. Clearly there was also a potentially huge additional symptom burden 
related to cardiovascular disease which may not have led to admission or death e.g. angina, 
peripheral arterial disease, atrial fibrillation and heart failure. Hypertension was another 
cardiovascular consequence of obesity not directly measured in this study. The analysis 
may also have underestimated the true risk of obesity as body mass index was only 
measured at baseline and may increase beyond middle-age i.e. some of our “normal” body 
mass index group may have become obese during the follow-up period. There is also the 
possibility of unmeasured confounding factors contributing to the findings. There is a 
possible lack of generalisability to other populations, as this is a cohort from Scotland and 
because the inception of the cohort occurred thirty years ago. By design, the non- 
cardiovascular effects of obesity were not quantified.
In summary, obesity is associated with an increased long-term risk of cardiovascular death 
and hospital admission from a wide range of cardiovascular problems in addition to 
coronary heart disease. There are 3 to 4 times as many admissions as deaths related to 
obesity. The rising prevalence of obesity will have a potentially huge impact not only on 
individual health but on the population and hospital sector.
263
12 OVERALL DISCUSSION AND CONCLUSION 
12.1Findings from current studies
I have reported on the epidemiology of important cardiovascular conditions in Scotland 
using data from primary caie (Continuous Morbidity Recording in General Practice 
Scheme), secondary care (Linked Scottish Morbidity Recording Scheme) and from a 
prospective cohort study (Renfrew-Paisley Study).
I used CMR data to examine the primary care burden of angina in Scotland. Most existing 
studies of angina were conducted over a decade ago, used selected cohorts or identified 
angina patients by either questionnaire or prescription data. In my study a GP reported 
diagnosis of angina was used. The prevalence of angina in Scotland was 28 per 1000 in 
men and 25 per 1000 in women (p<0.05) and increased with age. The incidence of angina 
was also higher in men (1.8 per 1,000) than in women (1.4 per 1000) (p=0.004) and also 
increased with increasing age. I also analysed current prescribing patterns for angina which 
is relevant given the emergence of new evidence-based treatments and the publication of 
guidelines. In men, 52% were prescribed (3-blockers, 44% a calcium channel blockers,
72% aspirin, 54% statins and 36% ACE inhibitors or angiotensin receptor blockers. The 
corresponding prescription rates for women were 46% (p<0.001), 41% (p=0.02), 69% 
(p<0.001), 45% (p<0.001) and 30% (p<0.001). In patients under 75 years 52% were 
prescribed a (3-blocker and 58% a statin. The corresponding figures for patients over 75 
years were 42% (p<0.001) and 31% (p<0.001). These prescription rates were better than 
prior studies, however there is still scope for improvement. Guideline recommended 
treatments for angina were underused in women and the elderly and these discrepancies 
warrant further investigation. Deprived individuals were more likely to have angina but 
were less likely to consult their general practitioner. Despite this lower contact rate, 
deprived patients were less obviously under-treated than women or older individuals. In 
fact deprived patients were more likely to be treated with ACE inhibitors. These sub- 
optimal practice patterns show the potential value of this sort of analysis in raising 
questions about under treatment and inequalities in health care.
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I have also examined the outcome of individuals with angina using the Renfrew-Paisley 
Study. Relatively little is known about the long-term natural history of angina at a 
population level, especially in women. Furthermore, most existing studies have focused on 
death or AMI however patients with angina are likely to be at increased risk of other 
complications of coronary heail disease (e.g. heart failure) and other non-cardiac vascular 
events (e.g. stroke). I have shown that angina in middle-age substantially increases the risk 
of death, myocardial infarction, heart failure and other cardiovascular events. All-cause 
mortality for those with angina on the Rose angina questionnaire was 67.7% in men and 
43.3% in women at 20 years compared to 45.4% and 30.4% in those without angina 
(p<0.001). hi a multivariable analysis, men with Rose angina had an increased risk of 
cardiovascular death or hospitalisation (HR 1.49 95%CI 1.33-1.66), myocardial infarction 
(1.63 (1.41-1.85)) and heart failure (1.54 (1.13-2.10)) relative to men without angina. The 
corresponding hazaid ratios for women were 1.38 (1.23-1.55), 1.56 (1.31-1.85) and 1.92 
(1.44-2.56). An abnormal ECG increased risk further and both angina and an abnormal 
EGG were associated with the highest risk of adverse events when compared to those with 
neither angina nor an ischaemic ECG. Relative to men with no angina and no ischaemic 
ECG changes, men with both angina and an abnormal ECG had a four fold increased risk 
of AMI and heart failure and a three fold increased risk of stroke (three fold, four fold and 
two fold for women respectively). Compared to men, women with Rose angina were less 
likely to have a cardiovascular event (HR 0.54 (0.46-0.64)), or myocardial infarction (0.44 
(0.35-0.56)), though there was no sex difference in the risk of stroke (1.11 (0.75-1.65)), 
atrial fibrillation (0.84 (0.38-1.87)) or heart failure (0.79 (0.51-1.21)) which is a novel 
finding. These findings shed new light on the prognosis of angina, particularly in women, 
and have obvious public health implications. They strongly reinforce the need for vigorous 
attempts to identify and treat patients with angina to reduce the burden of cardiovascular 
disease.
I examined trends in hospitalisation rates for suspected acute coronary syndrome and the 
prognosis following a hospitalisation with suspected acute coronary syndrome in Scotland 
using the Scottish Morbidity Record Database between 1990 and 2000. There have been 
many studies looking at the incidence and case-fatality related to AMI, however, there is 
little information on the clinical epidemiology of hospitalised angina and other types of 
chest pain.
I have shown that the pattern of emergency admissions with heart disease to Scottish 
hospitals has changed dramatically over recent years. Between 1990 and 2000 the 
population hospitalisation rate for AMI declined by 33% while the population
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hospitalisation rate for angina increased by 79% and for chest pain by 110%. Population 
hospitalisation rates for all suspected acute coronary syndromes (AMI, angina and chest 
pain) increased by 25% over the time period. These overall trends conceal striking age and 
sex differences e.g. the change in AMI and angina admissions has been greater in men than 
in women and the change in all groups has been greatest in the elderly. There are a number 
of potential explanations for this changing pattern of hospitalisations for acute coronary 
events, including an alteration in the natural history of coronary heart disease, changes in 
threshold for both admission and diagnosis over the period of study or more widespread 
use of anti-platelet or anti-thrombotic therapy. A new clinical challenge is the substantial 
increase in emergency admissions with chest pain. Regarding prognosis following a 
hospitalisation for suspected acute coronary syndrome, I have shown that emergency 
admissions with angina have a low risk of death in the short-term, but have a poor long­
term prognosis. After excluding deaths within 30 days, crude five year case-fatality was 
23.9% for men with angina versus 21.6% in men with acute myocardial infarction (23.5% 
versus 26,0% in women respectively). Furthermore, the longer-term risk of a subsequent 
fatal or non-fatal event within five years was high after both acute myocardial infarction 
(54% in men and 53% in women) and angina (56% and 49% respectively). Event rates 
after a hospitalisation for AMI or angina increased with increasing age and with different 
co-morbidities, but were lower in women than in men. These novel findings strengthen the 
case for aggressive secondary prevention in all patients presenting with an acute coronary 
syndrome.
In a study of the period 1988 to 1991, substantial variation in 30 day survival following 
admission with AMI was identified between hospitals in Scotland. Using the SMR scheme 
I re-examined inter-hospital variation in 30-day survival after AMI 10 years on (1998- 
2001) to see if the appointment of new Cardiologists and their involvement in emergency 
care has improved outcome after AMI. The average 30 day case-fatality rate following 
admission with an AMI has fallen substantially over the past 10 years. Between-hospital 
variation is also considerably less marked due to better survival in the previously poorly 
performing hospitals. Between 1988 and 1991, median 30 day survival was 79.2% (inter­
hospital range 72.1-85.1%). The difference between highest and lowest hospital was 13.0% 
(age and sex adjusted 12.1%). Between 1998 and 2001, median survival rose to 81.6%
(and range decreased to 78.0-85.6); difference 7.6% (8.8%). Admission hospital was an 
independent predictor of outcome at 30 days during the 2 time periods (p<0.001). Over the 
period 1988-1991, the odds ratio for death ranged between hospitals, from 0.71 (95% Cl 
0.58-0.88) to 1.51 (1.19-1.89) and, for the period 1998-2001 from 0.82 (0.60-1.13) to 1.46
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(1.07-1.19). The adjusted risk of death was significantly higher than average in 9 of 26 
hospitals between 1988 and 1991 but in only 2 hospitals between 1998 and 2001. It seems 
likely that the greater involvement of Cardiologists in the management of AMI has 
contributed to this reduction in between-hospital variation in short term case fatality. This 
study highlights the usefulness of this type of epidemiological research in revisiting such 
questions.
I also examined the epidemiology, primary care burden and treatment of heart failure using 
CMR. I have shown that heart failure is a common condition especially with advancing 
age. The prevalence of heart failure was 7.1 per 1000, increasing with age to 90.1 per 1000 
in those >85 years and the incidence of heart failure was 2.0 per 1000, increasing with age 
to 22.4 per 1000 in those >85 years. There is few data on contact rates for heart failure in 
primary care, the reason for consultation or how the primary care burden of heart failure 
compares to that of other cardiovascular conditions. I have shown that patients average 2-3 
heart failure related contacts per yeai'. There was a high rate of concomitant respiratory 
tract infection which emphasises the need for strategies to immunise patients with heart 
failure against influenza and pneumococcal infection. In the elderly, the community burden 
of heart failure was at least as great as that of angina or hypertension. Another important 
feature of my study is the description of the contemporary pharmacological management of 
heart failure in primary care across a whole country. Drugs proven to improve survival in 
heart failure were used less frequently in elderly patients and in women. This again 
highlights the benefit of this type of resear ch in highlighting discrepancies in treatment and 
also the potential of this type of analysis to examine the impact of the new GP contract on 
better treatment of coronary heart disease and heart failure. It has been shown previously 
that socioeconomic deprivation is associated with more frequent admissions to hospital and 
higher case fatality in patients with heart failure. These excess risks are independent of age, 
sex, comorbidities, disease severity and treatment adherence. I therefore examined whether 
there were socioeconomic gradients in the treatment and GP follow-up of patients with 
heart failure. Compared with affluent patients, socioeconomically deprived individuals 
were 44% more likely to develop heart failure, but 23% less likely to see their general 
practitioner on an ongoing basis. Contrary to speculation prescribed therapy did not differ 
between affluent and socioeconomically deprived individuals. This research highlights 
how routine datasets can be used to identify key modifiable factors in an attempt to 
properly direct efforts to reduce socioeconomic gradients. Further research is needed to 
determine why socioeconomically deprived individuals with heart failure are followed less 
closely. Once we understand the mechanisms behind this, programs can be devised to
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ensure that outcomes are optimised for all patients with heart failure irrespective of social 
class.
Again using primary care data, I examined the epidemiology of atrial fibrillation. The 
prevalence and incidence of atrial fibrillation are believed to be increasing probably 
because of the ageing population and improving survival from conditions predisposing to 
atrial fibrillation. In my study the prevalence of atrial fibrillation in Scotland was 9.4/1000 
in men and 7.9/1000 in women (p<0.0001) and increased with age (to 71/1000 in 
individuals >85 years). There is little information on the health care burden that atrial 
fibrillation exerts on general practice. Atrial fibrillation was not a common reason for a 
patient to contact their GP however the complete community burden related to atrial 
fibrillation is likely underestimated as anticoagulation monitoring in hospital based clinics 
was not included in this analysis.
There is relatively little contemporary information about the treatment of atrial fibrillation 
in the community. I have shown that digoxin was used much less commonly and rate 
limiting calcium channel blockers and beta-blockers more commonly when compared to 
the results of older studies. Prior studies have demonstrated that the risk of stroke in 
patients with atrial fibrillation can be substantially reduced with warfarin. I found that 
recommended treatments for atrial fibrillation including warfarin were underused in 
women and the elderly. This is of particular concern given current trends in population 
demographics and the evidence that both groups are at higher risk of stroke. The results 
from this study and from my analysis of angina and heart failure in primary care suggest 
that there is still a need for education regarding the risks and benefits of the 
pharmacological treatments of cardiovascular disease in women and the elderly. Deprived 
individuals were less likely to have atrial fibrillation, a finding raising concerns about 
socioeconomic gradients in detection and prognosis. This has not been reported before and 
contrasts to heart failure and angina where the incidence of these diseases increased with 
increasing socioeconomic deprivation. A possible explanation is that atrial fibrillation is 
often asymptomatic and picked up incidentally whereas heart failure and angina are 
symptomatic. Affluent individuals have more contact with GPs which increases the likely 
hood of detection of atrial fibrillation (e.g. greater uptake of “health screening” and more 
recording of electrocardiograms). Treatment did not vary according to socioeconomic 
status which is in keeping with my findings for angina and heart failure and may relate to 
the greater use of secondary care by more deprived individuals.
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The prevalence of obesity has reached unprecedented proportions in Europe and elsewhere, 
with huge implications for Cardiologists. While it is known that obesity is a recognised 
risk factor for coronary heart disease its effect on the risk of other cardiovascular events is 
much less clear. I examined the long-term cardiovascular consequences of obesity in 
middle aged men and women using the Renfrew-Paisley study. Compared with normal 
weight individuals (BMI 18.5-24.9), obesity (BMI >30) was associated with an increased 
adjusted risk of coronary heart disease (hazard ratio for death or hospital admission; 1.60, 
95%CI 1.45-1.78), heart failure (2.09, 1.68-2.59), stroke (1.41, 1.21-1.65), venous 
thromboembolism (2.29, 1.60-3.30) and atrial fibrillation (1.75, 1.17-2.65). The impact of 
obesity on cardiovasculai- health in a single population like this has not been quantified 
before. I also projected the cardiovascular consequences of the recent increase in 
prevalence of obesity. Obesity was associated with 9 additional cardiovascular deaths and 
36 additional cardiovascular hospital admissions for every 100 affected middle-aged men 
over the subsequent 20 yeais (7 deaths and 28 admissions in women). Assuming no 
change in cardiovascular risk profile and outcomes related to obesity, the increase in 
prevalence in 1998, compared to 1972, is projected to lead to an additional 4 
cardiovascular deaths and 14 admissions per 100 middle-aged men and women over the 
next 20 years. My findings strongly highlight the importance of public health strategies to 
combat obesity and primary preventive approaches to cardiovascular disease in obese 
individuals.
12.2HOW the datasets could be improved
12.2.1 Continuous Morbidity Recording in General Practice Scheme
As discussed previously the two main issues with CMR are whether it is a representative 
sample of general practitioners in Scotland and the completeness of information collected. 
By addressing these two issues the data collected from CMR could be further improved.
The age and sex characteristics of the populations registered with CMR practices are 
broadly representative of Scotland as a whole. The practices that participate in the CMR 
scheme differ in some respects from practices n a t i o n a l l y T h e  practice populations are
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more likely to be from rural areas and less likely to be from deprived areas. The CMR 
practices tend to be lai'ger partnerships and are more likely to be training practices. While 
improving the representation of practices would improve the data, there is evidence to 
suggest that the socio-economic deprivation discrepancies discussed in these studies are 
representative of the affluent and deprived groups in the population as a whole. Differences 
in contact rates between affluent and deprived population groups in CMR are not 
significantly different to that found in the Scottish Health Survey. Also the difference in 
prescribing costs between affluent and deprived CMR practices is comparable to the 
difference found between all affluent and all deprived Scottish practices.
The CMR scheme used in these studies collected data on GP contacts only and therefore 
did not capture all the workload such as duration of consultations, telephone contacts and 
nurse contacts. Any patient therefore who has a consultation with another member of the 
practice team other than the GP would be missed and therefore this may underestimate the 
prevalence of disease. The new general medical services (GMS) contract was introduced in 
2004 and has specific performance indicators to attempt to improve the management of 
patients with cardiovascular disease. This provides incentives for better identification and 
recording of cases and prescribing and therefore should result in improvements of the 
completeness and accuracy of primary care data. Since April 2003 the scheme was 
extended to include face-to-face consultations (in a surgery or the patient's home) between 
patients and any member of the Practice Team (general practitioners, practice nurses, 
district nurses and health visitors). The name of the scheme has been changed from CMR 
to Practice Team Information (PTI). Currently 44 practices are involved in PTI, covering 
around 5 per cent of the Scottish population.
The data available for the studies was for one calendar year. At least 44 general practices 
have participated in CMR since 1998 and therefore it would be useful to have data 
available for each year from 1998-2005 to enable analysis of temporal trends.
The data would be further improved by including diagnostic data such as the results of 
biochemical, haematological, radiological and other diagnostic tests. This would improve 
the validity of the conditions studied and also may partly explain the reasons why patients 
are on different medications. For example for the heart failure studies it would be useful to 
have information on cardiomegaly or pulmonary oedema on CXR and left ventricular 
systolic function on echocardiogram. Cai'diovascular risk factor profile would also be 
interesting for the angina study.
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Record linkage of CMR to SMR and to the Registrar Generars death certificate data would 
greatly improve the scope of analysis possible with CMR data. It would allow the analysis 
of both fatal and non-fatal outcomes of diseases recorded in primary care. It would allow 
the true burden of diseases in Scotland to be estimated in terms of primary care and 
secondary care burden. It would also mean that the studies using SMR data would have 
risk factor profiles and the potential for prescription data on admission to hospital. The 
Community Health Index (CHI) number is normally available for GRASS patients and has 
been linked previously to SMR. A pilot study is currently underway in ISD which involves 
linkage of Practice Team hiformation (PTI) data to SMR data in order to examine issues 
around emergency medical admissions in Scotland. It is hoped that this pilot study will 
address some of the technical and indeed ethical problems surrounding this potential 
linkage and lead to future linkages. The Scottish Health Survey is already record linked to 
SMR and the Scottish Longitudinal Study is in the progress of being linked to SMR.
12.2.2Liiiked Scottish Morbidity Recording Scheme
The Linked Scottish Morbidity Recording scheme provides large population-based robust 
databases. As discussed previously the quality of routine data is generally considered to be 
good, but there are some areas where the data are incomplete or lack accuracy. In addition 
there may be important pieces of information that are not collected routinely.
More accurate and more detailed secondary coding on hospital discharge forms would 
allow better identification of co-morbidities. It would also be useful to expand the coding 
of secondary diagnoses to include information on risk factors including smoldng, obesity 
and cholesterol. It would also be beneficial if the there was information as to whether these 
co-morbid conditions were new or longstanding, as is available in CMR.
The Linked Scottish Morbidity Recording would be further improved by inclusion of 
pharmacological treatment and the results of diagnostic tests. For example for the 
suspected acute coronary syndrome analysis information on thrombolysis, results of 
biomarkers such as troponin and results of coronary angiography would be very useful and 
would further strengthen these studies. National datasets for cardiology are currently being 
developed. These would contain detailed clinical and therapeutic information related to
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each episode of cai'e. Cardiology is at the forefront of these developments although it is 
likely to be sometime before such systems are fully integrated into routine data recording.
Linkage of SMR data to primary care data would be very useful as discussed previously. It 
would provide information on phaimacological treatment prior to admission. This would 
allow us to see whether the benefits seen in clinical trials translate into the general 
population. It would also provide information on concomitant conditions. This would 
enable a greater understanding of the predictors of diseases and better identification of high 
risk groups.
The SMR dataset would also be markedly improved if it was linked to Scottish census 
data. This would allow reseai'chers to explore the complex relationships between 
employment, social class, educational attainment and different diseases. In addition, it 
would allow the examination of the pattern of various diseases in different ethnic groups. 
Ethnicity is poorly completed in SMR. A linkage between SMR and census data has been 
achieved but has proved technically and ethically difficult.
12.2.3 Renfrew-Paisley Study
Follow-up of mortality was established at the time of the Renfrew-Paisley study with the 
Registrar General for Scotland and the Renfrew-Paisley study receives information on 
deaths of the study participants on a three monthly basis. Information on subsequent 
hospitalisations is obtained by record linkage to SMR and was only available up to 1996 at 
the time of my research. It was therefore necessary to censor all deaths and hospitalisations 
at exactly 20 years following the date of initial screening. The follow-up has recently been 
extended to 25 years however these data were not available at the time of my research. The 
database could be further improved if an extraction of hospitalisation data could be 
received at annual intervals from ISD. Inclusion of treatment and clinical data in SMR as 
discussed would also improve follow-up of the Renfrew-Paisley study.
The Renfrew-Paisley cohort was initially screened between 1972 and 1976 and 
approximately 60% of the cohort re-attended for repeat screening between 1977 and 1979. 
However, unlike the Framingham study, the cohort did not have any further follow-up 
visits and subsequent follow-up is available through linkage with hospitalisation and death
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certification data. Further follow-up visits would provide knowledge about changes in risk 
factors and development of non-hospitalised diseases such as diabetes.
12.3Further research
Following on from the work I have done showing the adverse effect of socioeconomic 
deprivation on cardiovascular health I helped prepare a successful grant application to use 
the Renfrew-Paisley study to examine the long-term cardiovascular effect of 
socioeconomic deprivation. The Renfrew-Paisley cohort is a mixed urban and rural one 
with a high proportion of socially deprived individuals. Baseline data includes Carstairs’ 
deprivation class and social class. The aim of this study is to look at the independent effect 
of socioeconomic deprivation on the risk of developing myocardial infarction, angina, 
heart failure, stroke, atrial fibrillation, aortic aneurysm or pulmonaiy embolism and the 
strength of the association between social deprivation and these conditions. In addition we 
will investigate the effect of socioeconomic deprivation not only on mortality from these 
individual conditions but also on first and recurrent non-fatal events and cumulative 
cardiovascular events of all types.
Subsequent to the studies I did on the primary care burden of angina, atrial fibrillation and 
heart failure it would be interesting to examine the primary care burden and prescribing 
practices for hypertension and look at age, sex and socioeconomic disparities. It would also 
be interesting to use the new Practice Team Information (CMR was superseded by PTI in 
2003) to examine trends in the incidence and prescribing practices of these conditions over 
time.
As a follow-up to the work I have done using the SMR Scheme to examine hospitalisations 
for acute coronary syndromes I helped prepare a successful grant application to do similar 
analyses for stroke. As a major priority research area, cerebrovascular disease and, in 
particular, stroke exerts a significant burden on the Scottish population and its health care 
system. There is a general paucity of related studies that have systematically examined the 
epidemiologic profile and impact of stroke within a whole population. Trends in hospital 
admissions for stroke between 1986 and 2002 and short to long-term case fatality rates 
could be examined as I have done for acute coronary syndromes. Between-hospital
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variations in morbidity and mortality could also be described. The economic burden of 
stroke and impact of stroke units/specialist services could also be investigated. It would 
also be interesting to project the future burden of stroke (2005 -  2025). Similar analyses 
could also be done for peripheral arterial disease.
I have shown a reduction in hospitalisations for AMI and an improvement in case fatality 
following a hospitalisation for AMI between 1990 and 2000. This study was performed 
prior to the application of widespread troponin testing and the new definition of AMI. The 
advent of sensitive and specific serologic biomarkers and precise imaging techniques 
necessitated the re-evaluation of the definition of AMI. In 2000 the European Cardiac 
Society and the American College of Cardiology published a consensus report for the 
redefinition of AMI The new definition requires documentation of a rise and fall in 
troponin or CK-MB as well as ischaemic symptoms or ischaemic ECG changes or 
coronary intervention. The previous WHO definition allowed a diagnosis to be made on 
the basis of serial ECG changes alone, or a combination of symptoms and ‘probable’ ECG 
changes and /or abnormal plasma enzymes. It would now be interesting to re-examine 
trends in hospitalisations and case fatality following the adoption of the new definition of 
AMI and the more widespread use of troponin. It is likely that hospitalisation rates for 
AMI will increase and case fatality rates for AMI will improve as a result individuals with 
a mild troponin leak being labelled as AMI that would previously been labelled as unstable 
angina.
It has previously been suggested that an improvement in survival following a 
hospitalisation for heart failure between 1986 and 1995 might have been due to increased 
use of ACE i n h i b i t o r s . I t  would be interesting to use SMR data to re-look at trends in 
survival of patients hospitalised with heart failure following the introduction of beta- 
blockers.
I know that national linked record databases are also available in Sweden, Denmark and 
New Zealand and provincial/ regional linked datasets are available in Canada, 
Leicestershire in England and Lombardy in Italy (and possibly in other countries/ regions). 
It would be interesting to compare and contrast trends in hospitalisation rates and short to 
longer term case fatality rates for different cardiovascular conditions between Scotland and 
other countries. A similar analysis to the one I have done in Scotland for acute coronary 
syndromes could be done for each country. This could then be repeated for other- 
cardiovascular conditions such as atrial fibrillation, heart failure and stoke. This would
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require using common definitions to extract comparable data. This would allow inter 
country comparison of differences in hospitalisation rates, practices (e.g. length of hospital 
stay), outcomes (short to longer term case fatality rates) and trends in each of these.
12.4 Conclusion
I have reported on the epidemiology of important cardiovascular diseases (including 
angina, AMI, acute coronary syndromes, heai't failure, atrial fibrillation and obesity) in 
Scotland using data from primary care (CMR Scheme), secondary cai'e (Linked SMR 
Scheme) and from a prospective cohort study (Renfrew-Paisley Study).
Using primary care data from a representative sample of all General Practices in Scotland,
I examined the epidemiology, primary care burden and prescribing practices of angina, 
heart failure and atrial fibrillation. I have shown that guideline recommended treatments 
for these conditions were underused in women and the elderly. I have also shown deprived 
individuals were more likely to develop angina or heart failure but were less likely to 
follow-up with their GP. This is in contrast with atrial fibrillation where deprived 
individuals had a lower prevalence of AF. There were no socioeconomic biases in 
prescribing.
Using secondary care data (SMR) I examined temporal trends in hospitalisation rates and 
short and longer-term case-fatality in all patients admitted with a suspected acute coronary 
syndromes in Scotland between 1990 and 2000.1 have shown a decline in hospitalisation 
rates for acute myocardial infarction between 1990 and 2000 but marked rises in hospital 
admission rates for angina and chest pain. The long-term prognosis, following an 
admission for AMI and angina are similar, when short-term deaths are excluded. In 
addition, I re-examined inter-hospital variation in short-term survival following a 
hospitalisation with AMI in Scotland. Between-hospital variation in 30-day survival 
following an AMI has declined between two time periods (1988-1991 and 1999-2001).
Using the Renfrew-Paisley study I examined 20 year follow-up data for 15,406 middle 
aged men and women who underwent comprehensive cardiovascular screening between 
1972 and 1976. I analysed all deaths and hospitalisations for cardiovascular reasons
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occurring over the subsequent 20 years according to baseline BMI category. Compared 
with normal weight individuals, obesity was associated with an increased adjusted risk of 
coronary heart disease, heart failure, stroke, venous thromboembolism and atrial 
fibrillation. Again using the Renfrew-Paisley study I analysed morbidity and mortality data 
over the 20 year follow-up period according to baseline Rose angina score. Individuals 
with Rose angina had an increased risk of cardiovascular death or hospitalisation, 
myocardial infarction and heart failure relative to individuals without angina. Compared to 
men, women with Rose angina were less likely to have a cardiovascular event, or 
myocardial infarction, though there was no sex difference in the risk of stroke, atrial 
fibrillation or heart failure.
Subsequent to this research, the long-term cardiovascular effect of socioeconomic 
deprivation in the Renfrew-Paisley cohort, the epidemiology of stroke in Scotland using 
SMR data, and the primary care burden of hypertension using the CMR scheme could be 
examined. Routine data could also be used to re-examine trends in AMI hospitalisations 
and case fatality, following the adoption of the new definition of AMI and to re-look at 
trends in survival of heart failure patients following the introduction of beta-blockers. 
Finally comparison of hospitalisation rates and case fatality rates for different 
cardiovascular conditions between different countries with similar national linked record 
databases would be of value.
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